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SUMMARY 
The discovery of antibiotics has played a significant role in raising public health 
standards and improving the outcomes for patients with bacterial infections. Unfortunately, 
drug discovery efforts have not kept pace with emergence and spread of antibiotic resistance.  
This project is part of a discovery programme designed to assess the metabolic potential 
of Actinoallomurus, a recently described genus within the Actinobacteria. The schedule of 
work included small-scale fermentations (from 200 strains) followed by bioactivity testing. 
The most promising positive samples were then subjected to a combination of bioassays with 
chemical analyses to determine the chemical identity of the active compounds, with the 
objective of finding novel antibiotics. The Results section is organized in four different but 
closely related chapters. These present Actinoallomurus as a potential new source for active 
metabolites. Firstly, by showing, in a sample of around 200 strains, over 40% inhibited 
antimicrobial growth in the conditions tested but also by adding to the elevated quantity of 
positive hits a high degree of diversity, with the major biosynthetic pathways being identified 
whether in the molecules screened or also in the genomes analysed.  
To illustrate not only the type of metabolites produced by Actinoallomurus, but also the 
multidisciplinary of Drug Discovery expeditions three chapters characterizing new compounds 
are presented followed by a genomic characterization of four Actinoallomurus Strains. These 
three chapters show how the delivery of new potential drug candidates demands an always 
broader set of diverse tools to be applied. While the three new molecules support not only the 
ability of Actinoallomurus to produce interesting active metabolites, but also the importance 
that a proper strain library plays in drug discovery, the genomic analyses predict, as for many 
other actinomycetes, an even brighter future, since the genetic potential for producing bioactive 
molecules surpasses the compounds that can be detected under routine cultivation conditions.  
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1.  INTRODUCTION 
1.1. State of the art - antibiotics 
Antibiotics are one of the most successful forms of chemotherapy in the history of 
medicine. The miscellaneous family of (usually) low molecular–weight compounds able to 
inhibit the growth of other microbes has been a key player in raising the society health 
standards, and setting the grounds for modern medicine. By the end of the 20th century’s first 
half, antibiotics held a great promise regarding the eradication of infections as a major health 
threat and by the mid-1980s infectious diseases were considered virtually conquered as 
antibiotics kept being introduced into clinical 
practice. (Coates et al., 2011; Davies and 
Davies, 2010; Powers, 2004)  
 However, in this very success lies also 
the main issue: antibiotics are a unique class of 
medicines with characteristics unlike most 
others, complicating and restricting their use 
and long-term efficacy. The use of antibiotics 
inevitably creates a selective pressure for 
sensitive microorganisms to escape the 
antibiotic's toxic effect by becoming not 
susceptible to that same antibiotic. (Wise, 
2002) Fig.  1.1 depicts the temporal succession 
of when the first instance of resistance to an 
antibiotic was observed along the year of 
introduction of that same antibiotic into the 
market. The striking observation from Fig.  1.1 
is that the longest it took for resistance to be 
recorded in a given pathogen was 15 years in 
the case of erythromycin; in most cases, 
Figure 1.1 - Timeline correlating the introduction of an 
antibiotic into the market and the first resistance to that same 
compound was observed. (adapted from 
http://www.cdc.gov/drugresistance/about.html  - October, 2015) 
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resistance was seen shortly after introduction of the corresponding antibiotic into the market 
or, as in the case of penicillin, even before.  
The closeness of these two events (beginning of antibiotic use and observation of the first 
resistant bacterium) shows how the introduction of new antibiotics into medicine will never be 
a one-time event but a continuous effort will be necessary to keep bacterial infections under 
control by supplying the antibacterial arsenal in a continuous and sustainable manner. 
However, while we must accept that resistance will eventually develop to any antibiotic, the 
misuse of this precious class of compounds has played also a very important role in promoting 
the selection of particularly hard to kill bacteria. Self-medication approaches, failure to 
complete treatment, or erroneous prescription of antibiotics are just examples often 
encountered in our society that may lead to the proliferation of highly resistant bacteria. This 
ill-use of antimicrobials is not limited to human medicine: in animal husbandry, the 
prophylactic use of antibiotics to prevent infections or their use as growth promotants has 
represented the major use for some classes of antibiotics, providing a constant selective 
pressure for resistant strains and their spread from animals to humans, or vice-versa (Gould, 
2009). 
Antimicrobial resistance is not a recent event, since it naturally occurs in the environment 
and, recently, it has been documented in bacterial strains from at least 30,000 years (D/'Costa 
et al., 2011). Yet, now more than ever, we are witnessing the spreading and increase of drug-
recalcitrant bacteria – for instance multidrug-resistant bacteria caused 25,000 deaths in the 
European Union in 2007, and antibiotic-resistant infections are estimated to result in excess 
health-care costs in the USA of US$20 billion per year, (Fauci and Morens, 2012) proving that 
a war against infectious agents is far from over and indicating that investment into new 
therapeutic options should not be disregarded (Donadio S., 2005). The increasing number of 
drug resistant infections with at least 480 000 new cases of multidrug resistant tuberculosis up 
to 2008 clearly portrays the landscape of drug resistant microbes and the risks that we, as a 
society, face in a near future (it is important to mention that similar figures are also observable 
beyond the antibacterial sector). Therefore, it seems straightforward to conclude that 
addressing antibiotic resistance is indeed an urgent matter.  
Antibiotics can induce cell death (bactericidal drugs) or merely inhibit cell growth 
(bacteriostatic drugs). Both have been successfully used in the treatment of infection by 
targeting critical pathways such as: cell wall synthesis, DNA replication, RNA transcription, 
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protein synthesis. To overcome these hurdles, bacteria have come up with different resistance 
strategies (Hermann, 2000; Kohanski et al., 2010; Nikaido, 2009). Relevant resistance 
mechanisms include: drug modification (e.g., β-lactamases that hydrolyse penicillin) (Bush, 
1989) ; target modification (e.g., mutations in the 30S ribosomal protein RpsL confer resistance 
to gentamycin) (Springer et al., 2001); restricted penetration and/or efflux of the drug (e.g., 
efflux of linezolid by the AcrAB–TolC multidrug pump in  Escherichia coli) (Eliopoulos et al., 
2004); or reduction of the intracellular target concentration (e.g., decreased expression of 
topoisomerase IV grants resistance to quinolones) (Ince and Hooper, 2003). 
Targeting critical functions as antibiotics may lead to the belief that resistant strains 
suffer a decrease in biological fitness. Thus, a possible strategy to deal with antibiotic resistance 
could rely on a reduced use of that particular antibiotic, with the expectation that there will be 
a selective advantage for the resistant bacteria to lose the resistance mechanism and become 
more fit, thus outcompeting resistant mutants over time (Andersson and Levin, 1999). 
However, studies have been showing that reducing the usage of an antibiotic as the sole 
solution to antibiotic resistance is not a viable option, as evolution might not necessarily do 
what we would hope for. Indeed, not all resistance mechanisms come with a fitness cost, (Luo 
et al., 2005; Sander et al., 2002; Sundqvist et al., 2010) or compensatory mutations can occur 
that make reversion to sensitivity an unlikely event.  Horizontal gene transfer of resistance 
determinants further complicates the scenario (Martinez et al., 2007). 
For all these reasons above, improving our antibacterial arsenal is imperative in order to 
provide alternative options to the most commonly used antibiotics. Enhancing the already 
available antibiotics to make them active against resistant strains has been the favourite 
approach by the pharmaceutical industry. However, this approach is not generally applicable 
to all antibiotic classes and it will just buy some time in the war against bacterial infections. It 
is widely recognized that only novel chemical structures will bring truly novel mechanisms of 
action and, most likely, will effectively surpass known mechanisms of resistance (Donadio et 
al., 2010). This rationale was the trigger for the work developed in this PhD project – to 
discover new structural classes of antibiotics with novel mechanisms of action.  
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During the last 20 years of research and development, the pharmaceutical industry has 
not kept pace with the rise of multidrug resistant pathogens and the number of new drug 
applications in this area it has been steadily diminishing, as described in Fig.  1.2 (Butler et al., 
2014). Different factors have contributed to the lack of new antimicrobials, but they can be 
reconducted to three main categories: biological, regulatory and economic factors. From the 
biological point of view, finding new antibiotics is not easy, since microorganisms have 
devised effective barriers (cell wall, membranes and efflux systems) to cope with chemical 
warfare in their natural environments. From the regulatory side, approval of new antibiotics 
requires meeting high clinical standards to enter the market, in which new compounds must 
show equal efficacy to existing drugs in a scenario where there is a lack of appropriate 
diagnostic tools that reflect the necessities of the healthcare system (e.g. in clinical trials it is 
very difficult to evaluate the drugs performance against multi-drug resistant pathogens). From 
an economical point of view, for an industry that covers the enormous costs of clinical 
development through sales of approved drugs, antibiotics against bacterial infections, an acute 
disease, are seen as a lower source of income compared to drugs that deal with chronic diseases, 
since the former will always have a smaller sale volume in respect to the latter. Furthermore, 
Figure 1.2 - Number of Antibacterial drugs approved in the United States from 1980 until 2012. * time 
intervals of 5 years except from 2010 to 2012. (Prevention, 2013) 
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in the case of antibiotics, a correct public health policy may curb their prophylactic use and 
reduce the revenue stream (Cassir et al., 2014; Gould; Michael et al., 2014; Shlaes, 2015; 
Tängdén and Giske, 2015). For large pharmaceutical companies that deal with many different 
therapeutic areas, antibiotic discovery and development represents a business with a low return 
on investment, with the result that largest pharma companies have abandoned antibiotic R&D 
altogether. 
Still, before leaving the antibacterial discovery sector, many pharma companies heavily 
invested in a screening strategy that has essentially failed to delivered new scaffolds useful for 
further optimization. Indeed, the genomics era in the 1990’s unveiled a plethora of new 
potential targets (essential genes conserved into many pathogens and not present in humans) 
that were explored by high throughput screening technologies on large collections of synthetic 
compounds derived from either historical (and thus biased) company collections or de novo 
generated through combinatorial chemistry. The underlying assumption to this approach was 
that any hit could be transformed into a lead compound by synthetic chemistry. Although this 
approach was successful in delivering potent inhibitors of selected targets, most of those hits 
turned out to be poor antibacterial agents, often because of inability to reach their targets within 
the cell cytoplasm.  Although there is still a dearth of compounds that are able to keep their 
interactions with a predetermined target in more complex environments, these last years of 
research did deliver a better understanding of the microbial cell by identifying critical functions 
within the cell’s metabolism (Arya et al., 2001; Collins and Donadio, 2011; Feng et al., 2007; 
Harvey, 2000; Hilpert et al., 2005; Pena et al., 2015; Scanlon et al., 2014). 
 
Figure  1.3 - Timeline of the introduction of new antimicrobial classes into the market (Adapted from 
Högberg, LD., et al. 2012 ) (Hogberg et al., 2010) 
Figure 1.3 shows the decade in which the first representative of a new class of antibiotics 
was introduced into the market and how the 40’s and 50’s yielded as many new classes as the 
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forthcoming 60 years. Up to 2012, among the 13 new antibiotics introduced into the market 
there are only two new classes: linezolid and daptomycin, an Oxazolidinone and a Lipopetide, 
respectively (Fig. 1.3) (Jabes, 2011). Moreover, the actual discovery programs that led to those 
drugs date back many years. For instance, linezolid belongs to a class known since the 50’s, 
the first molecules with antibacterial bacterial activity were described in the 70’s (Barbachyn, 
2012). Only in 1984 its potential for treatment in humans is registered in a patent. Then, E. I. 
du Pont de Nemours and Company - the original discoverer of the antimicrobial properties of 
this class - shuts down the development process due to toxicity issues (Moellering, 2003). Later 
on, in the 90’s, Pharmacia & Upjohn (now part of Pfizer) reactivated the Oxazolidinone 
program and developed new derivatives, amongst which was linezolid, that eventually received 
regulatory approval in 2000 (Barbachyn and Ford, 2003). Daptomycin, on the other hand, was 
originally discovered by Eli Lilly but later licensed and registered by Cubist (now Merck) 
(Tally and DeBruin, 2000). More recent examples of approved antibiotics include fidaxomicin, 
a new chemical class approved in 2011 for treating Clostridium difficile infections, (Mullane, 
2014) and dalbavancin, a second generation glycopeptide approved in 2014. The latter 
represents a dramatic example of a tortuous history, with six different companies contributing 
to its development (Maffioli et al., 2016). 
Although the antibiotic landscape is not attractive to big pharma, it represents an 
interesting area for smaller companies. In fact, despite a smaller market, the cost of clinical 
development is generally smaller for an antibiotic than for a drug in other therapeutic areas. 
Furthermore, in contrast to many other therapeutic areas, animal models of infections are highly 
predictive of efficacy in humans, so that the "attrition rate" (i.e., the probability that a drug will 
fail during its costly clinical development path) for antibiotics is far smaller than for other 
therapeutic areas, such as cancer or cardiovascular diseases. Thus, smaller companies can be 
attracted by the prospect of substantially "de-risking" a new antibiotic after the less expensive 
early clinical trials (Phase I and Phase 2). Rather than competing with big pharma on the so 
called blockbuster drugs, smaller companies take a limited financial risk and can later partner 
in late developmental stages to bigger companies. 
It should be noted most of the last approved antibiotics (daptomycin, fidaxomicin, 
dalbavancin) were discovered using traditional methods and represent either natural products 
or derivatives thereof (Harvey et al., 2015). This fact highlights not only the success of the 
classical approaches but also the potential of natural products to deliver promising leads, as 
discussed in the next section.   
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1.2. Importance of natural products  
Nature has contributed to improve our health and overall quality of life since the dawn 
of times. We passed from patching moistures of plants over injuries to chemically mimic 
natural products and even improve their properties. Any compound produced by a living 
organism can be considered a natural product. In this work, I will restrict this definition to the 
so-called secondary or specialized metabolites, molecules that are not associated with most 
living organisms (i.e. primary metabolites) but that are usually specific to a particular group of 
organisms, often a single species or strain. Most of these compounds do present a detectable 
biological activity, although it depends on the type of tests we apply. Nonetheless, these 
compounds are important for the producers as they represent tools to interact with the outer 
world, be it friends or foes. Quorum sensing is the classical example of microorganisms 
communicating using specialized metabolites. However, not all metabolites aim only at 
communication: some are used to gain a competitive advantage, usually by impairing the 
viability of predators or competitors in a very challenging environment. It is exactly that kind 
of molecules that we, as humanity, have always used and are still interested in.   
The importance of natural products to human health has been acknowledged over the 
past decades. A recent confirmation came in 2015, when the Nobel prize for medicine was 
awarded to William C. Campbell and Satoshi Ōmura for their discovery of avermectin, a novel 
therapy against infections caused by roundworm parasites, and to Youyou Tu for or her 
discoveries concerning a novel therapy against Malaria. Avermectin is a molecule produced by 
the actinomycete Streptomyces avermitilis, which was identified through a systematic 
screening for anthelminthic compounds. While artemisinin is a molecule produced by the plant 
Artemisia annua, which had been used in traditional Chinese medicine as a treatment for 
malaria. Natural compounds have found applications in virtually all therapeutic areas, from 
pain relief (morphine derived from poppies was the first isolated compound to enter the market 
back in 1817 (Luch, 2012)) to the treatment of patients with high cholesterol (mevastatin, a 
fungal metabolite, served as scaffold for the synthesis of atorvastatin (Endo et al., 1976)), and 
of course, penicillin, the first antibiotic introduced into the market (Glynn, 2005). Supporting 
these examples is the actual number of new chemical entities approved as drugs between 1981 
and 2010, where approximately 68% are directly derived or inspired from natural products. 
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This success, despite the growing disinterest by pharmaceutical companies in natural products 
as a source of drug leads, underscores Nature's ability to deliver complex and high affinity 
chemical scaffolds that have no match in most synthetic libraries. One therapeutic area that has 
been strongly dependent on natural products has been anti-infectives where, in the last 30 years, 
out of the 104 new chemical entities introduced into the market to fight bacterial infections, 77 
derived from natural products (Newman and Cragg, 2012). 
Natural products as defined above are mainly produced by bacteria, fungi, and plants, 
however my focus will be on those of bacterial origin. As mentioned, secondary metabolites 
are believed to play a role in interactions and communication with the surrounding 
environment. This expansion in functions results in different specializations, hence an increase 
in diversity. However, not all bacteria are efficient at producing secondary metabolites. Some 
groups of bacteria have evolved to become effective producers of secondary metabolites while 
other groups did not. This is because production of secondary metabolites comes with a cost 
associated with the often complex pathways required to produce these molecules which can 
represent a competitive advantage in some environments and under some circumstances. For 
example, many Actinobacteria (the taxonomic group containing the large majority of 
secondary metabolite producers) gave up on a fast growth rate as their genome increased to 
harbour, among other functions, the genetic information for the biosynthesis of specialized 
metabolites. Their life cycle became complex, involving growth as a multicellular mycelial 
structure probably important for catabolizing complex organic polymers, an abundant 
component of soil, their typical habitat, and ultimately producing spores, which can then 
colonise new niches. Consequently, their life cycle typically involves four different stages: a 
spore germinates, leading to hyphae formation to create the mycelium that can fully colonize 
the solid support to which it is attached. Then, aerial hyphae starts differentiating from the 
substrate mycelium, eventually producing spores (Kalakoutskii and Agre, 1976). While this 
life cycle is best described for Streptomyces spp., it is believed to occur in similar ways in most 
filamentous actinomycetes.  
Before endeavouring in a quest for new bioactive compounds among natural products, it 
is important to be aware of what kind of molecules one might encounter, which in turn depends 
on the types of biosynthesis machineries that are present in the group of bacteria under 
investigation, as discussed in the next section. 
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The polyketide natural products are produced by bacteria, fungi and plants. They 
represent a remarkable class of compounds not only for their chemical diversity, but also for 
the astounding range of important biological activities. This family of compounds has been 
able to deliver many clinically important drugs such as tetracycline and erythromycin 
(antibacterial), daunorubicin (anticancer), rapamycin (immunosuppressive), or lovastatin 
(cholesterol-lowering agent), making it the most successful and versatile group in terms of drug 
discovery. These compounds are assembled through the condensation of short chain fatty acids 
as Acyl-CoA precursors, in a process that has likely evolved from fatty acid synthesis. 
Nonetheless, important variations exist in the biosynthetic routes which have resulted in the 
classification of the responsible enzymes, the polyketide synthases or PKSs, into type I, II and 
III. (Shen, 2003) 
Type I PKS, or PKS-I, were firstly described in the beginning of the 1990’s with the 
discovery of erythromycin’s biosynthetic pathway. (Cortes et al., 1990; Donadio et al., 1991) 
Probably the most studied system, PKS-I is organized in modules of pluri-functional enzymes, 
each one catalysing a cycle of polyketide chain elongation on an intermediate enzyme-bound 
through a thioester linkage. These modules contain, as core units, the domains required to load 
a new acyl-CoA unit, condense it to the growing carbon backbone and transferring it onto the 
next module. Other domains may be present in each module to process the growing polyketide, 
increasing the number of chemical functionalities present in the polyketide. At the end of the 
cycle, the enzyme-bound polyketide chain is released - and often cyclized - by a dedicated 
thioesterase. In addition to this general architecture, some modules lack a specific core domain 
(i.e. the acyltransferase unit to capture the acyl-CoA precursor) which is instead provided in 
trans by a separate, promiscuous acyltransferases capable of interacting with different modules 
(Nguyen et al., 2008).  The PKS-I non-iterative system usually yields reduced and complex 
polyketides such as macrolides, polyethers or polyenes (August et al., 1998; Caffrey et al., 
2001), however there are also PKS-I systems that act in iterative mode and  yield aromatic 
polyketides, as type II PKS, or PKS-II, do (Gao and Thorson, 2008). Examples of molecules 
produced by PKS-I enzymes are shown in Fig. 1.4. 
PKS-II were firstly described during the mid-80’s with the analysis of the gene clusters 
responsible for the biosynthesis of tetracenomycin and actinorhodin (Malpartida and 
Hopwood, 1984; Motamedi and Hutchinson, 1987). PKS II relies on three distinct 
monofunctional enzymes, called a minimal PKS, formed by an acyl carrier protein (ACP), and 
a ketosynthase (KS) made of two subunits – alpha and beta – in which KSα makes the carbon-
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carbon bond while KSβ contributes to specifying the length of the carbon chain and its 
appropriate folding for the subsequent cyclisation and aromatisation reactions  (Daum et al., 
2009; Wendt-Pienkowski et al., 2005). Examples of molecules produced by PKS-II enzymes 
are shown in Fig. 1.4. 
Probably the least studied system, firstly reported in 1999, (Funa et al., 1999) is the type 
III PKS, or PKS-III, which lacks the ACP protein or domain required for covalently binding 
the growing intermediate. In PKS-III, chain elongation is performed on a CoA derivative, as 
with chalcone synthase, part of plant metabolism (Funa et al., 2002; Funa et al., 1999). PKS-
III systems represent the structurally simplest member of the PKS superfamily and often 
provide specialized precursors to be used by other enzymes (e.g. non-ribosomal peptide 
synthases – see below) in a complex biosynthetic pathway (Pelzer et al., 1999). Examples of 
molecules produced by PKS-III enzymes are shown in Fig. 1.4. 
In addition to the generation of secondary metabolites through the formation of carbon-
carbon bonds as in polyketides, microorganisms can assemble biologically active compounds 
through the formation of C-N bonds, as in the synthesis of small peptides. Also this biosynthetic 
strategy can provide wide chemical diversity and, hence, different biological activities. Two 
main families of peptides are distinguished in bacteria according to their route of biosynthesis: 
the non-ribosomally synthesized peptides (NRPs) and the ribosomally synthesized and post 
translationally modified peptides (RIPPs) (Arnison et al., 2013; Finking and Marahiel, 2004). 
NRPs are made by non-ribosomal peptide synthetases (NRPS), multi-enzyme complexes 
also organized in modules, where each module containing a set of enzymatic domains capable 
of recognizing and activating the substrate, delivering it to catalytic centres, where formation 
of the peptide bond occurs on an enzyme-bound intermediate. Therefore, in each module, three 
core enzymes are present: the A domain, which activates a specific amino acid and transfers it 
to the PCP (peptidyl carrier protein) domain, where it forms a thioester, and the C domain, 
which forms the peptide bond between the newly added amino acyl-ACP and the growing 
peptidyl unit. Additional domains may be present in each module for epimerisation, 
heterocyclisation or oxidation. NRPS biosynthesis usually yields macrocyclic structures, or 
dimers of identical structural elements. NRPS products have been key players in our 
antibacterial arsenal providing historical molecules as penicillin, our drug of last resort 
vancomycin, and one of the newest introductions, daptomycin. (Felnagle et al., 2008; 
Schwarzer et al., 2003) Examples of NRPS-produced compounds are shown in Fig. 1.5.
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Figure  1.4 - Examples of PKS metabolites from microbial source. 
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Adding one more level of complexity are the hybrid systems that bring together a PKS-I 
with NRPS. Usually these hybrid systems operate by adding a few amino acids to a polyketide 
backbone or, conversely, a few acyl units to a peptide backbone. The biosynthetic logics of 
PKS-I and NRPS are comparable, since they both involve the progressive elongation and 
processing of enzyme-bound intermediates, which facilitates a transition between NRPS and 
PKS modules. This flexibility is underscored by the fact that ACP domains in PKS-I are 
biochemically equivalent to the PCP domains of NRPSs and are utilized as carriers of 
biosynthetic intermediates. The NRPS- and PKS-derived portions of the final molecule can 
vary, and there are examples of molecules constituted mainly by their peptidic part with few 
units added by the PKS, like bleomycin A2, but also the opposite can occur as in epothilone, a 
polyketide that incorporates one amino acid (Fig. 1.5) (Du et al., 2000; Molnar et al., 2000). 
As mentioned, the other major class of peptide-based secondary metabolites is 
represented by the RiPPs. These molecules originate from a longer precursor peptide composed 
by an N-terminal leader peptide and a core peptide. The latter is post-translationally modified 
by dedicated enzymes, followed by proteolytic removal of the leader peptide and transport into 
its final, usually extracellular destination. According to their structural features, which in turn 
depend on the specific modifying enzymes, different classes of RiPPs exist, for example: the 
lanthipeptides (lanthionine containing peptides), with nisin, used in cheese manufacturing, as 
the most preeminent representative; or the Thiopeptides (characterized by several thiozole 
rings), for which thiostrepton, used in as a growth promotant, is a good example. It should be 
noted that seventeen additional classes of RiPPs have been documented (Breukink and de 
Kruijff, 1999). Examples of RiPPs are reported in Fig. 1.5. 
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Figure 1.5 – Example of compounds with antimicrobial activity from NRPs (Actinomycin), RiPPs (Nisin), and hybrid systems (Bleomycin A2). 
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The terpenes, a subclass of prenylipids, are a large and diverse class of naturally 
occurring organic chemicals (Nowicka and Kruk, 2010). Their activities span from anti-
parasitic and anti-microbial, to anti-inflammatory and immunomodulatory properties. These 
molecules are spread throughout a large portion of the animal kingdom with special emphasis 
in insects and plants. All together terpenes have become the largest group of natural products 
constituting about 60% of known natural products with artemisinin being a good example of 
terpenes’ value to today’s society (Ajikumar et al., 2008; Ishida, 2005; Tu, 2011).  Most are 
multicyclic structures that differ from one another usually in functional groups but also in their 
basic carbon skeletons (de las Heras et al., 2003). Examples of terpenes are reported in Fig. 
1.6. 
 
Figure  1.6 - Examples of biologically relevant terpenes 
Finally, adding to the cosmic amount of molecules produced by the previously 
mentioned routes there are other groups that have contributed antibiotics in current or past 
clinical use such as (Fig.  1.7): aminoglycosides, such as streptomycin; amphenicols such as 
chloramphenicol; or lincosamides, such as the semi-synthetic clindamycin. These molecules 
originate from other, specialized biosynthetic pathways that fall outside the scope of this 
dissertation. 
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Figure 1.7 - Examples of biologically relevant aminoglycosides (Streptomycin), Amphenicols 
(Chloramphenicol) and Lincosamides (Clindamycin) 
The mechanism of action of an antibiotic depends on the way it affects physiological 
processes within the target bacterial cell, which in turn results from which molecular target it 
binds to and how, a property that is intrinsically related to the chemical structure of the 
antibiotic. Resistance mechanisms that modify a cellular target prevent an antibiotic from 
binding to that target in a specific mode. These mechanisms confer to resistance to any 
antibiotic that binds to that same target in the same mode (e.g., in the same binding pocket) but 
not to other antibiotics that bind elsewhere on the same target. Similarly, resistance 
mechanisms that modify an antibiotic (for example, by hydrolysis or by acetylation) in order 
to be efficient, need to be highly selective for a particular chemical scaffold. As a consequence 
of the above, novel chemical classes of antibiotics, structurally unrelated to those in clinical 
use, have a high probability of bypassing current resistance mechanisms. [Resistance 
mechanisms based on export tend to be more promiscuous in terms of chemical class but less 
effective in the resistance level they confer] Hence, the search for new molecular structures is 
expected to unravel new mechanisms of inhibiting bacterial growth. 
A strategy that relies on Nature’s resources would seem the most reasonable approach 
to drug discovery. The richness and diversity of natural products has not yet ceased to amaze 
us (Harvey et al., 2015) (Walsh, 2003) (Strohl, 2000).  Among plants, fungi, and bacteria, 
Nature has a cornucopia of metabolite producers waiting to be screened that we have just 
started to explore. In fact, the theoretical chemical space is estimated to be greater than 1060 
molecules with 30 or fewer atoms other than Hydrogen (Bohacek et al., 1996). Which in turn 
could give some doubts on the probability of actually finding a new antimicrobial compound 
with the correct chemical features through this myriad of molecules. Furthermore, all natural 
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products are expected to have some biological activity, and indeed the high frequency in which 
these compounds are found when screening natural products shows that Nature is a rich and 
diverse source of compounds but also biased library towards biologically active compounds.   
Although plants and fungi play an important role in healthcare, this work will focus on 
the potential of bacteria. Earth belongs to bacteria, not humans. Through their metabolic and 
catabolic processes, these microorganisms control and sustain Life on Earth. Despite their 
omnipresence we still know little about these small creatures. In fact, it is estimated that 99% 
of the microbial flora is as yet uncultured under laboratory conditions. This is understandable, 
since culturing in the laboratory requires devising appropriate growth conditions (pH, 
temperature, oxygen levels, nutrient concentration, essential cofactors, etc.) that can vary 
greatly for different bacterial taxa. Furthermore, some of our basic techniques like autoclaving 
produce compounds (e.g. Hydrogen Peroxide) that selectively kill certain taxonomic groups 
(Lewis, 2013; Tanaka et al., 2014). But perhaps the most limiting factor is that we like studying 
bacteria in axenic cultures, a condition rarely occurring in Nature. In 2004, around five 
thousand species of bacteria were described (the genus of this work – Actinoallomurus – was 
formally described in 2009, see below) (Bull, 2004; MacNeil et al., 2001; Tamura et al., 2009). 
Despite these limitations, culture-independent techniques and dedicated isolation efforts are 
continuously expanding our knowledge. However, estimates about the actual number of 
existing bacterial species vary greatly from 104 to as many as 107 (Whitman et al., 1998). Since 
different isolates from the same species can produce different secondary metabolites, there is 
ample scope for bacteria to deliver a large number of additional bioactive products. The 
challenge now is how to effectively access this natural chemical diversity.  
 
1.3. Changing the screening paradigm  
1.3.1. The screening strategies 
Insanity has been defined as "doing the same thing over and over again and expecting 
different results” (Albert Einstein). This aphorism is certainly applicable to the most common 
approach employed in drug discovery, screening large collections of chemicals against a 
particular biological target, and especially to the approach universally employed during the 
golden era of antibiotic discovery: screening large collections of freshly isolated soil 
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microorganisms for their ability to inhibit growth of a relatively few target pathogens and keep 
expecting an infinite resource of novel chemical compounds. That is why it is imperative to 
change one or more of the screening conditions in order to increase the probability of finding 
new molecular structures (Donadio et al., 2010). 
In the early days of pharmacology, therapeutic drugs were obtained from medicinal 
plants exploiting thousands of years of traditional medicine. This was the case for aspirin, 
which was derived from the bark of the willow tree. As analytical chemistry, biology and 
pharmacology progressed, the discoveries went from the occasional serendipity (i.e. the 
discovery of penicillin) to a rational approach (cephalosporin was discovered as a solution for 
penicillin resistant infections) (Clever, 1999). 
At the beginning, drug discovery was essentially based on screening natural products, 
isolating the active ingredients and testing them for their ability to treat a given disease. 
Synthetic chemistry was mostly an aid in optimizing existing scaffolds against resistance 
mechanisms (e.g., analogues of penicillin that would be resistant to the action of known β-
lactamases) or in conferring more drug-like properties (e.g., transforming nalidixic acid into 
the fluoroquinolone class of antibiotics). The continuous progress in spectroscopy (NMR and 
MS) and separation techniques (HPLC) enabled determining the chemicals structures using 
increasingly lower amounts of natural products, making this approach the pillar of drug 
discovery by the pharmaceutical industry. 
In the early 1980s, the increases in computing power enabled a shift away from random 
searches to a “rational” computational approach to drug discovery, namely, computer-aided 
drug design. This shift was also possible thanks to significant advances in structural biology 
(and a growing number of solved 3D structures of biologically relevant proteins), an improved 
understanding of protein-protein interactions, and the identification of protein targets important 
for different pathologies. While there are a few successes of the  “rational drug design” 
approach (e.g., dorzolamide reached the market as a antiglaucoma agent in 1995 (Greer et al., 
1994)), this discovery approach performed surprisingly poorly and was supplanted by a return 
to the fundamentally empirical method of screening, albeit with important differences.  
By mid-1990’s a new strategy had taken over prompted, again, by new technological 
advances: combinatorial chemistry, laboratory automation and genomic sequencing. 
Combinatorial chemistry presented the opportunity of rapidly synthesising tens of thousands 
of compounds with a reduced effort, providing quick access to sensible libraries for screening. 
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Automation enabled the robotic handling of small amounts of liquids, enabling assays to be 
performed in small volumes in – originally – 96-well microtiter plates, which allowed increased 
throughput with a decreased use in reagents and chemicals. Finally, the ability to rapidly 
sequence whole bacterial genomes offered the possibility of rapidly accessing any target from 
any pathogen. At the same time, advances in the genetic manipulation of most bacterial (and 
fungal) pathogens enabled establishing the essentiality of any potential target, which had to be 
conserved in the desired spectrum of pathogens and absent, or significantly divergent, in 
humans. Such targets could then be expressed with a proper tag in a convenient host, single-
step purified by affinity chromatography and turned into powerful and miniaturized enzymatic 
assays. The scene was then set for rapidly screening every essential target in a given pathogen 
against synthetic and combinatorial libraries in a relatively short time. As mentioned above, 
this approach also delivered below expectations (and the investment made!).  
Science is a dynamic landscape that changes as knowledge is introduced and adapts to 
new discoveries. A great example of this feature is the case of the Lipinski’s rule of five. In the 
late 1990s Christopher A. Lipinski created a set of rules of thumb to help choose molecules 
that could have higher potential in terms of drug-likeness and oral availability (Lipinski et al., 
2001). These, shortly, consisted of: 
o No more than five hydrogen bond donors  
o No more than 10 hydrogen bond acceptors   
o A molecular weight under 500  
o A partition coefficient log P (a measure of lipophilicity) of less than 5 
Although these are still valuable guidelines, we are aware that these rules do not apply 
to every drug in the market. In fact, antibiotics like erythromycin do not fit completely to these 
rules and Lipinski himself had warned about this caveat. This represents another example on 
the power of million years of evolution for natural products, which have thus reached a degree 
of complexity that cannot be restricted to a set of rules devised for synthetic drugs. 
Therefore, a lack of truly effective screening alternatives, the availability of a large 
number of unexplored bacteria and the unusual chemical and biological of natural products 
make the latter source an attractive target for drug discovery.  
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1.3.2. Introducing elements of novelty 
One of the main issues with antibiotic discovery expeditions based on natural products 
is the probability of rediscovering known metabolites. This requires introducing one or more 
elements of novelty into the screening endeavour, which in turn requires an understanding of 
the screening approaches employed in the past. Most of the past screening efforts involved 
isolating, among bacteria, strains belonging to the genus Streptomyces from a variety of 
sources, growing them in nutrient-rich media, and testing the resulting cultures for the ability 
to inhibit growth of one or more pathogens relevant at that time. The compounds responsible 
for bioactivity were then purified by bioassay-based fractionation, characterized for their 
antibacterial properties and structurally elucidated. This approach introduced a number of 
biases, namely: i) the type of microorganisms isolated and screened; ii) the conditions under 
which those strains were grown; iii) the type of pathogens that were screened against; and iv) 
the requirement for growth inhibition. Overall, this approach favoured the discovery of 
compounds that were potent and/or were produced in high amounts. Therefore, an element of 
novelty could address any of the above biases. For example, it could involve the use of 
previously unexplored bacterial group; or it could involve growing known strains under 
conditions that trigger the expression of the several biosynthetic gene clusters (BGCs) present 
in their genomes and not expressed under routine cultivation conditions; or it could involve 
screening against pathogens that are of medical relevance today but not considered important 
few decades ago (e.g., Acinetobacter baumanii or C. difficile); or it could employ assays more 
sensitive than growth inhibition of a standard strain.  
An alternative, paradigm-shifting approach is the so called genome mining, in which 
genomic information is used as a starting point to identify metabolites predicted from the 
organization of the corresponding BCGs. If the strain does not normally produce the predicted 
metabolite, it can be engineered to do so by manipulating its regulatory circuits or the cluster 
can be moved and expressed in a heterologous host. While the genomic mining approach 
simultaneously addresses previous screening biases and it represents an enormous opportunity 
to unveil novel chemistry, awakening silent clusters is at the moment an ineffective trial and 
error procedure. For example, the most studied organism among actinomycetes, Streptomyces 
coelicolor is slowly delivering new chemical structures after the identification of the 
corresponding BGCs in its genome and thorough analyses of the metabolite profiles by 
different laboratories under a variety of conditions.   
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In the pursuit of my PhD program, it was decided to introduce an element of novelty 
by exploring different strains, namely a taxonomic group that had not witnessed extensive 
analyses of its secondary metabolites. Taxonomic diversity can be seen as a surrogate for 
chemical diversity (Jaspars and Challis, 2014; Kim et al., 2005).  The main idea is that 
organisms that have been subjected to different evolutionary pressures have developed unique 
biology to survive and secondary metabolites are also part of their biology. While horizontal 
gene transfer can blur this picture and lead to the transfer of BGCs between unrelated bacterial 
taxa, as it does occasionally with housekeeping genes, one would expect that, on average, the 
BGCs present in a given taxon would be more related to each other than to BGCs present in an 
unrelated taxon. Thus, there is a higher probability of discovering novel BGCs, and hence novel 
chemistry, by exploring novel taxa.  
Though we are aware of the universe of uncharacterized bacteria awaiting to be studied, 
we have also observed that production of secondary metabolites is not distributed equally 
amongst all species, with some groups – not surprisingly, those with large genomes – more 
prolific than others. Therefore, when endeavouring in a new expedition for bioactive natural 
products from new taxonomical groups it is important to select a taxon with a high potential to 
produce such compounds in order not to increase the probability of finding the desired 
compounds with a reasonable effort. A good example of a taxonomic group well known for the 
production of secondary metabolites is the phylum Actinobacteria, which stands out as being 
responsible for almost 9,000 molecules out of the 17,000 produced by microorganisms (Bull, 
2004; Goodfellow and Fiedler, 2010). Among them is the genus Streptomyces which is the 
most studied and the one that has contributed with the largest amount of compounds (Bull, 
2004; Goodfellow and Fiedler, 2010; Lazzarini et al., 2000; Pozzi et al., 2011; Stackebrandt et 
al., 1997; Tamura et al., 2009; Ventura et al., 2007; Watve et al., 2001). Previous reports have 
stressed the use of underexplored group of actinomycetes as an effective strategy to discover 
novel chemistry, an approach that has been recently reinvigorated by the results obtained from 
exploring unknown marine actinomycetes (Subramani and Aalbersberg, 2012). Moreover, drug 
discovery expeditions with new taxonomic groups have more than the obvious role of finding 
new drug candidates. The work goes beyond the screening itself, since it is also a 
characterization of the producer strains. For example, a significant amount of information is 
generated by simply recording which known metabolites are produced by the screened strains. 
This information will contribute to the better understanding of the chosen group, which can 
become an important factor for the success of posterior screening campaigns. In particular, this 
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work was designed to assess the metabolic potential of the genus Actinoallomurus while 
enriching the knowledge on this recently described group.  
 
1.3.3. The Genus of Actinoallomurus 
Associated to the Actinobacteria is the recently described genus Actinoallomurus, 
assigned to the family Thermomonosporaceae. This genus has been previously analysed in our 
laboratory and has showed a potential to produce different molecules (Pozzi et al., 2011). The 
genus Actinoallomurus was firstly described by Tamura et al. in 2009 while characterizing 
strains isolated from soil and dung samples collected in Japan (Tamura et al., 2009). Since its 
discovery at least eight new manuscripts reporting new entries in this genus were published, 
reporting the isolation of Actinoallomurus spp. as plant endophyte, from different soil samples 
and also from moss (Indananda et al., 2011; Koyama et al., 2012; Matsumoto et al., 2012; Pozzi 
et al., 2011; Thamchaipenet et al., 2010). 
Actually, the first description of Actinoallomurus spp. resulted from a reclassification of 
strains originally assigned to the genus Actinomadura. The new genus was named trying to 
differentiate a group of actinomycetes (Actino) that possess a different (allos) wall (murus), 
hence Actinoallomurus (Tamura et al., 2009). In fact, analysis of the cell wall components of 
the reclassified strains identified the presence of lysine in the peptidoglycan as a characteristic 
of Actinoallomurus. However, the structure of the peptidoglycan, including the position of 
lysine, has not yet been determined (Tamura et al., 2009). Fig.  1.8 contains a selected portion 
of a phylogenetic tree with some relevant genera appertaining to the order Actinobacteria. On 
the basis of the branching pattern, Actinoallomurus is in the same family as Actinomadura – 
Thermomonosporaceae (Bacteria; Actinobacteria; Actinobacteria; Streptosporangiales; 
Thermomonosporaceae). This proximity might indicate that, as the fellow taxonomical groups, 
it might also contain the genetic information for secondary metabolism as Actinomadura does, 
but because it is still relatively far from extensively studied genera, such as Streptomyces, it 
might provide a different set of bioactive compounds (Mariani et al., 2005; Venkateswarlu et 
al., 2005).  Actinoallomurus strains are slightly acidophilic, non-acid-fast, strictly aerobic 
actinomycetes that show extensive branching and non-fragmenting substrate hyphae with spore 
chains developing on the tips of the aerial mycelium (Inahashi et al., 2015; Mazzetti et al., 
2012; Pozzi et al., 2011; Pruesse et al., 2012).  
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 Figure 1.8 - Phylogenetic tree based on nearly complete sequences of the 16S rRNA gene. A – Phylogenetic analysis of the Thermomonosporaceae family. Adapted 
from (adapted from Wang, Y., et al., 2001)(Zhang et al., 2001)  B - Phylogenetic analysis of the Actinoallomurus genus (Adapted from Pozzi, R. et al., 2011) (Hou et al., 2012). 
Note how Actinoallomurus closely relates with Actinomadura which in turn belongs to the Thermomonosporaceae family.  
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The Actinoallomurus strains analysed in this work derive from the NAICONS strain 
collection, which contains about 45,000 actinomycetes. The library was created with an 
emphasis on strain diversification. During the last years of library creation (in 2003-2005), a 
16S-based isolation program was introduced, whereby morphologically different strains 
identified on isolation plates were systematically evaluated for phylogenetic novelty by 16S 
rRNA gene sequencing (Donadio et al., 2009; Monciardini et al., 2002). This endeavour rapidly 
yielded at five different groups, three of which were then formally described as Catenulispora, 
Actinospica and Rugosimonospora. Strains belonging to the groups originally dubbed "Alpha", 
and later established to coincide with Actinoallomurus, turned out to be relatively easy to 
isolate and, within one year, a collection of 1200 Actinoallomurus strains was isolated. Before 
the beginning of this study, an analysis of a small number of Actinoallomurus strains showed 
that at least 34 different phylotypes (Pozzi et al., 2011) were present within this taxonomic 
group, suggesting a substantial diversity in this genus (Busti et al., 2006; Donadio et al., 2010). 
Analysing the genus of Actinoallomurus thus brings one of the required elements of novelty 
previously mentioned for a successful screening program. 
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1.4. Hypothesis 
As discussed in the Introduction, only new classes of antibiotics, different from those in 
clinical use, can ameliorate the problem of antibiotic resistance. Because antibiotic 
development is a lengthy and costly process, it is essential that intellectual property rights are 
secured once an interesting compound is identified, which requires structural novelty. The 
underlying hypothesis of this work is that, by systematically screening a previously unexplored 
genus, new chemistry could be found. In this work, 200 independent isolated strains belonging 
to the genus Actinoallomurus will be cultivated, and their extracts screened for antimicrobial 
activity in order to understand at which frequency antibiotics are produced. Will the frequency 
be comparable to that of other known and well exploited actinomycete producers, such as 
Streptomyces, Amycolatopsis, Actinoplanes and the like, or will production of antibiotics be a 
rare event for Actinoallomurus? If Actinoallomurus does produce antibiotics at high frequency, 
are some classes of molecules produced more frequently than others? Are there metabolites 
that are encountered in different Actinoallomurus strains? How frequently are new molecules 
encountered? Answering these questions will help to understand the potential of 
Actinoallomurus as a source of new drug leads as well as basic aspects of its physiology under 
laboratory conditions. 
On the other side, the genome of Actinoallomurus will also be analysed to have insights 
into the number and types of BGCs it contains, and hence the type of chemistry that can be 
predicted. This analysis will thus complement the bioactivity-based screening and provide a 
complementary view of this genus.  
Therefore, the goal of this work can be divided in to two main objectives: 
 to verify the potential of a new taxon, specifically the genus Actinoallomurus, 
to deliver new chemical structures with antimicrobial activity and potential to become 
antibacterial drug candidates,  
 Increase the knowledge on the poorly characterized genus of Actinoallomurus 
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2. SCREENING ACTINOALLOMURUS 
2.1. Introduction 
In this work it was decided to analyse the recently described genus Actinoallomurus 
(Bacteria; Actinobacteria; Actinobacteria; Streptosporangiales; Thermomonosporaceae) 
which has showed to be a potential producer of bioactive compounds (Inahashi et al., 2015; 
Mazzetti et al., 2012; Pozzi et al., 2011; Pruesse et al., 2012). The genus Actinoallomurus fulfils 
some of the requirements to be used in a productive antibiotic discovery effort: it is a recently 
described genus with few reports in the literature, making it unlikely that this genus has been 
systematically screened in the past; it is related to known producers, being in the same family 
as Thermomonospora and Actinomadura, which makes it probable that strains belonging to 
this genus might contain several BGCs for different metabolites; and, last but not least, the 
NAICONS' strain collection includes about 1,200 strains belonging to this genus (Pozzi et al., 
2011) a sensible number for a screening endeavour. Other indirect but not exclusive evidence 
is its slow growth pace and the fact it presents a complex life cycle just like other known 
producers. 
 
Figure  2. 1 - Geographic origin and distribution of the soil sample where the strains used in this work 
were isolated from. 
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For my PhD work, 200 Actinoallomurus strains were randomly selected. Although this 
number is not large enough to draw conclusions, it is interesting to present the origins of the 
strains. The soil samples from which these strains were isolated came from different geographic 
locations as described in Fig.  2.1, where it can be seen that there is a high percentage of strains 
coming from European soil samples, especially Italy. Nonetheless, a significant number of 
strains were isolated from other continents, making the 200 strains set globally distributed 
(Pozzi et al., 2011).  Another analysed parameter is the type of environment from which these 
strains were isolated. Table 2.1 shows that the set under investigation includes strains isolated 
from a broad variety of environments, including densely vegetated areas (forest, semi-forest or 
woods), but also some harsh locations such as sulphur enriched craters of volcanic origin. It is 
also noteworthy the large amount of strains isolated from soils collected within the area that 
spawns the rhizosphere – one of the habitats from where the first strains were reported (Tamura 
et al., 2009). The data seems to indicate that Actinoallomurus is indeed a widespread genus 
able to colonize a broad range of environments. It would be interesting to confirm, in a future 
work, the relative abundance of this genus throughout the world. 
Table 2.1–List and relative abundance 
of the type of environment from which 
the Actinoallomurus strains screened 
in this work were isolated from 
High Altitude 3% 
Deep Soil <1% 
Semi forest 8% 
Woods 22% 
Agricultural Land 6% 
Forest 10% 
Not Described 15% 
Lawn 2% 
Rhizosphere 18% 
Inhospitable Terrain 3% 
Unspecified Soil 9% 
Freshwater 4% 
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2.2. Experimental Section 
Actinomycete strains and media. Actinoallomurus strains, which were isolated from 
soil samples across the world, are from the NAICONS strain library. Each strain was 
propagated on S1-5.5 plates (60 g/L oatmeal, 18 g/L agar, 1mL/L Trace Elements Solution) at 
30 °C for two to three weeks. From these plates, the grown mycelium was used to inoculate 
AF-A medium (10 g/L dextrose monohydrate, 4 g/L soybean meal, 1 g/L yeast extract, 0.5 g/L 
NaCl, 1.5 g/L  2-(N-morpholino)ethanesulfonic acid, pH adjusted to 5.6) in shake-ﬂasks.   After 
8 days in a rotatory shaker (200 rpm) at 30 °C, cultures were harvested.  
Antibacterial assays. Agar diffusion assays were prepared by inoculating 5x105 
CFU/mL in 15 mL of one of the two strains used in this work in Mueller-Hinton Agar media. 
After spotting 20 μl of the solution to test, plates were inoculated at 37ºC for 18-20 h. Strains 
used in this assay were Staphylococcus aureus ATCC 6538P and Escherichia coli L4242, an 
in-house ΔtolC mutant strain. All Minimal Inhibition Concentration (MICs) were determined 
by broth micro dilution in sterile 96-well microtiter plates according to CLSI guidelines, using 
Mueller Hinton broth (Difco Laboratories) containing 20 mg/L CaCl2 and 10 mg/L MgCl2 for 
all strains except for Streptococcus spp., which were grown in Todd Hewitt broth. Strains were 
inoculated at 5x105 CFU/mL and incubated at 37 °C for 20−24 h.  
Preparation of extracts. Three extracts were made throughout this work. Mycelium 
Extract(MycExt): A culture was centrifuged at 16,000 rcf for 5 min. The pellet was 
resuspended in 0.4 volume of ethanol and incubated at 55ºC for 1 h. The suspension was 
centrifuged once more (16,000rcf, 5 min) and the clear liquid transferred to a new tube and, 
unless stated otherwise, resuspended in 10% DMSO at 5x the original culture concentration by 
adding firstly the DMSO and only after the required volume of water. Clear Broth Extract: 
A culture was centrifuged at 16,000 rcf for 5 min. The pellet was discarded and 0.5x volumes 
of ethyl acetate was added to the cleared broth, mixing and then waiting until complete 
separation of the liquid phases. The organic phase was transferred to a new tube and further 
0.5 volumes of ethyl acetate was added to the exhausted broth, which was extracted as before. 
«e two organic phases were combined, dried and resuspended at 5x the original concentration 
in 10% DMSO adding it before the water. Creating two Extracts the organic phase, the Clear 
Broth Extract_EtoAc (CBE_EtOAc) and the aqueous phase, the Clear Broth 
Extract_Exhausted (CBE_Exh).  
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Biomass analysis. Biomass accumulation was measured as percent packed mycelial 
volume (PMV%) after centrifuging cultures for 10 min at 3000 rpm in a graduated tube.  
Analytical procedures.  For monitoring metabolites production analytical HPLC was 
performed on Shimadzu Series 10 spectrophotometer (Kyoto, Japan), equipped with a reverse-
phase column, Lichrospher RP-18, 5μm, 4.6 x 125 mm (Merck, Darmstadt, Germany), phase 
A as 0.1% trifluoroacetic acid (TFA)in water, phase B as acetonitrile, and the flow rate was 1 
mL/min.  The program consisted of a linear gradient from 10% to 36% phase B in 5 min; from 
36% to 50% phase B in 7 min; and from 50% to 80% phase B in 1 min; followed by a 4-min 
isocratic step at 80% phase B and column re-equilibration. UV detection was at 230 and 270 
nm. LC-MS analysis were performed with an Agilent 1100 series liquid chromatographer 
equipped with a Ascentis express Supelco RP18, 2.7 µm, 50 x 4.6 mm column eluted at 1 
mL/min at 40 °C.  Elution was with a 10 min multistep program that consisted of 5%, 95%, 
100%, and 5% phase B at 0, 6, 7, and 7.2 min, respectively (phases A and B were 0.05% TFA 
[v/v] in H2O and CH3CN, respectively) with detection at 220 nm.  The effluent from the column 
was split 1:1 into a photodiode array detector and into the ESI interface of a Bruker Esquire 
3000 plus ion trap mass spectrometer.  Mass spectrometry analyses were performed using as 
sample inlet conditions: sheath gas (N2) 50 psi, dry gas 10 L/min, capillary heater 365 °C; as 
sample inlet voltage settings: positive polarity, capillary voltage –4000 V, end plate offset –
500 V; as scan conditions: maximum ion time 200 ms, ion time 5 ms, full micro scan 3; as 
segment: duration 10 min, scan events positive (100–2400 m/z).  1H-NMR spectra were 
measured in CD3CN-D2O at 298K using an AMX 400 MHz spectrometer.  Chemical shifts are 
reported relative to D2O (δ 4.79 ppm). 
Strains and Media for C. elegans work. The strain of Caenorhabditis elegans used 
throughout this work was the AU37 strain [glp-4(bn2) I; sek-1(km4)] which has a temperature 
sensitive defect in germ-line proliferation during larval development. Defect can be reversed 
by shifting worms from restrictive (25ºC) to permissive temperature (16ºC), plus this strain has 
also a knockout at the sek-1 gene which is encodes a mitogen-activated protein (MAP) kinase. 
This deletion disrupts part of the innate immune response of the strain which renders it more 
sensitive for pathogen infection(Kim et al., 2002).  The E. coli strain OP50 was used a normal 
food source for the strains while the strains S. aureus ATCC 8325-4 and L100 (Naicons 
Collection) were used to perform pathogenic infections. The C. elegans was maintained on 
Nematode Growth Medium agar in Petri’s plates (Before Autoclaving: NaCl 3g/L; Agar 17g/L; 
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Peptone 2.5 g/L. After Autoclaving add: 1ml of 1 M KPO4 buffer pH 6; 1ml of 1M MgSO4; 
1ml of 5 mg/mL of Cholesterol in ethanol). For liquid Cultures S medium was used (5,85g/L 
NaCl; 1 g/L of K2HPO4; 6 g/L KH2PO4; 1ml of 5 mg/mL of Cholesterol in ethanol; 10ml of 1 
M Potassium Citrate solution - 20 g/L citric acid monohydrate and 293.5 g/L of Tripotassium 
Citrate monohydrate; 10 mL of Trace Metals Solution; 3 ml of 1M CaCO2).  The transfer and 
cleaning process of the nematodes was done using the M9 buffer (3 g/L K2HPO4; 6 g/L 
Na2HPO4; 5 g/L NaCl; 1ml of 1M MgSO4). Growth of C. elegans. The NGM media was 
previously inoculated with a layer of E. coli OP50 and then the nematodes were place onto it. 
Worms were transferred to a new plate every three to four days, depending on the quantity of 
E. coli still present in the plate. Transfer of C. elegans. A plate of fully 2nd and 3rd generation 
worms would be washed with M9 buffer, creating a suspension of bacteria and worms that was 
left to deposit for one minute. The clear broth was then replaced for new M9 buffer and the 
suspension dispensed through new NGM plates. Synchronizing C. elegans.  After 3 to 4 days 
of incubation of C. elegans at 16ºC a plate of fully 2nd and 3rd generation worms with the 
presence of eggs should be visible at a light microscopy. After adding 2 mL of M9 buffer and 
wash the worms onto to a 1,5 mL Eppendorf, centrifuge at 1300 g for 1 minute. Discard the 
supernatant and add 550 µL of water, 200 µL of Household bleach, and 250 µL of 2M NaOH. 
Mix gently and vortex occasionally until the worms disappeared. Centrifuge at 1300 g for 1 
minute, Discard the Supernatant and add 1 mL of M9 buffer, repeat the last two steps 3 times. 
On the last wash leave about 250 µL of M9 buffer and incubate the Eppendorf at 16ºC for 30 
hours. Disperse the suspension in new NGM plates with E. coli, incubate at 25ºC for 48 hours. 
At this point the worms are sterile, all at the same growth stage and ready to be used.  
2.3. The screening strategy 
Since Actinoallomurus is an unexploited genus, the simplest way to evaluate its 
potential to produce new antibiotics would be to use simple, phenotypic assays that 
simultaneously can detect an activity against many different targets: i.e., growth inhibition of 
one or more test strains. To this end, I decided to use Staphylococcus aureus, a Gram-positive 
pathogen, and E. coli, a Gram-negative. However, since Gram-negative bacteria are usually 
insensitive to many antibiotics because of the low permeability of their outer membrane, I 
selected as test strain a mutant lacking TolC, the major proteins involved in the expulsion of a 
number of toxic compounds (Wandersman and Delepelaire, 1990). I decided to test for 
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antibacterial activity three different types of culture extracts: Mycelium Extract – MycExt – 
and two extracts resulting from ethyl acetate extraction of the clear broth - CBE_EtOAc and 
CBE_Exh (see Materials and Methods). There have been reports of using prefractionated 
extracts for screening assays. These are obtained by resolving whole culture extracts in 
different fractions, in order to afford a more predictable (because of less complex samples) 
biological profiling before focusing on isolating and characterizing the active compounds 
(Wagenaar, 2008). However, since the purpose of my project was to rapidly identify the 
chemical nature of the active compounds, I preferred not to invest significant resources on 
preparing a prefractionated library and tested instead the extracts mentioned above.    
Once a positive extract is identified, the next step is to understand the chemical nature 
of the active molecule(s). This is achieved by resolving the extract in 30 different HPLC 
fractions, concentrating each fraction to a testable volume and identifying the fraction(s) 
associated with the original antibacterial activity. While the extract is fractionated, information 
is acquired on the UV spectra and MS peaks of each component of the fractionated extract. 
Then, the active fraction(s) can be associated with the presence of m/z ratios, MS fragmentation 
patterns and specific chromophores that help in database searches for enabling structural 
hypotheses on the type of compound(s) responsible for the activity. This process, designated 
as "dereplication", is an essential part of natural product screening and requires access to 
dedicated databases. Indeed, many large companies involved in microbial product screening 
created their own databases covering products described in the scientific and patent literature 
over several decades. One such database was available for my project, which reports 
information about 27,000 compounds of microbial origin, including – when known – the 
identity of the producer strain, molecular weight, empirical formula, UV maxima and 
biological activity of the compound. If the properties of an active compound identified in the 
screening do not match any of those described in the database, the compound is likely to be 
novel and worth of further investigation. In my project, a "hit" was designated as any compound 
endowed with antibacterial activity against at least one of the tested strains which was likely to 
be novel. According to this definition, extracts containing known compounds of whose activity 
was lost upon fractionation were not further investigated.  
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From a hit to the beginning of a lead optimization process lies a very personalized path 
of chemical and biological characterization to better understand the molecule and its activity. 
Each molecule has its own set of properties that needs to be addressed in a particular way. 
Discovering new molecules is a partnership between chemists and biologists that correlates 
biological activity and chemical proprieties, associated with preliminary structure activity 
relationship studies. This part has only been marginally addressed during my project (see 
Chapter 1.3.1). The whole screening process is described in Fig 2.2. Although the flow chart 
represents useful guidelines for the discovery process, an effective progress requires often some 
iteration of those steps and/or exploration of alternative routes. 
2.4. Screening Overview 
As mentioned earlier a pool of slightly over 200 strains was selected for antimicrobial 
screening. All strains were processed under the same conditions and yet, without any 
customization of the fermentation conditions, 104 out of 232 strains produced an extract that 
inhibited the microbial growth of S. aureus and, within those, 17 also prevented growth of the 
ΔtolC E. coli strain. As expected, the geographic origin of the active strains was scattered 
around the world in a manner that reflected their relative abundance (data not shown). Note 
that these 232 strains include 13 strains that were screened before the beginning of this project. 
While it is unrealistic to expect that 104 active strains will translate into 104 different and novel 
Selecting Library
Handling Library 
units
Screening assay Positive hits
Fractionation
Chemical 
analytical tools
Database 
mining
Biological and 
Chemical 
Characterisation
Selecting best 
Lead candidate
Figure  2.2 – Workflow of the High Quality Strategy adopted in this work. 
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active compounds, the high frequency of active strains supports part of the premise of this 
work, that taxonomical groups related to known producers have a high probability to produce 
active metabolites as well.  
The other important point to address is the understanding of how many of these strains 
do present new structures and how many produce already documented metabolites.  While 
screening 200 strains and characterizing some of the novel bioactive compounds they produced 
represented a realistic PhD project, the high frequency of positive extracts prevented analysis 
of every active metabolite from all active strains. However, to our understanding it was more 
important to characterise selected new compounds than to analyse superficially the 
metabolome of Actinoallomurus.  
Table 2.2 list all the strains that upon activity testing inhibited antibacterial growth. In 22 
cases the 16S rDNA gene was partially sequenced and a phylotype was given with nine of the 
previously 37 observed represented in this table. The third column list the Active Extract, as 
mentioned previously three different extracts were made and tested and the bioactivity was 
usually spread in more than one extract. However, for a matter of simplicity only the extract 
with the Higher inhibition halo was listed. On the forth column a qualitative evaluation of the 
intensity of the signal is given, which can be translated by the wideness of the inhibition halo 
just as explained in the footnotes of Table 2.2. Finally, a note on the type of metabolite 
identified from each strain is also given. When a compound was identified its name is provided 
(45 cases from which 12 were analysed previous to my arrival), when the identification of the 
compound was halted or not even started an acronym was given explaining the main reason for 
the interruption (See Chapter 2.4.1).  
     
Table 2.2 – The set of Actinoallomurus strains screened at Ktedogen up to September, 2015. 
When available, information is also provided on phylotype, active extracts, signal intensity and 
identified metabolite 
Strain ID Phylotypea Active Extractb Signal intensityc Compoundsd 
145113 Alp4 MycExt* ++ NAI-113d1 
145114 Alp4   Pradimycin 
145206 Alp35 CBE_EtOAc  NAI-113 
145219    CycloPhe-Leu 
145226 Alp24 CBE_EtOAc  Benanomycin 
145250 Alp22 CBE_EtOAc  Coumermycin 
145260 Alp22 CBE_EtOAc  Pyrrolosporin 
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145318    Pradimycin 
145414 Alp6   NAI-414 
145519 Alp22   Coumermycin 
145527 Alp36 MycExt ++ LAF 
145529 Alp37 CBE_EtOAc* + Allocyclinone 
145530 Alp24 CBE_EtOAc + Allocyclinone 
145531  CBE_EtOAc + LOW 
145532  MycExt + LOW 
145534 Alp24 CBE_EtOAc* ++ Allocyclinone 
145535 Alp24 CBE_EtOAc* + Allocyclinone 
145536  MycExt + NC 
145537  MycExt + NC 
145538 Alp24 MycExt* ++ Allocyclinone 
145539  CBE_EtOAc + NC 
145541 Alp24 MycExt + Allocyclinone 
145542 Alp24 MycExt* + Allocyclinone 
145543 Alp24 CBE_EtOAc* + Allocyclinone 
145544 Alp24 MycExt* + Allocyclinone 
145546 Alp24 CBE_EtOAc* ++ Allocyclinone 
145547  MycExt ++ NC 
145548  CBE_EtOAc + NC 
145550  CBE_EtOAc + NC 
145552  CBE_EtOAc + NC 
145553  CBE_EtOAc + NC 
145554  MycExt* ++ NAI-823 
145555  CBE_EtOAc + LOW 
145557  CBE_EtOAc + NC 
145559  MycExt ++ NC 
145610  CBE_EtOAc + NC 
145613  MycExt + NC 
145617  CBE_EtOAc + NC 
145626  CBE_EtOAc ++ NC 
145633  MycExt + New Macrolide a1 
145635  CBE_EtOAc + NC 
145638  MycExt ++ NC 
145639  CBE_EtOAc +++ NC 
145640  MycExt ++ NAI-107 
145641  CBE_EtOAc ++ NC 
145644  MycExt + NC 
145645  MycExt + NC 
145646  MycExt ++ NYC 
145649  CBE_EtOAc +++ Polyether 
  
34 
 
145654  MycExt; + NC 
145656  CBE_EtOAc ++ Polyether 
145663  MycExt + NC 
145665  CBE_EtOAc +++ Polyether 
145669  MycExt + LOW 
145672  MycExt + NC 
145673  MycExt + NC 
145676  CBE_EtOAc ++ Polyether 
145677  MycExt ++ LA 
145689 Alp9 MycExt* +++ Allocyclinone 
145695  CBE_EtOAc ++ NC 
145698 Alp9 CBE_EtOAc* +++ Allocyclinone d1 
145699 Alp7 MycExt ++ NAI-107 d1 
145705  CBE_EtOAc* +++ LAF 
145707  MycExt + LA 
145709  CBE_EtOAc + NC 
145711  MycExt ++ 
New Halogenated 
quinone 
145712  CBE_EtOAc* ++ LAF 
145713  MycExt* ++ LA 
145716  CBE_EtOAc ++ LA 
145722  MycExt +++ NC 
145723  MycExt +++ NC 
145724  MycExt + NC 
145726  MycExt + NC 
145754  CBE_EtOAc* ++ NAI-113 
145757  MycExt +++ Polyether 
145758  CBE_EtOAc ++ NC 
145763  MycExt ++ NC 
145770  MycExt  NAI-770 
145772  CBE_EtOAc + NC 
145778  MycExt +++ Polyether 
145779  MycExt +++ Polyether 
145802  MycExt +++ NAI-823 
145805  MycExt + LOW 
145806  MycExt + LOW 
145807  MycExt ++ NC 
145808  CBE_EtOAc ++ WIP 
145809  MycExt ++ LAF 
145811  MycExt +++ NAI-823 
145814    Pyrrolosporin 
145816    NC 
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145817    Octacyclomycin 
145823  MycExt +++ NAI-823d1 
145824  CBE_EtOAc ++ NC 
145828  CBE_EtOAc ++ LOW 
145829  MycExt ++ NC 
145830  MycExt + LOW 
145831  MycExt +++ Polyether 
145832  MycExt +++ NC 
145833  MycExt ++ NC 
145835  CBE_EtOAc ++ Coumermycin 
145837  MycExt + LOW 
145838  CBE_Exh +++ NC 
145841  MycExt* +++ NAI-823 
145846  MycExt +++ NC 
a - Phylotypes were assigned using the method described in Pozzi, R., et al. 2009 
b  - Only the most active extract is listed inthis table, which was the one ued for HPLC fractionations. Strains marked with * are active against S. 
aureus and E.coli ∆tolC otherwise activity was observed only against S. aureus 
c - + - Growth inhibition halo < 15mm; ++ - Growth inhibition halo > 15mm; +++ - Growth inhibition halo > 25mm 
d - LOW – Low Activity LA – Lost Activity LAF – Lost Activity upon Fractionation NC – Not yet Characterized; Metabolites were characterized 
by MS, UV; di – also confirmed with NMR analysis 
Strains in between dotted lines were characterized before the beginning of this project.  
  
 
As mentioned before, it would not be possible, within the time frame of this project, to 
ascertain every single active compound produced by 104 active strains. Actually, active 
compounds are often produced as a family of related molecules, the so-called complex, and 
characterization of the major congeners present in a complex further complicates this task. For 
example, identifying the active compounds from strain ID145698 involved structural 
elucidation of the four major components of the allocyclinone complex (see Chapter 4). Table 
2.2 lists a number of cases where, although structural elucidation has not been completed, 
dereplication has failed to identify known compounds with a similar molecular weight, MS/MS 
fragmentation, UV maxima and activity spectrum, which provides a high degree of confidence 
about the novelty of the corresponding molecule(s). To increase the throughput, active extracts 
were prioritized on the basis of their potency (i.e. inhibition halo), antibacterial spectrum and 
ease of purification of the active compound(s). Extracts that did not reconfirm antibacterial 
activity or presented a profile typical of known classes (e.g. polyethers) were not further 
investigated. When a metabolite matched known molecules by at least two parameters, no 
NMR confirmation was sought. Although we are aware of the possibility that, by doing so, we 
might have ignored a few new compounds, we decided to focus on those molecules that had a 
high probability of being novel and structurally interesting. Some examples of Actinoallomurus 
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metabolites with a high probability of having the identities assigned in Table 2.2 are described 
herein.  
2.4.1. The universe of the unknown 
Within the universe of the 50 strains with uncharacterized metabolites there are 
different categories. An extract may have been deprioritized for different reasons: the activity 
was not confirmed on subsequent fermentations (LA in Table 2.2); no active fraction was 
observed after fractionation (LAF in Table 2.2); or the observed inhibition halo was smaller 
than 15 mm, an empirical threshold set after observing that extracts with lower inhibition halos 
were unlikely to yield activity after fractionation (e.g., activity might get dispersed in several 
fractions), and thus set to low priority (LOW in Table 2.2). Those extracts that did not fall into 
the LA, LAF or LOW categories are marked as not yet characterized (NC in Table 2.2), and 
they actually represent the majority of them. From the strains with NC extracts, ID145633 and 
ID145808 stand out as producers of two unrelated new macrolides whose characterization 
could not be completed before the end of this project. 
2.4.2. Polyethers from Actinoallomurus 
Throughout the work several strains presented large inhibition halos against S. aureus. 
As explained below, these compounds were dereplicated as polyether antibiotics. Polyether 
antibiotics are produced by PKS-I and show a broad set of bioactivities in addition to 
antimicrobial (e.g. coccidiostatic, anticancer, etc.) The antimicrobial activity of polyethers is 
strictly connected to their ability to insert into cellular membranes and alter transport of metal 
cations, which leads to changes in the osmotic pressure inside the cytoplasm and cell death. 
(Rutkowski and Brzezinski, 2013) Although there are over 120 reported polyethers in the 
literature, this mechanism of action has been studied on a limited number of molecules and 
little is known on how to make polyethers more selective towards a particular cell type. This 
diminishes the interest in pursuing polyethers as understanding their value requires complex 
testing. In fact, to our knowledge no polyether has been shown to have in vivo efficacy for 
treating bacterial infections. (Kevin Ii et al., 2009) These limitations led us to abandon further 
analysis of any molecule likely to be a polyether.  
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Table 2.3 - List of polyether 
producing strains, tentative mass 
value along with confirmation of 
activity by fractionation 
 
Tentative 
m/z+ a 
Fractionationb 
145554 953 Yes 
145649 918 No 
145656 936 No 
145665 923 No 
145676 904 No 
145757 909 Yes 
145770 953 No 
145778 809 No 
145779 909 No 
145802 914 No 
145811 909 No 
145823B 914 Yes 
145831 884 Yes 
145841 914 Yes 
a – PUTATIVE MASS VALUE WITH ON POSITIVE 
CHARGE 
b – CONFIRMED BY NMR 
Work performed previous to the beginning of this project led to the characterization of 
the new polyethers NAI-823 and NAI-770 (work by Dr. Marianna Iorio - data not published). 
This experience was instrumental in devising a simple way to tentatively recognizing 
polyethers on the basis of their chemical and biological profiles: large inhibition halos of S. 
aureus with no or little activity against E. coli ΔtolC; no or limited UV absorption; high 
retention times on reverse phase HPLC; and, diagnostically, formation of Na adducts upon MS 
analysis with a characteristic loss of 14 (from a leaving methyl group) and 62 amu (loss of a 
carboxylic group). Active compounds presenting all these characteristics were categorized as 
polyethers and their analysis interrupted. Table 2.3 presents the strains producing compounds 
that had these characteristics and the m/z+ value of the most abundant congener of each strain.  
As an example, a large growth inhibition halo against S. aureus was identified from 
mycelium and ethyl acetate extracts of strain ID145757. The mycelium extract – the most 
active extract - was fractionated and each fraction tested for antibacterial activity. Growth 
inhibition was observed for fractions collected at high retention times, eluting in the presence 
of at least 60% of organic phase. The active fractions presented no UV absorption and m/z+ 
values between 909 and 938 (See Fig.  2.3). All these tentative masses presented the similar 
fragmentation patterns with characteristic losses of 14, 23, and 62. 
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Figure 2.3 – LC-MS of the mycelium extract of strain ID145757. Mass fragmentation pattern of the 
m/z signal at 909 (M+H)+ corresponding to polyether. 
The strains listed in Table 2.3 could potentially be producing a new entry in the 
polyether family (the m/z values did not match any of those present in the literature), although, 
without a confirmation through NMR, we cannot be sure be sure those molecules are actually 
polyethers and how different they are from known molecules. Nonetheless, those strains – and 
perhaps Actinoallomurus in general – may represent a valuable resource to explore new 
chemical space within the polyethers.   
2.4.3. The case of coumermycin 
The family of coumarin antibiotics is a successful member from the realm of natural 
products that actually made into the market as novobiocin, which was used to treat bacterial 
infections due to Gram-positive bacteria. It acts by targeting bacterial DNA gyrase 
(Montecalvo et al., 1995). Coumermycin is another member of the coumarin family that 
presents higher antibacterial activity than novobiocin.  
During the screening exercise we came across with strain ID 145835, whose ethyl acetate 
extract presented an inhibition halo of around 20 mm against S. aureus. The corresponding 
active fractions showed an MS signal of 1108 m/z+, associated with maxima at 220, 270, and 
340 nm. The MS/MS pattern of this compound matched that of pure coumermycin A1 that, 
during negative electrospray ionisation, fragments at the glycosidic, amide and ether bonds, 
producing ions at m/z- 1108, 1001, 620, 487 (Weinstein and Wagman, 1978; Wolpert et al., 
2008). Fig.  2.4 summarizes these data.  
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Figure  2.4 – UV and MS analysis of Mycelium extract from strain ID 145835 with chemical features 
equal to those of Coumermycin. See text for details. 
Also in this case, previous experience helped. Indeed, previous to this work, another 
scientist from the team (Dr. Matteo Simone) had previously characterized coumermycin from 
other Actinoallomurus strains, confirming its identity by 1H NMR and 13C NMR analyses, 
(Veneziani, 2009-2010) while production of coumermycin A2 had been reported previously 
(Pozzi et al., 2011).  Consequently, strain ID145835 was identified as a putative producer of 
coumermycin A1. The Actinoallomurus strains found to be producing coumermycin-related 
molecules are described in Table 3.4. 
Table 2.4 –Summary of the analysis done on the strains producing coumermycin 
STRAIN 
ID 
Tentative m/z+ Fractionation NMR Compound 
145250 1083 Yes Yes Coumermycin A2 
145519 1109 Yes Yes Coumermycin A1 
145835 1109 Yes No Coumermycin A1 
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2.5.  Another Screening Tool 
2.5.1. Rationale 
After realizing the enormous potential of Actinoallomurus for the production of 
bioactive compounds it was clear that it would not be possible to ascertain the bioactive 
compounds for all the positive extracts. Therefore, I decided to explore other techniques that 
would allow filtering the positive hits and focus only on those that showed a potential for 
further development. This requires extracts to be evaluated in a more complex environment 
than a Petri dish. Hence, the choice was on exploring a miniaturized infection model to 
establish potential efficacy of extracts. Several model organisms are available to develop these 
kinds of assays, and I decided to explore Caenorhabditis elegans as the host for the infection 
model. Since this expertise was not available at Ktedogen laboratories, I decided to resource to 
more experienced facilities such as Professor Anders Løbner-Olesen’s research group at the 
University of Copenhagen, Department of Biology, another beneficiary in the TRAIN-ASAP 
project. To support my initiative in Copenhagen I successfully applied for support by FEMS, 
through a FEMS Research Grants application and spent two months [March-May 2014] in 
Copenhagen. One of the requirements of a granted fellowship is the delivery of a report 
describing the results achieved throughout that period of time. This report includes all the main 
achievements of that period and was added at this point to show the work performed in 
Copenhagen. 
 By the end of the first half of 20th century, antibiotics held a great premise regarding 
the eradication of infections as major health threat and by the mid-1980s infectious diseases 
were considered virtually conquered as antibiotics kept being introduced into clinical practice 
(Coates et al., 2011; Davies and Davies, 2010; Powers, 2004).  Antimicrobial agents are one 
of the measures that have done more to improve public health in the last 50 years. However, in 
this very success lies also the major problem, the overuse of antibiotics has created a formidable 
selective pressure. We are now witnessing the increase of drug-recalcitrant bacteria, proving 
that, in these past few years, a war against infectious agents is far from over and showing that 
investment in this area should not be disregarded (Wise, 2002).  
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Despite substantial effort, the combination of genomics, high throughput screening and 
chemical libraries have not lived up to its promise:  although molecules with high target affinity 
in vitro were found, they failed to deliver the same results in more complex environments, such 
as in vivo testing or even whole cell experiments. In contrast, microbial products have been 
extremely successful in providing existing antibiotics. In this case however, effective screening 
strategies must be implemented to reduce the rediscovery of known compounds while 
increasing the probability of finding new molecules with efficacy against bacterial cells but 
lacking undesired effects on eukaryotic systems (Donadio et al., 2010; Monciardini et al., 
2014). 
One possible source to enhance the antibacterial arsenal is to look on what Nature has 
been using to solve the very same problem. My PhD project is part of a discovery program 
designed to assess the metabolic potential of the recently described genus Actinoallomurus. 
The schedule of work includes small-scale fermentations (from 200 strains) followed by 
bioactivity testing. Positive samples are then subjected to a combination of a bioassay with 
chemical analysis to determine the novelty of the active compounds. However, the screening 
strategy plays an important role in selecting the most promising antimicrobial candidates. 
Whilst traditional in vitro and whole cell drug screens are acknowledged as the established 
paradigm for identifying antimicrobial molecules, the whole animal approach allows for early 
and direct assessment of in vivo drug efficacy, thus, eliminating compounds that are toxic to 
the host or with poor pharmacokinetic properties. It is for these reasons that complementing 
work done in vitro with an in vivo analysis could lead to a set of new antimicrobial candidates 
that do have the potential to actually succeed as new antibacterials. 
In order to introduce a screening tool at an early stage of the discovery process, it is 
important to maintain a relatively high throughput and low costs. Hence, one would need the 
simplest differentiated organism, small enough to be handled in large numbers, easy to 
cultivate, with a short life cycle and with a relevant amount of biological processes conserved 
with other higher organisms (Segalat, 2007). Caenorhabditis elegans is a promising candidate 
fitting all the criteria mentioned above, the fact that a remarkably large number of human 
pathogens, including the Gram-negative Pseudomonas aeruginosa and the Gram-positive 
Staphylococcus aureus, can infect and kill this nematode, makes it a versatile platform for drug 
discovery (Tampakakis et al., 2008).   
  
42 
 
C. elegans model as a tool for drug discovery has been developed within the last decade 
with the first screen for antibacterial agents active against Enterococcus faecalis being reported 
in 2006 (Moy et al., 2009) and a subsequent screen that expanded the model also to Gram 
negatives (Durai et al., 2013). All those developments are transforming this nematode in a 
widely recognized assay amenable tool. 
2.5.2. Evaluation of the tool 
The main goal of this project was to learn the techniques for a further development of 
an assay to pinpoint the microbial extracts containing a compound able to rescue C. elegans 
previously infected with S. aureus.  Hosted in the University of Copenhagen, Department of 
Biology, I had the opportunity to work with Professor Anders Løbner-Olesen’s research group. 
Although mainly focused in cell cycle control of DNA replication in bacteria, they also perform 
small molecule screening in vitro and in vivo, using C. elegans as an animal model. Their last 
work on screening and analysing the effect of harmane in C. elegans reported the increase of 
life span of these nematodes when treated with this alkaloid (Jakobsen et al., 2013). The assays 
were all made in solid media using a pure compound instead of a mix of natural products such 
as the ones I work with at Ktedogen. 
Starting from the screening assay already established, two objectives were set for this 
assay improvement. Firstly, to transfer the assay from the solid media platform into a liquid 
one. Hence it would be important to verify the best infection conditions as well as the effect of 
solvents in the nematode’s life span. Secondly, to assess the feasibility of using complex 
mixtures, such as microbial extracts, as natural product libraries. Mainly by verifying if the 
microbial extracts could in fact rescue infected nematodes. 
The Liquid media assay. In order to synchronize AU37 worms, eggs from gravid adults 
were isolated and then hatched overnight in M9 buffer, L1-stage worms were plated onto lawns 
of E. coli on nematode growth medium agar media. Worms were grown to sterile, young adults 
by incubation at 25°C for 48h, washed off the plates with M9 buffer and transferred to 96 well 
plate. The first part of this process was to verify that microbial broth extract prepared would 
not disturb the nematodes’ viability. 
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Figure 2.5 - % of nematodes’ survival with different methods of infection.  liq-02 – nematodes fed with 
an anaerobic overnight culture; plate-liq-o2 – nematodes infected in a s. aureus plate and then incubated in an 
anaerobic o/n culture; liq – nematodes fed with an aerobic overnight culture; plate-liq – nematodes infected in a 
s. aureus plate and then incubated in an aerobic o/n culture: ampicillin and nai-107 were added as positive controls 
at 4 µg/l. 
To this point, 1% DMSO was confirmed as the best solvent to use to allow complete 
solubilisation of the complex mixture without interfering with the survivability of the 
nematodes. The infection with S. aureus was performed by feeding S. aureus on a solid media 
and then transferred into the liquid stage, or by directly feeding the nematodes with the 
pathogen on the liquid media. On this case, the liquid culture of S. aureus was prepared by 
fermenting an overnight culture aerobically and anaerobically. The presence/absence of oxygen 
could be a triggering factor for virulence factors and enhance the pathogenicity of S. aureus. 
Figure 2.5 shows the most effective method, achieved by feeding the nematodes with 
S. aureus on plate first and then with an overnight culture of the same bacteria grown 
anaerobically. However, the difference between the procedure just mentioned and direct 
incubation with S. aureus from an aerobic overnight culture is not significant which led me to 
select the latter as the method of infection due to practical reasons. From this moment on, 
synchronized nematodes were infected with S. aureus by feeding, the previously prepared 
overnight culture (in aerobic conditions), directly in the liquid media. Finally, it was also 
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observed that the survival of the nematodes was greatly influenced by the shape of the well 
were the assay was performed. Graph on Fig.  2.7 shows how nematodes do not survive more 
than 72 hours in U-shaped wells while they were able to live for over 120 hours in flat bottom 
wells. 
A possible explanation to the difference in surviving is the accumulation of bacteria 
and worm on the deepest point of U-shaped well and consequent death by asphyxiation. 
Although it was not ascertained the main reason for the nematode’s death it is also worth 
mentioning that the assay while using U-shaped 96 wells plates has a higher reproducibility 
rate. At this point, it was decided to use U-shaped 96-well plates to assess the microbial 
extracts. 
These extracts were prepared from 10-days cultures of 10 Actinoallomurus strains: from 
each strain an extract was obtained from the mycelium and two from the supernatant. All 
together 30 extracts were prepared and tested. These were previously tested for in vitro activity 
against S. aureus and selected in such way that I could test in this assay active and inactive 
samples from all sources. In addition, some of these metabolites are still unknown but others 
were already dereplicated. The goal here was to evaluate the feasibility of this assay more than 
the identification of the active compounds. Therefore, the focus was given more on pinpointing 
Figure 2.6 - % nematodes’ survival with two different types of 96-well plates 
iwhen inoculated with the S. aureus strain 
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extracts that promoted the survivability of the nematodes. The plot from Fig. 2.7 denotes the 
surviving after 72 hours of incubation: as shown Extract 1, 5 and 26 were able to promote worm 
survivability throughout the experiment (over 40% survival).  
As mentioned before, because the S. aureus infection is not a persistent one, it is not 
possible to know if the natural extracts are killing the bacteria inside the nematodes or only 
outside and C. elegans has cleansed the infection by eating dead bacteria and expelling the 
living into the bactericidal liquid media. However, the fact that nematodes are surviving in the 
presence of these active compounds, present in the previously mentioned extracts, is an 
indication that these molecules are not toxic to a higher organism such as the nematodes. 
Although it will be necessary to reconfirm the results achieved it is also worth mentioning that 
some of the extracts marked as non-active on the in vitro assay, promoted C. elegans survival 
(Extract 2 and 16). This kind of data reflects other characteristic of this assay, molecules that 
do not directly inhibit bacterial growth but help the host’s immune response may also be 
amenable to this screening exercise.  The other interesting point is the fact the nematodes died 
so quickly in the presence of the Extract 3 and 27 (100% mortality after less than 12 hours), 
which indicates that those might contain nematocidal compounds. Although it was not the 
purpose of this experiment to screen for such molecules the nature of the assay allows also to 
identify the extracts that might have such activity. Although the design of the assay has to be 
completed and improved, the main goal of the project was achieved and it was possible to 
transfer the technology to the laboratory where I am based. In the following months I will set 
up and validate the screening assay to apply it to our natural product libraries. 
Figure 2.7 - % of nematodes’ survival in the presence of S. aureus and different extracts 
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Even though several attempts to create a successful infection model were tried it was 
not possible to observe a clear killing curve of C. elegans due to the bacterial infection. The 
data obtained suggested that S. aureus 8325-4 kills the nematodes in liquid media by 
suffocation instead of bacterial infection, pointing to the need of extending the spectre of 
bacterial species to be used to convey the infection. Setting up methods appropriate for 
screening complex samples such as fermentation extracts would have required a significant 
amount of my time, with the risk of coming up with no useful results in time to implement the 
new assay for systematic screening. Therefore, the C. elegans assay was not further pursued 
during this project. 
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2.6. Discussion 
Overall, with 104 active strains, only 50 had their active compounds ascertained, 
sometimes tentatively, with a further 54 strains still waiting a more detailed analysis. 
Nonetheless, it is possible to start drawing some conclusions from the strains that were 
characterized. 
 
Figure  2.8 – Graphical analysis of the compounds discovered from screening the Actinoallomurus genus. Inner 
circle –Distribution of each specific identified compound from Table 3.2. Outer circle – biosynthetic 
classification according to the classification from Chapter 1.3. AMP – Antimicrobial peptides 
Focusing on the compounds from the characterized extracts, it is possible to observe that 
there is a large variety of chemical classes present, as illustrated in the graph from Fig.  2.8. 
Six distinct family of metabolites were identified, including compounds adverting from PKS I, 
i.e. polyethers (see sub chapter 0), and the spirotetronates pyrrolosporin and NAI-414 (Mazzetti 
et al., 2012); from PKS-II, i.e. NAI-113 (see chapter 3), allocyclinone (see Chapter 4), and 
pradimycin; from NRPSs, i.e. Cyclo Phe-Leu (work performed previous to my arrival); RiPPs, 
i.e. NAI-107 (see chapter 5); as well as compounds biosynthesized outside the major pathways 
described in the Introduction, i.e.  coumermycin (see subchapter 2.4.3).  It is also noticeable 
the large number of strains producing allocyclinone (12 representatives, as discussed in Chapter 
4) and polyethers (15 strains). While a little over 200 strains is a small number to draw strong 
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conclusions, the results obtained thus far suggest that angucyclinones and polyethers might be 
common encounters in Actinoallomurus and these compounds may play important roles in its 
physiology and be part of the so called 'core' metabolome. 
During the screening exercise the major hurdle was the high number of positive hits. The 
selection criterion was based on the presence of antimicrobial activity against a Gram-positive 
representative and a hyper-sensitive Gram-negative bacterium. This turned out to be a quite 
loose criterion as a large number of Actinoallomurus strains produced bioactive compounds in 
the conditions used and not all of them could be structurally characterized within the timeframe 
of this PhD. This limitation prompted investigating the use of nematodes as a screening tool. 
The advantage of nematodes was in the possibility of using a small but complex organism at a 
relatively high throughput without any ethical constraints. A successful venture in this case 
would have allowed the selection of extracts active against bacteria without adverse effects on 
a complex organism. However, the resilience of the nematodes to a S. aureus infection did not 
let this endeavour arrive in safe harbour.  
As mentioned before, the exploration of new taxa is an important tool to keep exploiting 
natural chemistry without a major investment on the early discovery process. Different 
evolutionary pressures and conditions may trigger diverse processes and alter metabolic routes 
which in turn may be reflected on a different panel of secondary metabolites produced.  The 
results of this expedition on Actinoallomurus brought already an interesting set of new 
compounds reinforcing the idea that new taxa do offer unseen chemistry. However, the finding 
of new chemistry is only the beginning for new genera. To fully understand the potential of 
Actinoallomurus, it would be important to understand how vast is the chemical space offered 
by this genus, as already at this early stage different strains were found producing the same 
compound (see Chapter 4), being interesting to understand how far is Actinoallomurus from 
reaching an exhaustion scenario similar to that more studied genera seem to face. 
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3. CONTRIBUTIONS FOR THE 
DISCOVERY OF A NEW METABOLITE 
3.1. Introduction 
A drug discovery expedition amongst natural products is, when correctly designed, a 
fructiferous endeavour to unravel new molecular structures with applications that go beyond 
the boundaries to which it was initially created. For instance, the use of antimicrobial assays 
for the discovery of new antibacterial compounds may deliver new molecules that although 
endowed with antimicrobial activity are better suited for other biological activities. The 
unmatched structural complexity of natural products bequeaths an equally broad range of 
activities that have been quite exploited by our society.  
The formation of aromatic rings is a common biosynthetic strategy from natural 
products, largely exploited by bacterial PKS II systems to deliver a renowned diversity of 
structures originating from different polyketide chain lengths and different folding/cyclization 
patterns, in addition to a large number of post-polyketide modifications. For instance, this 
biosynthetic logic has provided antibacterials such as tetracycline and antitumor agents like 
gilvocarcin (Hou et al., 2012; Wang et al., 2012).  A family of compounds from the PKS II 
system that supports the notion of activity beyond the purpose for which it was initially 
screened for, is represented by the anthracyclines. Anthracyclines, firstly described in 1960’s, 
are a diverse group of tetracyclic compounds that have become very successful in 
chemotherapy for cancer treatment (Minotti et al., 2004). Four mode-of-actions are known for 
this family that range from intercalating DNA strands to the generation of free oxygen radicals 
(Szulawska and Czyz, 2006). The high activity observed against eukaryotic cells make these 
compounds unsuitable as antibacterial candidates, but they do possess potent antibacterial 
activity and are readily picked up in such screens (Weiss, 1992). 
The diversity of natural products presents quite often different challenges that need to 
be addressed by multidisciplinary teams. Such was the case for the molecule currently 
designated as NAI-113, which had been identified as an Actinoallomurus metabolite previous 
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to the start of this project. However, due to its paramagnetic characteristic, the compound 
showed no distinct NMR signals and its structure remained unsolved. Similar MS and UV 
pattern were observed when a new Actinoallomurus producing strain was identified. My 
contribution to this work was the use of biological tools to help structural elucidation, through 
the preparation of 13C-labelled compound by inoculation in a specifically designed media 
containing 13C glucose and the in sillico analysis of the corresponding gene cluster. These 
results were integrated with chemical and spectroscopic data to eventually establish the 
molecular structure of NAI-113. 
3.2. Experimental Section  
Strains and growth conditions. Actinoallomurus strains were from the NAICONS 
collection. Strains were maintained on S1-5.5 plates.(Pozzi et al., 2011) For the initial 
screening, a loopful of mycelium was used to inoculate shake-ﬂasks containing AF-A medium 
(dextrose 10 g/L, soybean meal 4 g/L, yeast extract 1 g/L, NaCl 0.5 g/L, MES 1.5 g/L, adjusted 
to pH 5.6 before sterilization). Cultures were incubated on a rotatory shaker at 200 rpm and 30 
ºC and harvested after eight days unless stated otherwise. All extracts were assayed by agar 
diffusion against S. aureus ATCC 6538P and E. coli K2020, a ΔtolC strain of MG1641 (from 
NAICONS collection). Strain ID 145113 was inoculated in AF-N medium (13C-Glucose 5 g/L, 
Glutamine 1 g/L, yeast extract 0.5 g/L, NaCl 0.5 g/L, MES 1 g/L, adjusted to pH 5.6 before 
sterilization). 
Biological Activity. The antibacterial assays were performed a described in chapter 
2.2.  
Analytical Procedures. LC-MS and UV data were recorded on a Thermo LCQ equipped 
with HESI ion source with a Dionex Ultimate 3000 HPLC Column: Atlantis T3, 3µm, 100Å, 
4.6mm x 50mm. Phase A: HCOOH 0.1%. Phase B: MeCN. Flow rate: 0.8 ml/min. Gradient: 
10% of phase B for 1 minute followed by a linear gradient from 10 to 95% of phase B in 6 
minutes and additional 2 minutes at 95% of phase B. HPLC analyses and resolution were 
carried out using a Shimadzu LC-2010AHT equipped with a Merck LiChrosphere RP18 
column, 5 μm (125 × 4 mm). Phase A: 0.1% TFA. Phase B: MeCN. Linear gradient of B from 
10 to 90% in 30 minutes. Detection 270 nm.  
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Purification of NAI-113. A culture of strain ID145113 was harvested and centrifuged 
at 3000 rpm for 10 min to separate the mycelium from the broth. The latter (about 1.8 L) was 
concentrated under vacuum to about 1 L and acidified at pH 3.2 by using 7.2 mL HCl 6N. The 
suspension was kept at 4 °C overnight to allow total precipitation of the desired compounds. 
The pellet was then collected by centrifugation at 4000 rpm for 10 min, washed twice with 
acidic water and dried in a vacuum oven at 40 °C for 48 h. 595 mg of a black powder containing 
compounds 420 and 421 were obtained (named after their mz+ value). The same downstream 
process was applied on 200 mL culture of strain 145113 grown in 13C-labeled medium. 42 mg 
of 80% 13C-labeled 420-421 mixture were obtained. 56 mg of compound 393 were obtained 
using the same procedure starting from 200 mL of strain 145113 fermentation broth. After 
purification a 1 mg standard was created and used a reference for production analysis 
throughout this work. 
Genomic sequencing. the methods used for the genome isolation are described in 
Chapter 6.3. 
Bioinformatic analyses. the methods used for the bioinformatic analysis are described 
in Chapter 6.3. 
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3.3. Results  
Discovery of NAI-113. During a screening program for new antibacterials, three strains 
presented the same antimicrobial compound, Actinoallomurus ID145113, ID145206, 
ID145754 (being the latter found during this screening exercise; see Table 2.2). From those 
three, the best producer was strain ID145113, which was used for further analyses. The 16S 
rDNA phylogenetic analysis confirmed it as a member of the Actinoallomurus genus (Fig.  3.1), 
more accurately belonging to phylotype Alp 4.  
 
The extract showing the largest activity against both Gram positive and Gram negative 
bacteria – obtained with ethyl acetate – was fractionated using reversed-phase HPLC and each 
fraction was tested for antibacterial activity, which was observed against S. aureus and E .coli 
∆tolC spell out strains. The activity was correlated to two related peaks with m/z+ values of 420 
and 421, designated 1 and 2, as described in Fig.  3.2.  
Figure  3.1- Close up on phylogenetic tree of 16S rRNA gene sequences from 134 Actinoallomurus strains 
from the whole collection from NAICONS. Note that strain ID 145113 clusters together with Alp4 phylotype. 
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The compounds were recovered by precipitation of a concentrated and acidified cleared 
broth.  Washing the resulting pellet with acidified water and drying the residue afforded a black 
powder that was practically insoluble in water, slightly soluble in organic solvents through the 
addition of drops of acid (yellow solution), soluble in DMSO, and highly soluble in alkaline 
aqueous conditions (dark purple solution). LC analysis showed two major peaks with retention 
times of 13 and 14 min (Fig.  3.2) in a 4:6 ratio. The UV-Vis spectrum of 1 showed absorption 
maxima at 245, 280 and 455 nm, while 2 showed maxima at 254, 275 and 455 nm, suggesting 
a close relatedness of the two molecules. Both of them exhibited a characteristic bathochromic 
shift from 455 nm at pH ≤ 7.0 to 550 nm at higher pH. Previous HR-MS analyses established 
their chemical formula as C22H14NO8 for 420 [M+H]
+ (420.0714 found, 420.0719 calcd) and 
C22H13O9 for 421 [M+H]
+ (421.0557 found, 421.0559 calcd). 
The first NMR analyses of the 1-2 mixture showed total absence of signals, indicating 
interference between the sample and the instrument. This behaviour suggested the possible 
presence of a free radical as in the so-called “NMR-silent” compounds, paramagnetic 
compounds that can exist partially or totally as free radicals, interfering with the magnetic field 
of the NMR instrument, hence the missing NMR signals. This feature is usually associated 
with quinonic structures that undergo oxygen-mediated radical formation (Shin-ya et al., 1992). 
In the literature it has been possible to see and analyse NMR signals only in derivatives of such 
compounds, usually in their acetylated products.  
420 
421 
Figure 3.2 – HPLC trace of a clear broth of Strain ID145113 at 270 nm. Note the two 
peaks correspondent to the m/z+ values of NAI-113 active compounds 
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Acid-catalysed acetylation was thus performed on the mixture 1-2 leading to the 
formation of a complex mixture of reduced acetylated products (Wilgus and Gates, 1967). In 
particular, 1 and 2 incorporated up to four and three acetyl groups, respectively, with the most 
abundant peaks consisting of a three-acetyl-2H-1 and a diacetyl-2H-2. The two major 
acetylated molecules were resolved by preparative TLC and the purified compounds finally 
afforded sharp NMR signals. Selected data is reported on Table 3.1. In addition to the signals 
belonging to the introduced acetyls, whose positions were not investigated, the 1H-NMR 
spectrum of diacetyl-2H-1 showed a phenolic proton (147.2 ppm), three aromatic singlets 
(8.26, 7.85 and 7.67 ppm), a methylene (5.85 ppm) and two methoxy signals (4.11 and 3.98 
ppm). Further 2D experiments highlighted a NOESY correlation between the aromatic CH at 
7.85 ppm and the methoxy group at 4.11. HMBC correlations among the methyl groups at 3.98 
and 4.11 ppm and the quaternary carbons at 147.2 and 158.4 ppm, respectively, revealed a 
phenolic nature for these methoxy groups while only one carbonyl signal was detected (167.4 
ppm) correlating in HMBC with the methylene at δH 5.85. This one, in turn, showed a long-
range TOCSY correlation with the aromatic CH at δH 7.67. HMBC data also showed the 
presence of two unreduced quinonic signals (δC 181 and 180.6).  
Table 3.1 - Selected NMR spectroscopic data (400 MHZ, CDCL3) for compound 2AC-2H-
421, 3AC-2H-420 AND 4AC-2H-393. 
POSITION 2Ac-2H-421 3Ac-2H-420 4Ac-2H-393 
δC, type δH δC, type δH δC, type δH 
1 167.4, C  166.4, C  166.1, C  
3 147.2, C  162.9, C    
4 122.4, CH 7.67, s 124,2, CH 7.49, s 122.1, CH 8.14, s 
6 120.1, CH 8.26, s n.d. 8.41, s 116.1, CH 8.35, s 
8 158.4, C  n.d.    
9 108.7, CH 7.85, s 108.7, CH 7.91, s 119.9, CH 7.34, s 
14 70.9, CH2 5.85, s 70.6, CH2 5.77, s 71.1, CH2 5.81, s 
15 61.3, CH3 3.98, s 57.2, CH3 4.23, s   
16 56.5, CH3 4.11, s 36.1, CH3 3.25, s   
OH-11  14.75, brd  n.d.  14.86, brd 
 
1H-NMR data of the triacetyl-2H-2 showed a similar pattern (see Table 4.1) except for 
the presence of a single methoxy (4.23 ppm) and of an additional methyl (3.25 ppm) whose δC 
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at 36.1 was in agreement with an aromatic methyl-amino group. This suggested that the 
difference between 2 and 1 might consist in the substitution of a methoxy with a methyl-amino 
group, consistent with the HRMS-derived formulae. However, the paucity of protons together 
with the abundance of quaternary carbons prevented complete structure elucidation (Marianna 
Iorio, Personal communication).  Therefore, new strategies to overcome this hurdle were 
designed from using biological tools. 
Bioinformatic Analysis. A first strategy employed was a genomic approach. In this 
case, the genome of strain ID 145113 was sequenced and its 10.6 Mbp genome sequence (see 
Chapter 6 for further details on the genome sequence) was used to run the bioinformatic tool 
Antismash V3.0.0.4 (Weber et al., 2015), which is able to pinpoint the putative gene clusters 
for secondary metabolism. Looking through the generated list and aware of some of the 
structural features of 1 (quinonic structure, no halogens, high degree of decorative motifs across 
the core structure) it was possible to find the cluster most likely responsible for its production 
(Fig.  3.3).  
 
Figure  3.3 - List of the potential clusters for secondary metabolism from Strain ID 145113. Cluster 10 
–candidate for NAI-113 biosynthesis 
Cluster 10 was selected as the most likely candidate because it encodes a PKS II system, 
which usually produces this type of molecules. The ORFs present in cluster 10 were analysed 
  
56 
 
for similarity against the NCBI database but also with a recently introduced specialised 
database of BGCs responsible for compounds with known structure, available at MIBiG. 
(Medema et al., 2015) The results are described on Table 3.2. 
Table 3.2- Deduced Function of each ORF in the NAI-113 Biosynthetic Gene Cluster 
CDS 
Length 
(aa) 
Proposed function 
Best PKS 
Matcha 
Best hit  
(Ac Number) 
Identity 
NAI-113_3480 330 ABC Transporter  WP_010356765.1 65% 
NAI-113_3481 352 ABC Transporter  WP_041824945.1 77% 
NAI-113_3482 299 ABC Transporter   WP_026413477.1 79% 
NAI-113_3483 390 Myo-inositol 2-dehydrogenase  KND25197.1 65% 
NAI-113_3484 175 Cation-binding protein [Streptomyces flavotricini]  WP_030036697.1 31% 
NAI-113_3485 534 bilirubin oxidase  WP_012870914.1 56% 
NAI-113_3486 151 Monoxygenase RubQ AAM97373.1 47% 
NAI-113_3487 330 Malonyl CoA-acyl carrier protein TstB AGN11890.1 39% 
NAI-113_3488 621 EmrB/QacA subfamily drug resistance transporter  YP_001866562.1 52% 
NAI-113_3489 127 Glyoxalase  YP_003115770.1 66% 
NAI-113_3490 431 E2_dihydrolipoyl_acyltransferase  ACR50769.1 38% 
NAI-113_3491 344 Transketolase  AGD80611.1 53% 
NAI-113_3492 327 Pyruvate_dehydrogenase_E1_alpha_subunit  ACR50771.1 66% 
NAI-113_3493 130 Monoxygenase PdmH ABM21754.1 42% 
NAI-113_3494 107 tetracenomycin F2 cyclase  WP_043504911.1 46% 
NAI-113_3495 184 PadR Regulator  AAV48829.2 71% 
NAI-113_3496 287 Trasncriptional Regulator - SARP family  CAA60570.1 62% 
NAI-113_3497 123 Cyclase Lcz30 ABX71147.1 52% 
NAI-113_3498 421 Type II PKS ketoacyl synthase PdmA ABM21747.1 70% 
NAI-113_3499 432 Chain Length Factor SnoA2 CAA12018.1 61% 
NAI-113_3500 84 Acyl Carrier Protein SimA3 AAK06786.1 53% 
NAI-113_3501 155 Cyclase RubF AAG03070.2 72% 
NAI-113_3502 349 O-methyltransferase PokMT3 ACN64847.1 50% 
NAI-113_3503 576 Acetyl Carboxylase PokAC1 ACN64837.1 58% 
NAI-113_3504 167 Biotin Carboxyl carrier protein PokAC3 ACN64838.1 45% 
NAI-113_3505 452 Acyl-CoA carboxylase PokAC2 ACN64839.1 63% 
NAI-113_3506 53 Unknown Function  YP_001539692.1 51% 
NAI-113_3507 357 O-methyltransferase PokMT2 ACN64843.1 41% 
NAI-113_3508 562 Hydroxylase  TcmB2 CAP12596.1 47% 
NAI-113_3509 331 O-methyltransferase PbtM4 AGY49596.1 53% 
NAI-113_3510 299 Nucleoside-diphosphate sugar epimerase   ABP54642.1 47% 
NAI-113_3511 53 AAA family ATPase  WP_055481033.1 74% 
NAI-113_3512 282 LigA protein   EWM17234.1 50% 
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Best PKS matches are based on MiBIG Database. 
Dashed lines define the limits of the putative gene clusters within the Antismash output 
 
Looking into more detail at cluster 10 it was possible to locate the minimal PKS – the 
group of enzymes responsible for the construction of the initial backbone chain – but also other 
enzymes (such as cyclases or methyltransferases) important to the definition of the final 
structure.  Previous studies have shown that the KSβ is directly related to the type of molecule 
its cluster synthesizes and it can even be used to predict novelty (Kang and Brady, 2014; Metsa-
Ketela et al., 1999). Using this line of thought, a phylogenetic analysis was performed as 
described in Fig.  3.4. By aligning KSβ from cluster 10 with 35 different sequences from other 
PKS II systems, it was possible to establish that the enzyme responsible for the synthesis of the 
compound under analysis (dubbed "NAI-113") aligns best with the KSβs responsible for the 
synthesis of pradamycin-like compounds. These molecules derive from a carbon backbone 
made of 12 to 13 acetate units. Although the NAI-113 KSβ appears to diverge from other 
enzymes of the same pradimycin-like branch, it is nonetheless more related to these enzymes 
than to those from the angucycline or tetracycline branches. The lack of close sequences, while 
suggestive of novel structural features, prevented a tentative identification of a close structural 
homologue for NAI-113. 
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Figure 3.4 - Phylogenetic tree of the KSβ from 35 different biosynthetic clusters with known product. 
The KSβ from NAI-113 cluster is close to the Arixanthomycin KSβ within the Pradamycin-like cluster 
Production of 13C-labeled NAI-113. By increasing the frequency of 13 C present in 
the metabolite, the NMR response is also expected to be increased and also, the labelled 
compound can be used in oxidation reactions to enhance the detection of the numerous 
quaternary carbons and complete structural characterization. The first step to produce labelled 
compound was to design a minimal media convenient for Actinoallomurus growth without 
compromising its ability to produce the desired metabolite. The simple introduction of a 
labelled carbon source in the place of regular glucose did not yield satisfactory results (data not 
shown). The medium used as a starting point was the M9 minimal medium, with glucose 
substituted by its labelled form. In this case there was no production and growth was very 
limited, indicating that M9 was not appropriate. Dobrova et al., 2004, had reported a minimal 
medium for Actinomadura – actually, it was Nonomurea sp. producing the glycopeptide 
A40926 – able to support growth and where the nitrogen source played a key role for triggering 
secondary metabolism. (Technikova-Dobrova et al., 2004) This data was also corroborated 
with Streptomyces coelicolor by Wentzel et al., 2012. (Wentzel et al., 2012) Taking inspiration 
from this work, different nitrogen sources were used with M9 media, achieving a detectable 
production with glutamine, but still insufficient for further work. Therefore, a new strategy was 
used, starting with the AF-A medium (used for growth of Actinoallomurus) and reducing and 
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replacing individual components. Eventually, a new recipe was devised with a different 
nitrogen source, with reduced yeast extract and a new Nitrogen source. (Table 4.3). 
Table 3.3 – Differences in components between the media used 
Components AF-A AF-X M9-X 
Glucose 10 10 10 
Soy flour 4 - - 
N-source - 2 2 
Yeast extract 1 0,5 - 
MES 1,5 - - 
MOPS - 1,5 1,5 
NaCl 0,5 0,5 0,5 
 
The new media were called AF-X and M9-X, where X indicates different nitrogen 
source. Fig.  3.5 compares NAI-113 production in the six best media. Both glutamine and 
nitrate allowed production of 15-20 µg/mL NAI-113 in AF-X media, whereas production levels 
in the presence of ammonium as a nitrogen source were much lower. Note the importance for 
NAI-113 production of the small amount of yeast extract, present in AF-X but not in M9-X 
media. Yeast extract usually contains elicitors important for bacterial growth and a higher 
amount of biomass may also lead to an increase of produced compound. As mentioned in the 
literature, the use of glutamine seems to enhance the production of secondary metabolites, so 
AF-Gln medium was used for further optimisation. 
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Figure  3.5 - Comparison of production in six different media. Media are named “AF-X” where “X” is 
replaced by the indicated Nitrogen source (n=3). 
Figure  3.5 shows the impact on NAI-113 production of altering the concentrations of 
glucose and glutamine. Under the best conditions (5 g/L glucose and 1 g/L glutamine), it was 
possible to increase NAI-113 production up to 20 fold compared to AF-Gln. Although, it was 
noted that for glucose concentrations of 10 g/L the inverse was observed and the production 
was higher with the increase of glutamine for 2g/L, while in the case of 20g/L no trend was 
observed, further studies would be necessary to explain such behaviour from Actinoallomurus 
which was not the goal of this project but instead we were only interested in achieving a 
sustained production of labelled NA-113 which was accomplished. Finally, instead of using 8 
eight days of cultivation (the standard procedure), it was accidentally observed that longer 
incubation times (10 days) yielded a culture with a darker colour, which was due to a higher 
quantity of NAI-113, reaching concentrations of 400 μg/mL. Note that there was no linear 
relationship between glucose concentration and NAI-113 production, nor there was a consistent 
effect of increasing glutamine concentration (Fig. 3.6). This phenomenon was not further 
investigated.  
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Figure  3.6 - Comparison of production in AF-based media, after eight days, containing different concentrations 
of glucose and glutamine. The concentrations of glucose, and glutamine (in g/L) are indicated by the first and 
second number, respectively. 
According to mass analysis, the labelling reached, on average, up to  8 out of 10 of 13C 
incorporation, showing mainly a shift of 18 mass units from the original value as described in 
Fig.  3.7 (according to High resolution mass, 22 carbon atoms are present). Although glutamine 
is known to be involved in the primary metabolism and, mainly in the amino acid synthesis, it 
still can be used as a carbon source for secondary metabolism (as it was already established by 
Kanehisa, et al., 2004 (Kanehisa and Goto, 2000)) which can be one of the reasons for the lack 
of a higher degree of incorporation. However, two other facts may have played a role: the 
presence unknown compounds present in Yeast Extract, and a carryover of unlabelled carbon 
from the inoculum. Anyhow, the labelled compound was sufficient for the chemical 
degradation studies described below. 
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Figure  3.7 – m/z+ values of  13C labelled NAI-113 
Degradation studies.  In order to break the quinone system and thus eliminating the 
radical behaviour, the mixture 1-2 was treated with 30% H2O2 in water, which led to the 
formation of a more hydrophilic molecule with m/z of 399 [M+H]+ and UV maxima at 230, 
280 and 420 nm. This result indicated that oxidation had removed the portion responsible for 
the mass difference between 420 and 421. As predicted, the purified compound was no longer 
paramagnetic and clear 1H-NMR signals were observed. Moreover, MS data combined with 
absence of one aromatic proton and one methoxy group in 2 (or the methyl-amino in 1) were 
in agreement with oxidation of a terminal quinone moiety cleaved and replaced by two 
carboxylic acids as reported in the literature. (Ogawa and Natori, 1965) This oxidation reaction 
was thus repeated on a sample of 13C enriched compound to enhance the detection of the 
numerous quaternary carbons and complete structural characterization. The resulting NMR 
analyses allowed determination of the structures of 1 and 2 as reported in Fig. 3.8 (M. Iorio et 
al, personal communication). All the data combined led to the conclusion that the compounds 
described in this work are new members of the anthracyclinone family, presenting an unusual 
lactone condensed to ring D. These structures are consistent with a biosynthetic route in which 
a longer polyketide is cleaved to afford the lactone system, consistent with the bioinformatic 
predictions of a 12- or 13-unit polyketide.  
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Figure 3.8 - Molecular Structure of NAI-113 complex 
Related metabolites from a different Actinoallomurus strain. Compounds 
indistinguishable from 1 and 2 were also found as minor congeners in the fermentation broths 
from strains ID145206 and ID145754, belonging to a different Actinoallomurus phylotype 
from strain ID145113. The main compound produced by strain ID145206 is congener C (Fig. 
3.8), which is also NMR silent. Its structure was elucidated following the same acetylation and 
degradation procedures applied to NAI-113. 
Biological activity. As expected for anthracyclinones, NAI-113 was highly active 
against Gram-positive bacteria (M. Iorio, personal communications). 
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3.4. Discussion 
The discovery of NAI-113 starts before my personal project. The first time this 
molecule was found was two years before the beginning of my project (Marianna Iorio, 
personal communication) with strains ID 145113 and ID145206. In a similar manner to what 
was done during this screening exercise, these strains were identified as producers of an 
unidentified compound that upon NMR analysis revealed silent and thus impossible to have its 
structure solved. Already at that time, the first attempts on designing a minimal medium for 
Actinoallomurus were performed with no usable results. The major hurdle when working with 
a poorly characterized genus, such as Actinoallomurus, is the lack of literature information that 
renders every experiment with many unknowns. Designing a new medium was a good example 
of such obstacles.  
There is no doubt that it would have been of interest to actually pinpoint the compounds 
that actually are indispensable for the production of secondary metabolites in Actinoallomurus, 
however a de novo approach for media design might reveal a time consuming process with no 
guarantee of results in the desired timeframe. Since the main goal of this project is the 
characterization of the new compound, it was important to devise conditions usable for the 
efficient uptake of labelled carbon (13C) to be incorporated in NAI-113. The use of chemically 
defined media such as M9, used successfully with Streptomyces, Nonomurea and many other 
organisms, was not possible with this Actinoallomurus strains. The presence of yeast extract, a 
rather complex component, in the media seems essential for NAI-113 production. On the other 
hand, soy flour, another complex ingredient, could be replaced by suitable nitrogen sources 
such as nitrate or glutamine without a significant decrease of NAI-113 production. Despite no 
visible effects were observed in biomass growth these changes altered significantly the 
production of the secondary metabolite. This discovery may have implications for future drug 
discovery expeditions as the use of soy flour can lead to bioactivity artefacts. Indeed, some 
Actinoallomurus strains can metabolize soy flour components into genistein and other soy 
saponins that present a detectable antibacterial activity (Pozzi et al. 2011), complicating the 
screening endeavours. In addition, soy saponins have little UV absorption but give strong MS 
and NMR signals, complicating purification and analysis of Actinoallomurus metabolites.  
These issues could be avoided if glutamine could be systematically used to replace or reduce 
the amount of soy flour in culture media. However, this remains an unexplored possibility. 
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In medium AF-Gln containing labelled glucose, NAI-113 contained around 80% 13C, 
suggesting that additional carbon source(s) were used as substrates. Nonetheless it is quite 
remarkable that in a medium containing diverse sources of unlabelled carbon such as biomass, 
carry-over from previous inoculum, glutamine, or yeast extract still such a high percentage of 
13C uptake was already achieved. Although a complete labelling would be interesting, 
components such as Yeast extract or Glutamine will always render the task quite difficult. Still, 
it would be wise to verify if with the use of nitrate instead of Glutamine, the percentage of 
labelled carbons in NAI-113 would vary. Although a complete characterization of a chemically 
defined media for Actinoallomurus was not achieved. Important insights were made into this 
strain’s metabolism that shall be of value in future drug discovery expedition.  
The structural insights provided by analysis of the NAI-113 BGC were less incisive 
than those derived from 13C-labeled compound. The bioinformatic analysis suggested possible 
polyketide scaffolds for NAI-113 while making others less likely. The study of the Minimal 
PKS, and namely of the KSβs, is becoming an important tool to predict with a high degree of 
confidence the type of aromatic polyketide scaffold produced by the PKS (Szu et al., 2011; 
Tang et al., 2003), with the tantalizing corollary that divergent KSβs might in turn lead to novel 
polyketide scaffolds. Hence, the bioinformatic techniques used in this and subsequent chapters 
might also be useful in genome mining approaches to select strains potentially producing 
unusual aromatic polyketides 
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4. ALLOCYCLINONES, HYPERCHLORINATED 
ANGUCYCLINONES FROM ACTINOALLOMURUS 
4.1. Introduction 
The importance of natural products to human health has been acknowledged over the 
past few decades and still is. According to recent analyses, among the new chemical entities 
approved as drugs between 1981 and 2010, approximately 68% are directly derived or inspired 
from natural products. This success, despite the growing disinterest by pharmaceutical 
companies in natural products as a source of drug leads, underscores Nature's ability to deliver 
complex and high affinity chemical scaffolds that have no match in most synthetic libraries 
(Ganesan, 2008; Newman and Cragg, 2012). One therapeutic area that has been strongly 
dependent on natural products has been the anti-infectives, particularly antibacterial agents that 
have derived almost exclusively from microbial products. The past few years have seen a 
dramatic change in the landscape of infectious diseases, with a steady emergence and spread 
of antibiotic resistance giving origin to pathogens that can escape most available therapeutic 
options (Wright, 2012). 
The so-called golden era of antibiotics has yielded the vast majority of microbial 
metabolites, most of them presumably discovered because of their antibacterial potency, the 
amount produced by the corresponding strains, and/or the natural frequency of occurrence in 
nature (Baltz, 2008; Monciardini et al., 2014). As these 'low-hanging fruits' were discovered, 
random screening of microbial isolates led to progressively diminished returns in terms of 
chemical novelty. Therefore, different approaches have been proposed and implemented to 
increase the probability of making metabolite discovery from microbial sources a cost-effective 
endeavour (Baltz, 2007; Donadio et al., 2009; Gengenbacher and Dick, 2015; Ling et al., 2015; 
Pena et al., 2015).  
One possible approach to identify new metabolites is to explore microbial taxa that have 
not been previously systematically evaluated for the production of bioactive metabolites. In 
this respect, screening for antimicrobial activity may be a simple surrogate for other biological 
effects, since over half of the antimicrobial compounds discovered so far can exhibit other 
bioactivities (Berdy, 2012). The main premise to the choice of using poorly characterized taxa 
is that taxonomic divergence can be a marker for chemical diversity. In particular, the genus 
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Actinoallomurus has proving to be a versatile producer of bioactive compounds, including 
novel ones (Inahashi et al., 2015; Mazzetti et al., 2012; Pozzi et al., 2011).   
This chapter coincides with the manuscript submitted to the Journal of Antibiotics, the 
work reports new entries in the angucyclinone family and the first natural product bearing an 
aromatic trichloromethylene substitution. Allocyclinone, as the molecules have been dubbed, 
seems to be quite common amongst different Actinoallomurus isolates. The molecule possesses 
an interesting antibacterial activity and the first insights on structure-activity relationship have 
been surmised from an evaluation of the purified component of the allocyclinone complex. 
Along with influential insight of the biosynthesis of this molecule to which the gene cluster 
was putatively identified by in sillico analysis. 
4.2. Experimental Section 
General procedures. NMR spectra were measured in CDCl3 on a Bruker 400 MHz 
instrument using tetramethylsilane as an internal reference. HR-MS analyses were performed 
on an Exactive benchtop mass spectrometer (Thermo Fisher Scientific), equipped with a NSI- 
ESI ion source by direct infusion of the mixture 1, 2, 3, and 4 dissolved in MeOH:H2O 8:2. 
LC-MS and UV data were recorded on a Thermo LCQ equipped with HESI ion source with a 
Dionex Ultimate 3000 HPLC Column: Atlantis T3, 3µm, 100Å, 4.6mm x 50mm. Phase A: 
HCOOH 0.1%. Phase B: MeCN. Flow rate: 0.8 ml/min. Gradient: 10% of phase B for 1 minute 
followed by a linear gradient from 10 to 95% of phase B in 6 minutes and additional 2 minutes 
at 95% of phase B. HPLC analyses and resolution were carried out using a Shimadzu LC-
2010AHT equipped with a Merck LiChrosphere RP18 column, 5 μm (125 × 4 mm). Phase A: 
0.1% TFA. Phase B: MeCN. Linear gradient of B from 10 to 90% in 30 minutes. Detection 
270 nm.  
Strains and growth conditions. Actinoallomurus strains were from the NAICONS 
collection. Strains were maintained on S1-5.5 plates.(Pozzi et al., 2011) For the initial 
screening, a loopful of mycelium was used to inoculate shake-ﬂasks containing AF-A medium 
(dextrose 10 g/L, soybean meal 4 g/L, yeast extract 1 g/L, NaCl 0.5 g/L, MES 1.5 g/L, adjusted 
to pH 5.6 before sterilization). Cultures were incubated on a rotatory shaker at 200 rpm and 30 
ºC and harvested after eight days. The mycelium was separated from the clear broth by 
centrifuging at 12000 rpm for 5 min. The clear broth was extracted with one volume of ethyl 
acetate and the two resulting phases were dried and resuspended in 10% DMSO in 1/5 the 
original volume using the same strategy described in Chapter 2.2. The mycelium was 
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resuspended in 0.4 vol EtOH and incubated at room temperature for 2 h. After separating the 
mycelium by centrifugation as above, the supernatant was dried and resuspended in 0.2 vol 
10% DMSO. All three extracts were assayed by agar diffusion against S. aureus ATCC 6538P 
and E. coli K2020, a ΔtolC strain of MG1641 (from NAICONS collection). 
For characterization of allocyclinones, frozen stocks of Actinoallomurus sp. ID145698 
were used to inoculate AF-A medium and incubated for 72 h as above. Then, a 5% inoculum 
was transferred into fresh medium and incubated as above for the required amount of time. 
Biomass accumulation was measured as percent packed mycelial volume (PMV%) after 
centrifuging cultures for 10 min at 3000 rpm in a graduated tube. For metabolite analysis, 
culture samples were mixed with 2 vol MeOH-AcOH (92:8), incubated for 1 h at room 
temperature and analysed by HPLC as above after separating the residual biomass. Congener 
ratio was established assuming identical molar absorptions at 270 nm. Compounds 
concentrations were measured using pure 4 as reference standard. 
Compound purification. After 192 h cultivation in medium AF-A, the entire culture 
(400 mL) was acidified to pH 5 with AcOH, and centrifuged (3000 rpm for 10 min) to separate 
the mycelium from the cleared broth. The mycelium was extracted with EtOH (100 mL), 
incubating in shaker, at room temperature for one hour, after centrifugation the resulting 
supernatant was separated from the mycelium and evaporated. The cleared broth was extracted 
with EtOAc (150 mL) and the organic phase was separated and evaporated. The two extracts 
showed similar congener distributions and were separately submitted to the following 
purification procedure with comparable results. Preparative TLC were performed in 
dichloromethane-MeOH = 9:1 containing 0.5% (v/v) AcOH. The main spot with 0.9 Rf was 
isolated, recovered by elution with MeOH resulting in a mixture of compounds 1–4 (13 mg). 
Additional spots with 0.2 and 0.5 Rf, recovered in the same way, resulted in pure compound 5 
(4mg) and compound 6 (1 mg). 
An aliquot (500 μg) from the mixture 1-4 was then further purified by HPLC obtaining 
pure samples of 1 (65 μg), 2 (178 μg), 3 (100 μg) and 4 (176 μg). Quantities were estimated by 
integrating the area of the respective peak from the HPLC chromatogram. 
Oxidation and stability analyses. Solutions of 2, 3 and 4 in DMSO at a concentration 
of 10 mg/mL were analysed by LC-MS before and after treatment at 60°C overnight. 
Antimicrobial Assays. All MICs were determined by broth microdilution in sterile 96-well 
microtiter plates, using Müller Hinton broth (Difco Laboratories) containing 20 mg/L CaCl2 
and 10 mg/L MgCl2 for all strains except for Streptococcus spp., which were grown in Todd 
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Hewitt broth (Difco Laboratories). Strains were inoculated at 5x105 cfu/mL and incubated at 
37 °C for 20 h.  For growth inhibition of E. coli K2020, the same procedure was used except 
the OD590 was continuously measured in the BioTek's plate reader, Synergy2. Tested 
compounds were dissolved in DMSO at 10 mg/mL and diluted with the culture medium 
immediately prior to testing. All strains were either from the ATCC or the NAICONS 
collection and the relevant resistance phenotypes are reported in Table 5.3.  
Sequence analyses. PCR amplification of the 16S rRNA sequences was performed as 
previously described (Monciardini et al., 2002) and the amplified products were sequenced by 
Cogentech (Milan, Italy). Whole genome sequencing was performed by Universität Bielefeld 
Centrum für Biotechnologie (Bielefeld, Germany). Sequence alignments were made using 
ClustalW (for 16S rRNA) (Thompson et al., 1994)and strains were assigned to the same 
phylotype when their identity was higher than 99.5%. Phylogenetic trees were made with the 
neighbor-joining method (Saitou and Nei, 1987). Secondary metabolite gene clusters were 
searched with the ANTISMASH v3.0.4 tool (Weber et al., 2015). Blast analysis were done 
using data from DoBISCUIT and MIBiG as a reference (Ichikawa et al., 2013; Medema et al., 
2015). Phylogenetic analysis of all Chain lengths factors was done using MUSCLE algorithm. 
All the bioinformatic work was done with the support of the workflow platform Armadillo. 
The putative allocyclinone gene cluster has been deposited in GenBank under Accession 
Number KT996129. 
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4.3. Results  
Identification of new angucyclinones. The procedure for screening has been 
previously described, and can be summarized by the use of strain cultivation in shake-flasks, 
followed by testing the resulting extracts for antimicrobial activity. Active extracts are then 
evaluated for the novelty of the active compound(s) (Monciardini et al., 2014). With this 
approach, we identified Actinoallomurus strain ID145698 as a strain worth of further 
investigations. Extracts derived from this strain inhibited growth of Staphylococcus aureus and 
of a hyper-permeable Escherichia coli strain. Upon LC-MS analysis, the antimicrobial activity 
was associated to a complex of related halogenated molecules 1-4 (Appendix 1 - Figure 1).  
 
Figure  4.1 - Molecular structures of compounds 1–7. 
 
Structure determination. The structures of compounds 1-4 are shown in Figure 4.1 
and were determined as follows. The UV-spectra of the purified molecules were very similar 
with absorption up to 650 nm and the presence of three maxima at 240, 300 and 480 nm, 
suggesting an angucyclinone chromophore (Potterat et al., 2007). The isotopic pattern in the 
ESI mass spectra clearly revealed the presence of at least one chlorine atoms in all congeners. 
The experimental isotopic patterns and those calculated from the HR-MS-derived molecular 
formulas (Table 4.1) were in full agreement (Appendix1 – Figure 2) and confirmed that 
compounds 1 to 4 contain one to four chlorines, respectively. 
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Table 4.1 - HR-MS data for congeners 1 to 4 of allocyclinone. 
Compound Observed massa Calculateda Formula 
1 469.0681 469.0690 C24H17ClO8 
2 503.0289 503.0300 C24H16Cl2O8 
3 536.9899 536.9911 C24H15Cl3O8 
4 570.9510 570.9443 C24H14Cl4O8 
a for [M + H]+ adducts 
 
 1H-spectra were acquired on each single, purified compound 1–4 (Appendix 1 - Figure 
3–6). However, there was insufficient material to obtain strong carbon signals in the 2D NMR 
spectra, which were instead obtained using the 1-4 mixture (Appendix 1 Figure 7–9). A 
comparison of the 1H-spectra of the purified compounds with the 2D NMR spectra of the 
mixture enabled assigning signals from the latter spectra to each congener. This approach was 
possible thanks to the low complexity of the proton spectra originating from a single aromatic 
AB system and a few singlets. 
When comparing the 1H-spectra of compounds 1–4 we observed a downfield shift of 
low intensity peaks (which turned out to arise from protons at positions 5 and 6 in the aromatic 
AB system). A similar behaviour was observed for the third aromatic signal at position 4, 
whose chemical shifts ranged from 7.63 in 1 to 8.6 in 4, reflecting the electron withdrawing 
power of the substituent at the vicinal position 3, where the molecules differ (Appendix 1 
Figure 10). Specifically, the substituents at position 3 range from CH3 in 1 to CCl3 in 4 through 
a stepwise replacement of each hydrogen with a chlorine atom. The corresponding protons 
were clearly identifiable in each 1H-spectrum (Appendix 1 – Figure 3 to 6) while the position 
of the C-13 groups was assigned through its HMBC correlation with H-4 (Appendix 1 – Figure 
9). The TOCSY signals observed between CH3, at 2.60 ppm, with the H-4, at 7.63 ppm, in 
compound 1 and the chloromethylene, at 4.90 ppm, with the H-4, at 7.92 ppm, in compound 2, 
provided an additional confirmation (Appendix 1 – Figure 10). On the contrary, the signals 
arising from common groups further away from position 3 were isochronous in compounds 1-
4: two methoxy, one methyl, two phenols and a quinone moiety. Interestingly, the HMBC 
correlations between the quaternary carbon 14 and each of the methyl group at positions 17 
and 15 (Appendix 1 – Figure 11) indicated the presence of a lactone ring.  The position of the 
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additional chlorine atom present in all congeners at position 2 was also confirmed by HMBC 
correlations. The position of the methoxy group on ring A, indicated by the HMBC correlation 
between C-1 and H-4, was confirmed after reaction with 30% H2O2 thus observing by LC-MS 
the oxidative rupture of the internal quinone affording a degraded compound comprising the 
AB ring system and the methoxy moiety (data not shown). The observed oxidation products 
are also consistent with the presence of the quinone moiety in ring C. The 1H and 13C 
assignments are reported in Table 4.2. 
 
Table 4.2 - 13C and 1H-NMR assignments for compounds 1, 2, 3, 4, 5 and 6. 
 1 2 3 4 5 6 
Position δC 
1 155.5 155 Nd 
2 130 128.2 125.7 nd  Nd 
3 140.7 138.9 140.3 136.5 nd Nd 
4 124.8 125.1 123.7 123.2 127.4 Nd 
5 135.1 135.2 135.9 136.2 136.1 Nd 
6 122.3 - 122.7 122.4 Nd 
7 187.8 187.8 Nd 
7a 117.4 117.4 Nd 
8 150.2 149.9 Nd 
9 144 144 Nd 
10 123.3   
11 152.4 154 Nd 
11a 117.5 117.4  
13 21.3 43.3 67.1 94 169 62.7 
14 107 107 Nd 
15 23.5 23 23.2 
17 52 52 51.8 
MeO-C-1 61.8 61.5 61.6 
Position δH (m, J Hz) 
4 7.63 (s) 7.92 (s) 8.36 (s) 8.59 (s) 8.34 (s) 7.95 (s) 
5 8.13 (d, 8.5) 8.22 (d, 8.5) 8.30 (d, 8.5) 8.33 (d, 8.5) 8.3 (d, 8.5) 8.23 (d, 8.4) 
6 8.3 (d, 8.5) 8.35 (d, 8.5) 8.38 (d, 8.5) 8.42 (d, 8.5) 8.41 (d, 8.5) 8.33 (d, 8.4) 
13 2.66 (s) 4.92 (s) 7.29 (s) - - 5.03 (s) 
15 2.02 (s) 2.02 (s) 2.02 (s) 2.02 (s) 2.03 (s) 2.02 (s) 
17 3.31 (s) 3.3 (s) 3.3 (s) 3.31 (s) 3.32 (s) 3.30 (s) 
MeO-C-1 3.85 (s) 3.89 (s) 3.89 (s) 3.87 (s) 3.95 (s) 3.86 (s) 
OH-8 and OH-11 12.28; 12.36 12.24; 12.36 12.22; 12.34 12.24; 12.34 12.36 12.4; 12.3 
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It should be noted that the fermentation broth of strain ID145698 contained additional 
molecules that, on the basis of their UV spectra and MS fragmentations, appeared related to 
the main components 1–4. Among them, compounds 5 and 6 present a carboxylic acid 
(Appendix 1 – Figure 11–13) and a benzylic alcohol (Appendix 1 – Figure 14–15), 
respectively, at position 3, suggesting that they originate by formal "hydrolysis" of the 
halogenated congeners. Indeed, 2, 3 and 4 converted into 7, 6 and 5, respectively, after storage 
for several weeks in DMSO at 4 ºC, or overnight at 60 ºC (Appendix 1 – Figure 16). In 
agreement with the literature e(Ogawa, 1965), compound 7 showed m/z values consistent with 
the presence of an aromatic aldehyde. With hindsight, compound 7 was also detected as a minor 
peak in the fermentation broth (Appendix 1 – Figure 17). Overall, these data suggest that 
compounds 5–7 are likely to be degradation products and not pathway intermediates.  
 
Figure 4.2 - Time course of biomass accumulation, and total angucyclinone production by Actinoallomurus sp. 
ID145698. The concentrations of the individual congeners 1–4 are also indicated. Values correspond to the 
average measurements of five flasks and the Error bars to the respective standard deviation. 
Under our experimental conditions, Actinoallomurus sp. ID145698 reached stationary 
phase after about 72 h, while angucyclinone production started when growth ceased and 
proceeded at a steady rate up to 168 h, when 380 μg/mL (as the sum of compounds 1 through 
4) were observed. Thereafter, the angucyclinone content declined (Fig.  4.2). In the 72-168 h 
interval, the relative ratio among the four main congeners remained approximately constant – 
with 4 always as the main product. This observation suggests that 4 is the end product of the 
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biosynthetic pathway and that full chlorination of the aromatic methyl at position 3 is not a 
consequence of accumulation of incompletely chlorinated compounds.  
Only a few chlorinated angucyclinones have been described so far: JBIR-88, 
chlorocyclinones, and marmycin B (Potterat, 2007).  Among them, chlorocyclinone D is most 
related to the compounds described herein, sharing, in addition to the chlorine at position 2 and 
the methoxy at position 1, a lactone fused to ring D. However, while only one member of the 
chlorocyclinone family contains such a lactone ring, this moiety is a common feature of 
compounds 1–4 where it is further decorated with a methoxy group. The most remarkable 
feature, however, is that chlorination in compounds 1–4 is not limited to the aromatic rings, as 
found in other chlorinated angucyclinones, but involves also the methyl group at position 3. 
Indeed, to our knowledge 4 represents the first instance of a natural product containing an 
aromatic trichloromethylene substituent. Aliphatic trichloromethylene groups are however 
known, for example in barbamide, produced by a cyanobacterium, and muironolide, isolated 
from a marine sponge. 
 
Biological Activity. The entire complex (compounds 1–4) showed MIC values in the 
range of 0.25–1 µg/mL against all Gram-positive bacteria tested, with the exception of 
Enterococcus faecium, which was about one order of magnitude less sensitive (Table 4.3). As 
expected, none of the evaluated resistance mechanisms affected the activity of the compounds. 
It should be noted that there were no measurable MICs at 20 h against the hyper-permeable E. 
coli strain used in the initial screening. However, >50% growth inhibition was observed with 
32 µg/mL 1–4 (Appendix 1 – Figure 18). 
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Table 4.3 – Antibacterial activities of angucyclinones from Actinoallomurus sp. ID145698 
Strain Strain code 
MIC (μg/mL) 
resistance 
phenotypea 
Complexb 
cpd 
1 
cpd 
2 
cpd 
3 
cpd 
4 
VANc GENc  
Staphylococcus aureus ATCC6538P  0.5 32 2 1 0.25 1 0.5 
 
Staphylococcus aureus ATCC25922 MR 0.13     1 >64 
Staphylococcus aureus L3797 GI 0.25     16 >64 
Streptococcus pyogenes L49  0.5 4 16 2 0.25 0.5 8 
Streptococcus 
pneumoniae 
L44  2     0.5 8 
Enterococcus faecalis L559  0.25     2 4 
Enterococcus faecalis  L560 VanA 0.5 64 16 1 0.5 >64 4 
Enterococcus faecalis A3650  1     2 >64 
Enterococcus faecium L568  16     4 16 
Enterococcus faecium L569 VanA 8 >64 >64 8 4 >64 8 
Escherichia coli ATCC25922  >64     >64 0.5 
Escherichia coli L4242  >64     >64 1 
a Abbreviations: MR/MS-Methilicin Resistant/Susceptible; VanA/VanS-Vancomycin Resistant/Susceptible;  GI- Glycopeptide Intermediate 
b : relative complex composition, determined as described in Experimental Section 
c 'VAN' and 'GEN' designate vancomycin and gentamicin, respectively. 
 
The purified molecules 1–4 were also evaluated for their antibacterial activities. With one 
exception, the results indicate a direct relationship between number of chlorines atoms and 
antibacterial activity, with each additional chlorine contributing to a 2-4 fold decrease in the 
MIC (Table 4.3). Therefore, 4 is the most abundant and most active compound in the complex. 
In contrast, compounds 5-7 did not present a noticeable antibacterial activity. 
Chlorinated angucyclinones possess different biological activities, ranging from antitumor 
as for JBIR-88 to modulators of a potential target in diabetes, like chlorocyclinones.16,17 Further 
studies will be necessary to evaluate the full potential of compounds 1–4 as antibacterial agents 
or for other therapeutic applications. 
Analysis of additional Actinoallomurus strains. We next analysed other 
Actinoallomurus strains for the presence of similar compounds. Remarkably, compounds 1–4 
were a relatively common encounter in Actinoallomurus, since we identified eleven additional 
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independent strains (out of 200 analysed) producing this family of angucyclinones, as indicated 
by similar HPLC profiles (Fig.  4.3) and confirmed by LC-MS (Appendix 1 – Figure 19–21). 
The twelve Actinoallomurus strains were isolated from three distant geographic areas and 
belong to three different phylotypes (Table 4.4), with nine and two strains clustering with to 
the previously described Alp24 and Alp9 phylotype, respectively.(Pozzi et al., 2011)  This 
analysis also identified the new phylotype Alp37 (Table 4.4).  
 
Figure  4.3 - HPLC at 270 nm traces of MeOH extracts from the twelve Actinoallomurus isolates identified as 
producers of allocyclinones (Table 4.4). Note the 10fold enlargement of the chromatograms for the extracts 
derived from four strains. 
 
When analysed in a single medium and at a single time point, all the Actinoallomurus strains 
produced variable amounts of the complex. However, for all strains, 4 appeared to be the main 
congener, consistent with the hypothesis that this hyperchlorinated angucyclinone is the end 
product of the pathway. Overall, the relatively high frequency at which compounds 1–4 have 
been detected (i.e., in 12 out of 232 screened strains) and their production by three 
phylogenetically distinct strains suggests an important role for these angucyclinones in 
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Actinoallomurus physiology.  We thus designated the compounds allocyclinones because of 
their association with and possible importance for Actinoallomurus. Thus, compounds 1–4 
would be Allocyclinone A–D, respectively. 
Table 4.4 - Allocyclinone-producing Actinoallomurus strains. 
Strain ID Country (area) of isolation Phylotype Accession No. 
145529 Togo (unknown) Alp37 KR781097 
145530 Madagascar (Masoala) Alp24 KR781088 
145534 Italy (Tuscany) Alp24 KR781089 
145535 Italy (Tuscany) Alp24 KR781090 
145538 Italy (Tuscany) Alp24 KR781091 
145541 Italy (Tuscany) Alp24 KR781092 
145542 Italy (Tuscany) Alp24 KR781093 
145543 Italy (Tuscany) Alp24 KR781094 
145544 Italy (Tuscany) Alp24 KR781095 
145546 Italy (Tuscany) Alp24 KR781096 
145689 Madagascar (Masoala) Alp9 KR781099 
145698 Italy (Lombardy) Alp9 KR781098 
 
 
Identification of the putative Allocyclinone gene cluster.  From a draft genome 
sequence of Actinoallomurus sp. ID145698, we identified a likely candidate for allocyclinone 
biosynthesis within a 43 kbp genomic segment (Table 4.5). This segment contains 34 Coding 
DNA Sequences (CDS) possibly involved in allocyclinone biosynthesis, regulation and 
perhaps resistance. In addition to CDSs for the minimal PKS, the cluster specifies polyketide 
cyclases, O-methyltransferases, hydroxylases, hydrolases, oxidoreductases and halogenases 
that can account for many of the structural features of allocyclinones (Table 4.5). From this 
preliminary analysis, the allocyclinone cluster presents two relevant features: the KSβ/Chain 
Length Factor of the minimal PKS is more related to the dodeca/tridecaketide (e.g. pradimycin) 
than to the decaketide (e.g. jadomycin) clade of type II PKSs (Fig.  4.4); and the cluster encodes 
two distinct, closely related halogenases (Table 4.5). These observations suggest that 
allocyclinones are biosynthesized as a dodecaketide precursor, with the fifth ring cleaved to 
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ultimately afford the lactone ring (presumably an identical biosynthetic pathway occurs for 
Chlorocyclinones); and that two distinct halogenases are responsible for chlorination of the 
aromatic ring and of the methyl moiety. Experimental data will be necessary to corroborate 
these bioinformatic predictions about the allocyclinone cluster. 
 
Figure  4.4 -  Phylogenetic comparison of KSβ enzymes from characterized type II PKS clusters with 
NAI698_9173 from putative allocyclinone gene cluster (Table 4.5). The structures of one representative 
aglycone for each clade is also shown. Supporting Table 5.1 provides additional information on the KSβ’s used 
for the phylogenetic analysis. 
Table 4.5 – Description of CDSs identified by Antismash v3.0.0.4 and proposed functions of gene products. Dotted 
line denotes the putative edges of the cluster 
CDS Length (aa) Putative Function 
Best PKS 
Match 
Accession Number - 
Best PKS Match 
Identity 
NAI698_9155 369 Hypothetical Protein  CAD89764.1 36% 
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NAI698_9156 961 
Lux family Transcriptional 
Regulator 
 AEK75494.1 30% 
NAI698_9157 177 Regulator Protein  CAF32368.1 37% 
NAI698_9159 218 Putative Cyclase FR9Q AIC32703.1 29% 
NAI698_9160 301 Putative DNA-binding protein  CAF32370.1 63% 
NAI698_9161 289 Putative DNA-binding protein  CAF32370.1 54% 
NAI698_9162 172 Oxidoreductase MmyF CAC36752.1 44% 
NAI698_9163 262 
SARP-like transcriptional 
Regulator 
 AGH68913.1 45% 
NAI698_9164 342 O-methyltransferase Lcz35 ABX71152.1 47% 
NAI698_9165 318 Hypothetical protein  CAI94709.1 33% 
NAI698_9166 308 Transcriptional regulator  AHA12085.1 44% 
NAI698_9167 294 Putative Hydrolase PedQ AAW33976.1 38% 
NAI698_9168 211 Unknown Function NapU4 ABS50471.1 42% 
NAI698_9169 108 Polyketide synthesis cyclase  ABW11821.1 60% 
NAI698_9170 537 Decarboxylase SimA12 AEA30254.1 71% 
NAI698_9171 138 Putative cyclase PdmL ABW11824.1 63% 
NAI698_9172 424 Ketoacyl synthase - alpha XanF ADE22315.1 70% 
NAI698_9173 407 Chain Length Factor FdmG ADG86316.1 60% 
NAI698_9174 243 Polyketide cyclase RubF AAG03070.2 71% 
NAI698_9175 67 Hypothetical protein  CAF05638.1 33% 
NAI698_9176 245 Acyl Carrier Protein GrhO10 AAM33668.1 54% 
NAI698_9177 112 Monooxygenase FdmJ AAQ08920.1 35% 
NAI698_9178 108 Monooxygenase FdmQ AAQ08928.1 35% 
NAI698_9179 393 Oxidoreductases SHC52 CDF96615.1 36% 
NAI698_9180 153 Hydroxylase GrhM AAM33665.1 38% 
NAI698_9181 583 
Acetyl-CoA carboxylase biotin 
carboxylase 
 CAD55505.1 66% 
NAI698_9182 168 
MarR-like transcriptional 
regulator 
 AGS77345.1 34% 
NAI698_9183 569 Drug resistance transporter  BAJ52670.1 43% 
NAI698_9184 255 ACP-reductase SanS ADG86311.1 40% 
NAI698_9185 276 O-methyltransferase PieB2 AEZ54383.1 47% 
NAI698_9186 555 Halogenase PrlN AGC24268.1 53% 
NAI698_9187 145 Ester Cyclase SnoL ACB47065.1 32% 
NAI698_9188 168 Cupin domain protein  CAQ64713.1 35% 
NAI698_9189 146 Ester Cyclase Lct51 ABX71134.1 31% 
NAI698_9190 435 Membrane antiporter  ADU86006.1 61% 
NAI698_9191 560 Halogenase CtcP AEI98659.1 52% 
NAI698_9192 147 Hypothetical protein  AEH42476.1 29% 
NAI698_9193 530 Monoxygenase RdmE AAA83424.1 45% 
NAI698_9194 590 Peptidase  AAC26133.1 29% 
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4.4. Discussion 
This work describes the first hyper-halogenated angucyclinone. They represent an 
additional example of halogenated metabolites produced by Actinoallomurus. Indeed, this 
genus has been previously reported to produce spirotetronates with multiple halogens in the 
pyrrole moiety and a lantibiotic with a halogenated tryptophan residue (Cruz, 2015; Mazzetti 
et al., 2012). While the presence of a third chlorine atom in the pyrrole moiety resulted in a 
lower antibacterial activity in the spirotetronate NAI-414, allocyclinones almost present a 
linear relationship between antibacterial activity and number of chlorine substituents on the 
methyl group.  The increased number of chlorines results in progressively higher molecular 
weight and is expected to result in higher lipophilicity. The most halogenated compounds 3 
and 4 possess the highest antibacterial activity (in µg/ml), which suggests that lipophilicity is 
important for antibacterial potency. However, compounds 1 and 2 show an inversion in their 
HPLC retention times and also in their relative potency against Streptococcus pyogenes (but 
not with the other strains), suggesting the interplay of different factors in antibacterial potency 
and HPLC retention times.  
Other to the compounds 1-4 that were analysed in more detail, additional molecules 
were 5, 6, and 7, all differing for the substituent at position 3 (Figure 4.1): a carboxylic acid 
(5), an alcohol (6), or an aldehyde (7). Above we presented evidence that these compounds can 
be formed by conversion of the halogenated counterparts 4, 2 and 3, respectively, which 
suggest they are not biosynthetic intermediates but form as the results of formal hydrolysis of 
the chlorinated metabolites. Indeed, the methyl at position 3 is likely to derive from the acetate 
starter unit of the polyketide chain, and to be subsequently converted into 2, 3 and 4 by the 
progressive action of halogenase(s). In this respect, it is tempting to speculate that one of the 
two halogenases specified by the allocyclinone BGC is involved in halogenation of the 
aromatic ring, while the other modifies the methyl group. 
Allocyclinones, although previously unreported, might not be uncommon metabolites 
within the genus Actinoallomurus, since we identified several producer strains. A retrospective 
analysis by Baltz highlighted the correlation between the frequency at which different 
antibiotics were encountered during screening programs and the history of antibiotic discovery 
during the so called 'golden era' (Baltz, 2007). It is thus not surprising that, when systematically 
evaluating a poorly explored taxon such as Actinoallomurus, the first identified metabolites 
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would represent the 'low-hanging fruits' for this genus. Indeed, the most abundant and most 
active congener, allocyclinone D, fits well within this definition: it is produced by different 
phylotypes (or by a frequent phylotype such as Alp24); it is produced in relatively high amounts 
by different isolates (>100 µg/mL); and it has good antimicrobial activity (MIC < 1 µg/mL 
against S. aureus). Compounds like this are thus hard to miss in a screening program. 
Nonetheless, the low-hanging fruits within an unexplored taxonomic groups may still provide 
interesting structural features and bioactivities. 
This work was halted with the discovery of the molecular structure of allocyclinone and 
the partial characterization of the organism. Although it could have been interesting to deepen 
the characterization of both, the overall goal of this PhD project is to deliver new molecular 
structures that have the potential to become leads in a drug discovery pipeline. The 
angucyclinone family does not fall in this category. Angucyclinones are a very large family of 
compounds with a broad range of activities, however it is also true that none of the members 
has succeeded as an antibacterial agent, with lipophilicity and cytotoxicity as major hurdles. 
Moreover, completing the whole characterization of this molecules required time and 
techniques that went beyond the scope of this project. 
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5. A BROMINATED VARIANT OF THE 
LANTIBIOTIC NAI-107 WITH ENHANCED 
ANTIBACTERIAL POTENCY 
 
5.1. Introduction 
The threat posed by the increasing prevalence of antibiotic resistant bacterial pathogens 
is prompting a renewed interest in additional classes of antibacterial agents not affected by 
prevailing resistance mechanisms.  One class that is attracting increasing attention is 
represented by the lantibiotics.  These ribosomally-synthesized peptides, characterized by a 
variable number of lanthionine residues, bind to lipid II, a key intermediate in peptidoglycan 
biosynthesis that is also targeted by the glycopeptides (Arnison et al., 2013). While some 
bacterial pathogens can produce alternative lipid II intermediates that escape glycopeptide 
action, they remain equally sensitive to lantibiotics (Schneider and Sahl, 2010). This feature, 
and the increasing number of lantibiotics discovered by bioassay-based screening or genome 
mining, are among the driving forces behind this renewed interest in this class of antibacterial 
agents (Arnison et al., 2013; Zhang et al., 2015). 
 
Figure  5.1 - Structure of NAI-107 and NAI-108 and of the corresponding major congeners. 
 
The lantibiotic NAI-107 (Fig.  5.1) is among the most potent lantibiotics reported so 
far.  It belongs to the same class as nisin, the most studied lantibiotic, with which it shares the 
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two N-terminal lanthionine rings.  NAI-107 can form complexes with bactoprenol-
pyrophosphate-coupled precursors of the bacterial cell wall, including lipid II, and interferes 
with membrane function, (Munch et al., 2014) consistent with its high potency and rapid 
bactericidal activity.  These features, together with sustained concentrations observed in 
plasma, explain NAI-107's efficacy in different animal models of infection (Jabes et al., 2011; 
Lepak et al., 2015)  Unusual among lantibiotics, NAI-107 is produced by Microbispora sp. 
ID107891 as a complex of related molecules, differing for the extent of hydroxylation at proline 
residue 14 (zero, one or two hydroxyl groups can be present) and for the presence of chlorine 
or hydrogen on tryptophan residue 4 (Fig.  5.1)(Maffioli et al., 2014). 
This chapter contains a manuscript, published on J Nat Prod (DOI: 
10.1021/acs.jnatprod.5b00576), the manuscript reports the substitution of chlorine with 
bromine in the lantibiotic NAI-107, which is a promising drug candidate for Gram-positive 
infections. This substitution was effectively performed firstly by a recently discovered new 
producer of NAI-107, Actinoallomurus strain ID145699 that was originated from the screening 
exercises performed in this project, and later by the unrelated actinomycete Microbispora sp. 
ID107891. In addition to representing the first example of a brominated lanthipeptide, the 
brominated NAI-107 variant shows a small but consistent increase in potency against bacterial 
pathogens, which are killed at equivalent rates as the parent lantibiotic but at lower 
concentrations. The brominated lantibiotic reported in the manuscript thus further expands 
chemical diversity in this family of lantibiotics and provide further insights into structural 
features that make these compounds highly potent against bacterial pathogens. 
5.2. Experimental Section 
General experimental procedures.  For monitoring metabolites production analytical 
HPLC was performed on Shimadzu Series 10 spectrophotometer (Kyoto, Japan), equipped 
with a reverse-phase column, Lichrospher RP-18, 5μm, 4.6 x 125 mm (Merck, Darmstadt, 
Germany), phase A as 0.1% trifluoroacetic acid (TFA), phase B as acetonitrile, and the flow 
rate was 1 mL/min.  The program consisted of a linear gradient from 10% to 36% phase B in 
5 min; from 36% to 50% phase B in 7 min; and from 50% to 80% phase B in 1 min; followed 
by a 4-min isocratic step at 80% phase B and column re-equilibration. UV detection was at 230 
nm.  
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LC-MS analyses were performed with a Dionex UltiMate 3000 liquid chromatographer 
equipped with an Atlantis T3 RP18, 3 µm, 50 x 4.6 mm column eluted at 0.8 mL/min at 40 
°C.  Elution was with a 11 min multistep program that consisted of 10%, 10%, 95%, 95%, and 
10% phase B at 0, 1, 7 and 9 min, respectively [phase A was 0.05% TFA (v/v) in H2O and 
phase B was CH3CN].  The effluent from the column was split 1:1 into a photodiode array 
detector and into the ESI interface of a Thermo scientific LCQ Fleet mass spectrometer with a 
tridimensional ion trap in the positive ionization mode.   
1H-NMR spectra were measured in CD3CN-D2O at 298K using an AMX 400 MHz 
spectrometer.  Chemical shifts are reported relative to D2O (δ 4.79 ppm). 
The concentrations of NAI-107 and of NAI-108 in microbial fermentation extracts or 
partially purified fractions were established by measuring areas of relevant HPLC peaks in 
comparison with an internal standard of pure NAI-107 obtained from Microbispora sp. 
ID107891 as described (Monciardini, P., et al. 2015). 
Actinomycete strains and media. Actinoallomurus strain ID145699, which was 
isolated from a soil sample collected in Northern Italy (GPS: 45.633207, 8.964064), is from 
the NAICONS strain library. It was propagated on S1-5.5 plates at 30 °C. A loopful of 
mycelium was used to inoculate AF-A medium (10 g/L dextrose monohydrate, 4 g/L soybean 
meal, 1 g/L yeast extract, 0.5 g/L NaCl, 1.5 g/L  2-(N-morpholino)ethanesulfonic acid, pH 
adjusted to 5.6) in shake-ﬂasks.   After 8 days in a rotatory shaker (200 rpm) at 30 °C, cultures 
were harvested and stored at -80 ºC.  Subsequent inocula were made using a 10% (v/v) 
inoculum from frozen stocks.  When appropriate, NaCl was substituted with 1.03 g/L KBr, 1.4 
g/L KI or 0.5 g/L KF in AF-A medium. It should be noted that yeast extract and soybean meal 
provide chloride at a calculated concentration of 19 mg/L, whereas a 10% inoculum from AF-
A medium is expected to contribute further 30 mg/L of chloride. PCR amplification of the 16S 
rRNA gene sequence was performed as described and the resulting sequence from 
Actinoallomurus sp. ID145699 has been deposited under accession number KT225504.  
Microbispora sp. ID107891 was maintained and grown as described 
previously(Monciardini, 2015). The GE82G10 medium used for Microbispora sp. ID107891 
consisted of: 10 g/L dextrose monohydrate, 20 g/L maize dextrin, 15 g/L soymeal, 5 g/L yeast 
extract, 2 g/L NaCl, 1 g/L CaCO3, 1/g L agar, 0.15 ml/L polypropylene glycol P2000, pH 7.3; 
when appropriate, NaCl was substituted with 2 g/L KBr. 
Production and recovery of NAI-108. After a 5-days cultivation of Microbispora sp. 
ID107891 in KBr-supplemented GE82G10 medium, a 1.6-L culture (containing approximately 
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200 mg lantibiotic) was acidified to pH 3 with sulfuric acid and paper-filtered. The collected 
material (0.5-L) was treated with one volume EtOH-AcOH 92:8 v/v and shaken overnight at 
room temperature.  This procedure was repeated twice.  After centrifugation (3200 rcf, 10 min), 
the combined extracts (2-L) contained 113 mg lantibiotic.  After evaporation under vacuum, 
the residue was resuspended in 5 mL H2O-dimethylformamide 1:1 and purified by reverse-
phase medium pressure liquid chromatography in a Combiflash system (Teledyne ISCO, 
Lincoln, NE, USA) using an RP18 60 g column, a 30-min linear gradient of 0.01 M AcOH - 
acetonitrile (from 20% to 90% of eluent B) at 30 mL/min with a 230-nm detection wavelength.  
Fractions eluting at 50% acetonitrile were combined and, after removing solvent under 
vacuum, afforded 265 mg of a solid residue containing 21% total lantibiotic, as established by 
HPLC.  The residue was suspended in 25 mL H2O-EtOH (2:3) and, after adjusting the pH to 
3.5 with hydrochloric acid, it was resolved by ion exchange chromatography using 40 mL of 
activated Toyopearl SP 550C resin in a column (3x40 cm column) previously equilibrated with 
five bed volumes (BV) of 50% EtOH at 5 mL/min.  The resin was washed with 8 BV of 0.04 
M AcONH4-EtOH 1:1 (adjusted to pH 5.2 with AcOH) and the lantibiotic was eluted using 20 
BV of 0.05 M NH4Cl-EtOH 1:1 (adjusted to pH 3.5 with diluted hydrochloric acid).  
Lantibiotic-containing fractions were pooled and, after drying under vacuum, the residue was 
washed twice with water and once with acetone.  The product was recovered by centrifugation 
at 1800 rcf for 10 min and dried at 40 °C overnight under vacuum, yielding 30 mg of beige 
solid. 
Antibacterial assays. MICs were determined as previously described (Monciardini, P., 
et al. 2015), using media supplemented with 0.02% bovine serum albumin.  Time-kill assays 
were performed using 10 mL of Staphylococcus aureus ATCC 29213 (or Enterococcus 
faecium L568) exponential cultures in Müller-Hinton broth. Antibiotics were added as 0.1 mL 
solutions in 10% DMSO at appropriate concentrations to achieve the desired final 
concentration values after a 100 fold dilution.  Controls were made adding an equivalent 
amount of 10% DMSO to the culture.  At defined time points, aliquots were withdrawn and the 
number of viable colonies was determined by placing 0.1 mL from serial dilutions onto Müller-
Hinton agar plates.  Plates were incubated at 37 °C. All strains were either from the ATCC or 
from the NAICONS collection (the latter indicated by L- or ND- prefixes). The profile of both 
NAI-107 and Nai-108 complex are described in Table 6.1. 
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5.3. Results  
Discovery of NAI-107 from Actinoallomurus.  While screening 200 Actinoallomurus 
isolates for antimicrobial activity, an extract from strain ID145699 inhibited growth of Gram-
positive bacteria. HPLC fractionation of a mycelium extract led to the identification of the 
active fractions (Fig.  5.2), whose UV spectra, masses and lack of fragmentation corresponded 
to those of NAI-107 purified from Microbispora sp. ID107891 (Appendix 2  - Figure 1) 
(Maffioli et al., 2014). Under the tested conditions, strain ID145699 produced approximately 
5 µg/ml NAI-107. 
Figure 5.2 - HPLC profile at 230 nm of Actinoallomurus sp. ID145699. The boxed area highlights the HPLC 
fractions that inhibited bacterial growth with the main NAI-107 congeners labelled. Under these 
chromatographic conditions, F2 and F0 are only partially resolved. 
On the basis of its 16S rRNA gene sequence, strain ID145699 was confirmed to belong to 
the genus Actinoallomurus. The finding of a NAI-107 producer among a few Actinoallomurus 
strains was somehow unexpected: this lantibiotic emerged after screening 120,000 microbial 
fermentation extracts derived from 40,000 actinomycetes(Monciardini et al., 2014), and has 
been identified only as a product of two strains belonging to the genus Microbispora 
(Castiglione et al., 2008; Foulston and Bibb, 2011).  It should be noted that the genera 
Actinoallomurus and Microbispora belong to the distinct families: Thermomonosporaceae and 
Streptosporangeacea within the order Streptosporangiales.  Within the Firmicutes, it has been 
reported that the same lantibiotic is generally produced by the same bacterial species or by 
members of the same genus but this general rule might not apply to actinomycete-derived 
lantibiotics.  While this manuscript was in preparation, Carrano and co-workers reported NAI-
107 production by an apparently independent Actinoallomurus isolate (Carrano et al., 2015). 
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Actinoallomurus strain ID145699 produced NAI-107 as a complex of the A0 and A2 
congeners, with m/z+ of 1108 and 1116, respectively, and of their dechlorinated counterparts 
F0 and F2, with m/z
+ of 1091 and 1099, all corresponding to their double-charged ions 
[M+2H]2+ (Appendix 2 – Figure 1). Congeners A2 and F2 carry a mono-hydroxylated Pro14 
residue (Fig.  5.1). Under the examined conditions, only traces were detected of A1, carrying a 
di-hydroxylated Pro14 residue, and of the corresponding dehalogenated congener F1. In terms 
of proline hydroxylation, the complex produced by the Actinoallomurus strain ID145699 thus 
appears to be intermediate between the complex produced by Microbispora corallina 
NRRL30420, which yields the non-hydroxylated A0 as the main peak, and that of Microbispora 
sp. ID107891, which produces the mono- and di-hydroxylated Pro14 variants in equivalent 
amounts, with only traces of A0 (Maffioli et al., 2014).  
Incorporation of bromine into NAI-107 by Actinoallomurus. Previous work had indicated 
that Actinoallomurus frequently produces chlorine-containing metabolites (Mazzetti et al., 
2012; Pozzi et al., 2011), including hyper-chlorinated angucyclinones (Cruz, 2015). 
Furthermore, we were able to show an effective substitution of two chlorine atoms with 
bromine in the pyrrole moiety of NAI-414, a recently described spirotetronate from 
Actinoallomurus (Mazzetti et al., 2012).These results prompted us to investigate whether strain 
ID145699 could also effectively incorporate other halogens into NAI-107.  
The medium used for NAI-107 production (AF-A; see 5.2 Experimental Section) is a 
complex medium containing 0.5 g/L (8.6 mM) NaCl. Thus, experiments were carried using the 
same medium but substituting NaCl with KBr at an identical molar concentration. The addition 
of 8.6 mM KBr to the medium readily resulted in the formation of new peaks having retention 
times similar to those of the NAI-107 complex but slightly more lipophilic (Fig.  5.3A). The 
m/z+ values of the corresponding molecules, 46 amu higher than the chlorinated congeners, 
were consistent with the replacement of the single chlorine atom by a bromine in the A0 and 
A2 congeners (Appendix 2 – Figure 1). Under these conditions, strain ID145699 produced 
around 7 µg/ml of brominated lantibiotic consisting mainly of the A2 and A0 congeners in a 3:2 
ratio. 
One of the observed consequences of adding bromide to the medium was the appearance of 
additional compounds (Fig.  5.3A) whose m/z+ ratios were consistent with N-terminally 
extended variants of A0 and A2 carrying a Gly-Pro-Ala tripeptide preceding the N-terminal Val 
in mature NAI-107 (Fig.  5.1). These N-terminal extensions were previously detected in the 
non-hydroxylated NAI-107 congeners when Microbispora sp. ID107891 was grown in 
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minimal medium (Maffioli et al., 2014). It should be noted that, with an increase of the F 
congeners to approximately 1.5 µg/ml, we were occasionally able to detect small amounts of 
the GPA-extended variants of congeners F0 and F2 in the KBr-fed culture of Actinoallomurus 
sp. ID145699 and of Microbispora ID107891 (Appendix 2 – Figure 1).  
Thus, at least the last three C-terminal amino acids in the leader peptide must be identical 
between the Actinoallomurus and the Microbispora producers. Furthermore, these results 
suggest that abnormal processing of the precursor peptide occurs at the same secondary 
location in two different Actinobacteria genera, despite the fact that the NAI-107 gene cluster 
does not encode a recognizable precursor-processing protease (Foulston and Bibb, 2010; Sosio 
et al., 2014). Indeed the lack of a protease LanP seems to be a common characteristic of clusters 
responsible for the biosynthesis of other lanthipetides, which can be heterologously expressed 
and processed by apparently promiscuous host proteases present in different Actinobacteria 
(Krawczyk et al., 2013). 
We also investigated the effects of adding either KF or KI to the medium. Although no 
significant changes in biomass or culture pH were seen under these conditions, we could only 
detect traces of A and F congeners, and no evidence for incorporation of other halogens into 
the lantibiotic (data not shown). The presence of a small amount of chlorinated congeners might 
result from a carryover from the inoculum grown in medium AF-A, which contains NaCl or 
from residual chloride in medium components (see 5.2 Experimental Section). The lack of 
fluoride or iodide incorporation is consistent with the properties expected from halogenases 
which can readily use supplemented bromide but not fluoride or iodide (van Pee, 2012). 
Nonetheless, the overall low yield of lantibiotic in KF- and KI-supplemented media suggests 
that halogenation is necessary to trigger full production of NAI-107 in Actinoallomurus 
ID145699. 
Incorporation of bromine into NAI-107 by Microbispora. We next wondered whether 
Microbispora sp. ID107891, which is a better characterized NAI-107 producer than 
Actinoallomurus sp. ID145699 (Maffioli et al., 2014), was also able to produce a Br-containing 
lantibiotic.  When grown under the same conditions (i.e., AF-A medium with KBr substituting 
NaCl), Microbispora sp. ID107891 readily produced brominated compounds, even if overall 
titers were one third that in NaCl-supplemented medium (Fig.  5.3B).  Nonetheless, strain 
ID107891 produced more Br-containing congeners than strain ID145699 (compare blue line in 
Fig.  5.3 A and B).  Thus, once we achieved proof of concept that Br incorporation into NAI-
107 was not confined to Actinoallomurus, we resorted to the better-characterized Microbispora 
  
89 
 
sp. ID107891 to obtain sufficient amounts of brominated lantibiotic for further 
characterization. It should be noted that in the AF-A based media Microbispora sp. ID107891 
produced significant amounts of GPA-extended congeners (Fig.  5.3B).  
 
Figure 5.3 - Incorporation of Br into the lantibiotic. Selected portion of the HPLC profile of extracts from 
Actinoallomurus sp. ID145699 (panel A) or from Microbispora sp. ID107891 (panel B) grown in medium AF-A 
(red line) or AF-A containing KBr instead of NaCl (blue line). Numbers 1, 2 and 3 over the shaded areas denote 
the F, GPA-extended and A congeners, respectively. Note the differences in retention times of peaks 2 and 3 
between red- and blue-line chromatograms, due to the different halogens present in the lantibiotic. Note also that 
the F congeners are F2 and F0 in panel A, and F1 and F2 in panel B, whereas the A congeners are A2 and A0 in 
panel A, and A1 and A2 in panel B. 
In a suitable medium with acceptable concentrations of Cl-containing ingredients, 
supplemented with 2 g/L KBr (see 5.3. Experimental Section), Microbispora sp. ID107891 
produced a complex consisting mostly of brominated congeners. The overall production after 
a 5-day cultivation was around 50 mg/L, comparable to the levels observed in KBr-free 
medium. As seen for the production of chlorinated lantibiotics (Monciardini, P., Unpublished 
experiments), addition of 1 g/L ammonium sulphate allowed a 3-fold increase in the titer of 
brominated molecules (data not shown). 
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Characterization of the brominated lantibiotic. The lantibiotic was recovered from a 2.4-
L culture of KBr-supplemented medium (see 5.3. Experimental Section), leading to about 30 
mg of purified complex with a relative congener distribution summarized in Table 6.1. The 
presence of a Br-Trp residue was confirmed by 1H-NMR analysis that highlighted differences 
in the chemical shifts of protons belonging to the indole ring (Appendix 2 – Figure 2). Among 
them, the aromatic proton at position 4 was particularly diagnostic: the resonance at 7.35 ppm 
in the chlorinated congeners was shifted to 7.5 ppm in the brominated congeners, in agreement 
with the values expected for halogenated aromatic systems (Spiesecke and Schneider, 1961). 
All other chemical shifts were superimposable with those of NAI-107 (Appendix 2 – Figure 
2). While the chemical shifts derived from the Pro14 residue fall in a complex region of the 
spectrum (Maffioli et al., 2014), the overall results are consistent with the presence of 4-OH or 
3,4-di-OH Pro14 residue. 
 
Table 5.1 - Relative congener distribution in the NAI-107 and NAI-108 batches 
purified from Microbispora sp. ID107891. a 
Congener RT  amu Cl (%) b Br (%) c 
F1 8.5 2232 <1 <1 
F2 8.5 2194 <1 <1 
F0 8.0 2178 <1 <1 
NAI-107 A1 10.0 2244 58.7 6.3 
NAI-107 A2 10.0 2228 39.0 6,6 
NAI-107 A0 10.5 2212 - 2.3 
NAI-108 A1 10.25 2290 - 34.7 
NAI-108 A2 10.25 2274 - 34.3 
NAI-108 A0 10.75 2262 - 6.3 
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a Established by integrating UV-absorbing HPLC peaks. b Internal 
NAI-107 reference standard. c Purified NAI-108 batch as described 
in this work. 
 
Thus, these experiments confirmed that the Br-containing lantibiotic is identical to 
NAI-107 except for the substitution of 5-Cl- with 5-Br-Trp and is produced as a complex of 
closely related congeners, differing for the presence or absence of halogen at Trp4 and for the 
presence of zero, one or two hydroxyl groups at Pro14 (Maffioli et al., 2014).  Further variation 
is brought by the – presumably spontaneous – sulfur oxidation of the first lanthionine (Fig.  
5.1). For the sake of simplicity, we refer to the batches of lantibiotic consisting mostly of Cl- 
and Br-containing metabolites as "NAI-107" and "NAI-108", respectively. This artificial 
distinction allows maintaining the same nomenclature for the brominated variants as for the 
NAI-107 congeners (Monciardini, P., et al. 2015). Accordingly, NAI-108 A1, A2 and A0 
represent compounds carrying two, one and zero hydroxyl groups, respectively, at Pro14. 
Obviously, the F congeners, which are devoid of halogens, are identical minor congeners of 
both NAI-107 and NAI-108 preparations (Fig.  5.1).  
Antibacterial activity of the brominated lantibiotic. The newly prepared NAI-108 
batch consisted mostly of A1 and A2, and contained lower amounts of chlorinated or non-
halogenated congeners (Table 5.1).  We next investigated whether the presence of a Br-Trp 
residue had any impact on antibacterial activity.  The results are reported in Table 5.2.  
Interestingly, on the basis of its minimum inhibitory concentrations (MICs), NAI-108 turned 
out to be about twice as active as NAI-107 against Staphylococcus, Streptococcus and 
Enterococcus spp.  
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 One important feature of NAI-107 is its rapid in vitro bactericidal activity, which 
results in >99.9% killing of an exponential culture within 30 min after addition of the 
compound at 1xMIC (Munch et al., 2014). We thus investigated whether this effect could also 
be observed with the more potent variant NAI-108.  Fig.  5.4A reports the results of an 
experiment in which the killing activity of identical concentrations of NAI-107 and NAI-108 
was evaluated against Staphylococcus aureus ATCC29213.  At the lowest concentration tested 
(1xMIC, or 0.25 µg/ml), NAI-108 rapidly killed the strain, leading to a 5-log reduction in viable 
cells within 30 min.  Conversely, the same concentration of NAI-107 (equivalent to 0.5xMIC) 
resulted in only a 3-log reduction in viable counts, followed by strain growth at a rate 
Table 5.2 – Antibacterial activities of NAI-107 and NAI-108 
Strain 
MIC (μg/mL) 
Resistance 
 typea 
NAI-108 NAI-107 VANa 
Staphylococcus aureus ATCC2913 MSSA 0.25 0.5 0.5 
Staphylococcus aureus L100 MSSA ≤0.06 ≤0.06 0.5 
Staphylococcus aureus ND523 MRSA 0.25 0.5 n.d. 
Staphylococcus aureus ND605 MRSA 0.125 0.25 1 
Staphylococcus aureus L1400 MRSA 0.5 0.5 2 
Staphylococcus aureus L3797 GISA 2 4 8 
Staphylococcus aureus L3798 GISA MRSA 2 2 16 
Streptococcus pneumoniae ATCC49619  0.004 0.004 0.25 
Streptococcus pneumoniae L44  0.03 0.06 0.5 
Streptococcus pyogenes L49  0.001 0.002 0.5 
Enterococcus faecalis L559  2 2 1 
Enterococcus faecalis L560 VanA 0.25 1 >64 
Enterococcus faecium L568  4 8 2 
Enterococcus faecium L569 VanA 2 4 >64 
a Abbreviations: MRSA/MSSA/GISA, methicillin-resistant/ methicillin-susceptible/ 
glycopeptide-intermediate Staph. aureus; VanA, vancomycin resistant; VAN, vancomycin. 
n.d., not determined. 
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comparable to that in the absence of antibiotic (Fig.  5.4A).  As expected, higher lantibiotic 
concentrations resulted in an equivalent extent of killing for both lantibiotics. 
 
Figure 5.4 - Time-kill assays. Viability of an exponential culture of Staph. aureus ATCC 29213 (panel A) or E. 
faecium L568 (Panel B) exposed to NAI-107 (dashed line) or NAI-108 (red line) at the indicated concentrations. 
Empty symbols with solid black line refers to untreated controls. 
When an equivalent experiment was performed with Enterococcus faecium (Fig.  5.4B), 
superimposable results were seen with identical concentrations of both lantibiotics.  With this 
strain, killing occurred at a lower rate and 6 h were necessary to achieve a 5-log reduction in 
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viable counts, which required ≥8 µg/ml of each lantibiotic, equivalent to 2x and 1xMIC for 
NAI-108 and NAI-107, respectively.  Interestingly, a significant killing effect of NAI-107 was 
also observed at 0.5xMIC, suggesting that, as with Staph. aureus (Fig.  5.4A), exponentially 
growing cultures are more sensitive to NAI-107 than the stationary phase cultures used for 
standard MIC determination. 
In conclusion, the data reported indicate that NAI-108 is slightly but consistently more 
active than NAI-107. Furthermore, NAI-108 shows time-kill activity against two different 
bacterial pathogens at 1xMIC, as does NAI-107, suggesting the possibility of using lower 
therapeutic doses of the former compound. 
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5.4. Discussion 
Variations in type I lantibiotics have been found within Actinobacteria. Indeed, strains 
belonging to the genera Streptomyces, Streptosporangium and Planomonospora have been 
recently reported to produce lantibiotic variants with one to three amino acid differences  
(Maffioli et al., 2015). These molecules, designated as "97-like", share the same amino acid 
length and lanthionine rings with NAI-107, but possess lower antibacterial activity than NAI-
107, with interesting MICs observed only with semi-synthetic derivatives. In one case, the 
same lantibiotic was identified as the product of two strains belonging to the unrelated genera 
Planomonospora and Streptomyces (Maffioli et al., 2015). It should be noted that the 97-like 
lantibiotics present just the minimal set of post-translational modifications (i.e., dehydration 
and lanthionine formation) required for this family of RiPPs (Arnison et al. 2013), whereas 
NAI-107 undergoes additional modifications (i.e halogenation of Trp4, hydroxylation of Pro14 
and decaboxylation of the C-terminal Cys). Thus, the finding that a lantibiotic with the same 
amino acid sequence and the same extensive post-translational modifications is produced by 
microorganisms belonging to the unrelated genera Microbispora and Actinoallomurus is per 
se an interesting event, which casts further shadow on the early assumption that lantibiotics are 
species-specific compounds. The occurrence of NAI-107 as a product of Microbispora and 
Actinoallomurus can result from one of two possible explanations: either the corresponding 
gene cluster was recently acquired by horizontal gene transfer, or NAI-107 offers little room 
for amino acid substitutions while maintaining all the post-translational modifications, and the 
corresponding gene cluster has been transmitted vertically within a common ancestor of the 
Streptosporangiales but lost in most of the progeny. Personally, I am more inclined to the 
former possibility, since variations in amino acid sequence of the 97-like molecules have been 
observed and it is likely that the further post-translational modifications of NAI-107 are the 
result of later gene acquisition events. 
Several examples have been reported in the literature in which, under appropriate 
conditions, Br can substitute Cl in microbial metabolites.  This feature relates to the higher 
reactivity of Br- than Cl- ions and is consistent with the mechanism of halogenating enzymes 
(van Pee, 2012). To our knowledge, NAI-107 represents the only reported example of a 
chlorinated lantibiotic (Arnison et al., 2013) and, hence, the work reported here represents the 
first description of a Br-containing lantibiotic, suggesting that the Trp halogenases specified 
by the mib clusters from Microbispora (Foulston and Bibb, 2010; Sosio et al., 2014) and by 
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the corresponding cluster from Actinoallomurus sp. ID145699 are also capable of efficiently 
incorporating Br when exposed to sufficient bromide concentrations. 
It should be noted that most Br-containing microbial metabolites are usually less active 
than the corresponding chlorinated congeners with, sometimes, significant drops in 
antibacterial activity (Ajisaka et al., 1969; Bister et al., 2003; Castiglione et al., 2008; 
Hochlowski et al., 1997). There are also occasional reports of brominated metabolites showing 
higher antimicrobial activity (Ezaki et al., 1983) or higher toxicity toward tumour cells (Ogawa 
et al., 1989) than their chlorinated analogues. NAI-108 is slightly but consistently more active 
than NAI-107.  
It has been previously shown that the F congeners, which contain a naked Trp4 residue, 
are less active than the chlorinated A congeners and that the former are more hydrophilic than 
the latter, suggesting that the hydrophobicity at Trp4 influences antibacterial potency (Maffioli 
et al., 2014). This observation is further corroborated by the results presented here, since 
substitution of Cl with Br is expected to enhance the hydrophobicity of this lantibiotic, 
consistent with the slightly higher retention time of the brominated versus chlorinated 
congeners (Table 5.1).  It is worth mentioning that the peptide backbone of the first two N-
terminal lanthionine rings of NAI-107 is likely to be involved in lipid II binding (Munch et al., 
2014). This in turn suggests that Trp4 might directly interact with the bacterial membrane, 
explaining why a higher hydrophobicity at this residue leads to improved antibacterial potency. 
NAI-107 has pharmacological properties that make it a suitable candidate for treating 
serious infections by Gram-positive pathogens (Lepak et al., 2015). The same lanthionine ring 
topology as in NAI-107 is present in a recently described actinomycete-produced lantibiotics, 
whose antibacterial activity can be substantially enhanced by a simple semi-synthetic 
derivatization (Maffioli et al., 2015). The work described here provides additional players in 
this promising family of antibacterial agents.  
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6. GENOMIC ANALYSIS OF 
ACTINOALLOMURUS 
6.1. Introduction  
The final part of my project involved the characterization of the genome sequences of 
four Actinoallomurus strains. Throughout these three years two strains were initially sequenced 
as part of the metabolite characterization by analysing the putative BGCs devoted to the 
synthesis of the compounds: strain ID145113, with analysis of the BGC providing insights for 
the structural elucidation of NAI-113 (Chapter 3); and strain ID145698, with the BGC 
revealing unusual biosynthetic features of allocyclinone (Chapter 4). By the end of the project, 
I decided to analyse two more Actinoallomurus strains in order to have a reasonable number of 
strains for some genomic analysis of the genus. The four Actinoallomurus genomes were 
compared amongst each other and against reference genomes, which were chosen on the basis 
of their phylogenetic relatedness to Actinoallomurus or their relevance as producers of 
secondary metabolites within the class Actinobacteria.  
6.2. Experimental Section  
For Genome sequencing: Five mL of a three days old culture was centrifuged at 1800 
rcf for 10 minutes, the pellet was resuspended in 10 mL of 10.3% Sucrose. A new 
centrifugation was performed (1800rcf, 10 min) and the pellet was resuspended in 5 ml of SET 
buffer. pH was adjusted to 8 with NaOH. Lysozyme was added to a final concentration of 
20mg/mL, and left to incubate at 37ºC for 24h, then 100 μg of ribonuclease were added and 
incubated for another 4 hours at 37ºC. Finally, 12mg of Proteinase K were added leaving it 
incubating for 2 more hours. At this point SDS was added to a final concentration of 1% and 
put to incubate at 55ºC for 20 hours. On the next day added 2 mL of 5M NaCl followed 2 mL 
of phenol-chloroform-isomylalcohol (pH8). Mixed gently and let the two liquid phases 
separate by centrifuging at 1800 rcf during 10 min. Retrieved the aqueous phase and added 2ml 
of fresh phenol-chloroform-isomylalcohol, mixed, centrifuged and discarded the heavy phase. 
Added one volume of ice cold isopropanol. Mixed gently until DNA precipitates. Using a 
sealed Pasteur pipette transferred the DNA to a new tube. Washed it with 70% ethanol and let 
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it dry. Resuspended in water. Sequencing of the amplified PCR products was done by 
Cogentech. 
Bioinformatic analysis. The sequencing was conducted on an Illumina MiSeq, 
reading  2x250 bases of a paired-end and a mate-pair library. These libraries had pair sizes of 700 bp 
and 7.600 bp, respectively. Alignments of single genes or gene products were done through the 
workflow platform Armadillo v1.1. For DNA alignments, ClustalW2 was used with a gap 
opening penalty of 10; Extension penalty of 0.2. The alignment of protein sequences was 
performed using MUSCLE algorithm at a maximal number of iteration of 4. Distances were 
calculated based on Jones-Taylor-Thornton matrix which was then used to create the 
phylogenetic trees. The visualization of all phylogenetic trees was achieved with 
Archaeopteryx tool. (Edgar, 2004; Han and Zmasek, 2009; Thompson et al., 1994) Genome 
sequencing was performed by Universität Bielefeld Centrum für Biotechnologie – CeBiTec. 
For the orthology analysis, annotated proteins were subject to all-vs-all BLASTP. OrthoMCL 
package that provided all the tools was used with the following parameters: identity of 50% 
and evalue threshold at 0.00001. (Chen et al., 2006) For the synteny analysis the Symap tool 
was used with a cutoff of 85% identity. (Soderlund et al., 2006) The discovery of the putative 
gene clusters for secondary metabolism was performed using Antismash v3.0.1 tool at the 
default conditions. (Weber et al., 2015) Blast analysis of the genes clusters identified by 
Antismash were also blasted against MIBiG database using the evalue above 0.00001 as a 
cutoff.  
Fosmid library preparation and screening. The DNA extraction was achieved using 
Promega’s Wizard Genomic DNA Purification Kit which, although providing a smaller amount 
of DNA than the method used for genome sequencing, afforded a larger average fragment size. 
After the retrieving the DNA sample with the corrected characteristics the ligation reaction was 
performed with pCC2FOS vector and consequent packaging and transfection using the 
CopyControl HTP Fosmid Library Production Kit with pCC2FOS Vector and following the 
correspondent protocol but the clones were stored in a semiliquid media using SeaPrep agarose 
as described in Gurgui et al. (Gurgui and Piel, 2010) The screening for the inserts of interest  
was performed through PCR using primers designed to amplify fragments at the two ends of 
the cluster (Table 6.1). 
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Table 6.1 – PCR primers for the NAI-113 and Cin-like clusters 
in strain ID145113 genomic library 
Lantipeptide primers 
Left flank (5'->3') Tm 
Forward primer CGGTCCAGTGTTCCGAGTC 60.08 
Reverse primer AATCGCTCGTGGAGGGGATA 60.47 
Product length 588 
Right Flank  (5'->3') Tm 
Forward primer GAGCATCGATCGTCTGGGAC 60.32 
Reverse primer CCGGACAGGAAGATCATCGG 59.97 
Product length 322 
NAI-113 
Right Flank Sequence (5'->3') Tm 
Forward primer ATCTACAGTCTGGTCCCGCT 60.03 
Reverse primer CCCGTGATGACGAGGTTGAA 60.04 
Product length 701 
Left Flank Sequence (5'->3') Tm 
Forward primer GGTGACACGTTCTGGGACAT 59.97 
Reverse primer GTCGATGCTCTTGTCCTGCT 60.11 
Product length 510 
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6.3.  Results  
The features of the four sequenced Actinoallomurus genomes are reported in Table 6.2. 
The genome sizes vary from 8.5Mbp for strain ID145716 to 10.9 for strain ID145698 The four 
genomes show a similar GC content (from 69.4 to 71.2%), coding density (from 89.8 to 85.6%), 
with a number of CDSs ranging from 8325 to 10174 (Table 6.2). In selecting the genomes to 
be used for comparative work, I picked two more representatives of the Thermomonosporaceae 
family (order Streptosporangiales): one Actinomadura sp. and one Thermomonospora sp. 
(Table 6.2). Unfortunately, no additional genomes were available from these genera, and the 
genome of Thermomonospora curvata is substantially smaller than the others (Table 6.2). 
Additional genomes were selected taking advantage of previous analyses performed on one 
strain, each from three distinct genera (Microbispora, Planobispora and Streptosporangium) 
within the Streptosporangiaceae family (order Streptosporangiales). (Tocchetti et al., 2015) 
As outgroup genomes, I selected Streptomyces coelicolor (order Streptomycetales) and 
Actinoplanes friuliensis (order Micromonosporales), both with a large genomic potential to 
produce secondary metabolites.  Table 6.2 shows the general genomic features of all the strains 
used throughout this work.  
Table 6.2 – Features of the genomes used throughout the analyses 
 
Strains Family Order 
Length 
(Mbp) 
GC 
Content 
(%) 
Gene 
Density 
(%) 
CDS 
Accession 
Number 
Actinoallomurus 
ID145113 
Thermomonosporaceae 
Streptosporangiales 
10.7 69.4 85.6 10174 This work 
Actinoallomurus 
ID145698 
10.9 69.9 87.3 10070 This work 
Actinoallomurus 
ID145711 
9.5 71.1 89.8 8899 This work 
Actinoallomurus 
ID145716 
8.47 71.2 86.7 8325 This work 
Actinomadura 
oligospora 
9.35 72.1 85.6 8178 
NZ_JADG0
0000000.1 
Thermomonospora 
curvata 
5.6 71.6 84.8 4895 
NC_013510
.1 
Microbispora sp. 
Streptosporangeacea 
8.7 71.3 89.0 7966 
NZ_JNZQ0
0000000.1 
Planobispora rosea 8.7 70.0 88.0 8071 SRP041970 
Streptosporangium 
roseum 
10.34 70.9 87.4 9043 
NC_013595
.1 
Streptomyces 
coelicolor 
Streptomycetaceae Streptomycetales 8.67 72.1 83.3 8152 
NC_003888
.3 
Actinoplanes 
friuliensis 
Micromonosporaceae Micromonosporales 9.38 70.4 90.4 8621 
NC_022657
.1 
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From the taxonomical point of view, Table 6.2 covers three orders and four different 
families, but the emphasis is on a comparative analysis of members of the Streptosporangiales. 
From the general traits (genome size, GC content and coding density), Actinoallomurus fits 
well with the features observed for filamentous actinomycetes (Table 6.2).   
6.3.1.  Whole-genome comparisons 
The orthology analysis to the panel of strains is described on Table 6.3. That is an all-
vs-all blast analysis of the protein sequences from the eleven strains, with every sequence being 
compared as subject or query. This fact may affect the scoring of the alignments, especially the 
Expect value (e-value) that takes into account also the length of the query sequence. As a 
consequence, there may be cases where the same alignment gives an e-value just below the 
threshold (0.00001) when one of the sequences is used as query and the other as subject, but 
when the roles are reversed the e-value goes above the threshold. As a consequence, the number 
of observed homologues when a proteome is used as a query cannot be identical to that 
observed when it is used as a subject. Nonetheless, the numbers of orthologues observed in 
each pairwise comparison when switching subject and query are very similar (Table 6.3). Note 
also that in Table 6.3 the values in the diagonal actually represent the total of homologs seen 
against all the remaining strains. Thus, these numbers represent the total number of CDSs 
present in any strain minus the singletons (Table 6.3) and those excluded from analysis (see 
below).  
Table 6.3  – Number of homologous proteins among the 10 selected genomes. Top panel absolute values. Bottom 
panel relative values. 
Absolute Values 
Query 
Subject 
ID145113 ID145698 ID145711 ID145716 
Actinom
adura 
Thermomo
nospora 
Microbi
spora 
Planobis
pora 
Streptospo
rangium 
Strepto
myces 
Actinopl
anes 
ID145113 8110 5595 5422 5596 2976 3077 4120 3800 4299 3610 3317 
ID145698 5473 8175 6236 4838 2911 3061 4197 3661 4169 3495 3231 
ID145711 5387 6313 7706 4793 2900 3023 4144 3630 4044 3485 3248 
ID145716 5580 4939 4825 6706 2720 2918 3756 3430 3707 3234 3011 
Actinomadura 2967 2909 2904 2710 4768 2138 2838 2922 3013 3001 2892 
Thermomonosp
ora 3099 3113 3051 2932 2174 4019 2770 2821 2985 2465 2342 
Microbispora 4138 4253 4159 3758 2845 2760 6586 4240 4617 3301 3135 
Planobispora 3779 3696 3627 3412 2887 2789 4215 6473 5022 3171 3162 
Streptosporangi
um 4287 4186 4040 3694 2998 2947 4567 5012 7357 3518 3259 
Streptomyces 3588 3524 3464 3205 2998 2428 3275 3169 3493 5658 3067 
Actinoplanes 3307 3257 3245 2993 2896 2313 3119 3213 3262 3074 5391 
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CoOrthologs 739 829 654 624 682 452 673 691 800 819 864 
Paralogs 566 802 359 320 723 280 407 647 678 919 1077 
Singletons 1683 1571 1041 1436 1757 744 1231 1373 1337 1674 2243 
Total 9970 9971 8816 8247 6917 4891 7978 8072 8946 7768 8248 
Relative Values 
Query 
Subject 
ID145113 ID145698 ID145711 ID145716 
Actinom
adura 
Thermomo
nospora 
Microbi
spora 
Planobis
pora 
Streptospo
rangium 
Strepto
myces 
Actinopl
anes 
ID145113 81% 56% 62% 68% 43% 63% 52% 47% 48% 46% 40% 
ID145698 55% 82% 71% 59% 42% 63% 53% 45% 47% 45% 39% 
ID145711 54% 63% 87% 58% 42% 62% 52% 45% 45% 45% 39% 
ID145716 56% 50% 55% 81% 39% 60% 47% 42% 41% 42% 37% 
Actinomadura 30% 29% 33% 33% 69% 44% 36% 36% 34% 39% 35% 
Thermomonosp
ora 31% 31% 35% 36% 31% 82% 35% 35% 33% 32% 28% 
Microbispora 42% 43% 47% 46% 41% 56% 83% 53% 52% 42% 38% 
Planobispora 38% 37% 41% 41% 42% 57% 53% 80% 56% 41% 38% 
Streptosporangi
um 43% 42% 46% 45% 43% 60% 57% 62% 82% 45% 40% 
Streptomyces 36% 35% 39% 39% 43% 50% 41% 39% 39% 73% 37% 
Actinoplanes 33% 33% 37% 36% 42% 47% 39% 40% 36% 40% 65% 
CoOrthologs 7% 8% 7% 8% 10% 9% 8% 9% 9% 11% 10% 
Paralogs 6% 8% 4% 4% 10% 6% 5% 8% 8% 12% 13% 
Singletons 17% 16% 12% 17% 25% 15% 15% 17% 15% 22% 27% 
Values in diagonal correspond to the total number of homologous of that strain shared with the universe of 10 strains used. The Colouring of the cells ranges from dark 
red to dark green correspond from the lowest to the highest values.  
 
Looking at Strain ID 145113, and going from the top cell onto the bottom of each panel, 
it is observable that 8110 sequences from the analysed 9970 proteins find a homologue with at 
least one other sequence from the set of sequences used for this analysis. On the second table, 
at the same position it is possible to see that this corresponds to 81%. Moving on to the next 
three cells below, a high number of homologues to its peers of the same genus (ID145698; 
ID145711; ID145716) is observed, with the number of sequence around 5500, corresponding 
to 54% to 56% of the strains proteomes. Dropping the reader’s eyes for further two cells it is 
possible to see a comparison of Strain ID 145113 with Actinomadura oligospora and 
Thermomonospora curvata, the other genera belonging to the same family as Actinoallomurus. 
In this case, the number of homologous sequences drops to 2967 for A. oligospora and 3099 
for T./ curvata, corresponding to 30 and 31% of the proteome, respectively. The next three 
cells contain the results from the Streptosporangeaceae family members (Microbispora sp., 
Planobispora rosea, Streptosporangium roseum). In this case the numbers of homologues 
increase, with Microbispora (4138 – 42%) and S. roseum (4287 – 43%) as the most similar 
organisms, while P. roesa (3779 – 38%) has a somewhat lower number. Finally, Streptomyces 
and Actinoplanes, which were chosen as outgroups, show lower number of homologues.  
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The last three lines of Table 6.3 report "Singletons" – protein sequences that have no 
match in the tested conditions and probably represent the proteins unique to this organism 
within the chosen comparators; "Paralogs" – sequences that find homology within the same 
genome; and Co-orthologs – proteins that find a match in the own proteome and in the set of 
proteomes tested. In the case of strain ID145113, Singletons, Paralogs and Co-orthologs are 
1683, 566 and 739, respectively, which correspond to 17, 6 or 7% of the whole proteome. The 
number of Singletons is significant if one considers that three more genomes from the same 
genus were analysed. The very last line of the top panel shows the total of sequences analysed 
during this work. The total number of Table 6.3 does not match that presented in Table 6.2, 
since RNAs and proteins with less than 50 amino acids were removed from the analysis.   
A comparison horizontally reveals the number of homologues found in ID145113 when 
the entire proteome from the other strains was used as query. This cross-comparison is useful 
because of the different numbers of homologues observed when inverting subject and query, 
as explained above, and for taking into account different genome sizes (Table 6.2). For 
example, while "only" 3077 T. curvata sequences find a match in ID145113, this number 
represents 63% of the T. curvata proteome.   
Overall, the data in Table 6.3 provide the following picture. As expected, the four 
Actinoallomurus strains share the largest number of orthologues among themselves, with 
strains ID145698 and 145711 appearing as the most related by this criterion. Nonetheless, each 
strains contains 12-17% of Singletons, not very different from the numbers seen in the other 
strains used in the comparison, where one strain per genus was used. Unexpectedly, however, 
the four Actinoallomurus strains share the highest number of orthologues with other members 
of the Streptosporangiacaea and not with members of Thermomonosporaceae, as would be 
expected from their taxonomic position. 
Although we have performed a comparison with the Cluster of Orthologous Groups 
(COG) database, the results showed no obvious trend (data not shown). However, it is 
important to mention that there seems to be a tendency to abandon this kind of analysis as the 
last published update of COG is over a decade old. Furthermore, the COG database includes 
only four Actinobacteria from the Corynebacterium and Mycobacterium genera, thus far away 
from the group of organisms analysed in this work  (Tatusov et al., 2003). 
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The orthology analysis was taken to a more detailed level with a selected few organisms 
based on the data gathered from Table 6.3. An initial analysis was done amongst the four 
Actinoallomurus strains.  Two main features can be easily observed from the Venn diagram 
(Fig. 6.1A): a significant number of orthologues (3942) common within the four organisms, 
which are likely to include the core Actinoallomurus genome; and an elevated number of 
singletons (between 2569 and 3756 CDSs in each genome). While the former number is 
expected from a number of conserved functions within Actinoallomurus, the high number of 
singletons provides grounds for the existence of an extended pangenome within this genus. It 
should be noted that a significant fraction of the singletons from this four-strain comparison 
find a match within at least one of the other analysed genomes (i.e., compare the "Singleton" 
line in Table 6.3 with the numbers reported in Fig. 6.1A).  
The next question was to ask how many of the 3942 Actinoallomurus core CDSs (Fig. 
6.1A) are shared with other organisms from the same order. This analysis was first applied to 
A. oligospora (the most similar species according to 16S-based phylogenetic analysis) and T. 
curvata (the other member of the Thermomonosporaceae family, but with a smaller genome). 
Fig.  6.1B shows that less than half of the shared Actinoallomurus orthologues (1688 out of 
3942 sequences) find a match in both A. oligospora and T. curvata. Furthermore, despite its 
smaller genome, T. curvata shares a larger number of CDSs with the Actinoallomurus core 
than does A. oligospora. This result is consistent with the data reported in Table 6.3, and 
suggests that the overall closer relationship of Actinoallomurus spp. with T. curvata than with 
A. oligospora is due to sharing a larger number of core functions. 
Finally, we extended this type of analysis by including two representatives from the 
Streptosporangiaceae, S. roseum and Microbispora sp., together with either A. oligospora (Fig. 
6.1C) or T. curvata (Fig. 6.1D). [This type of analysis can be easily visualized with up to four 
different genomes.]  Consistent with the previous observations, there is a larger number of 
shared orthologues (1969; Fig. 6.1D) when T. curvata is included in the comparison than when 
using A. oligospora (1669; Fig. 6.1C). Interestingly, the inclusion of two representatives from 
the Streptosporangiaceae does not alter significantly the number of core CDSs (compare Fig. 
6.1B with either 6.1C or 6.1D), suggesting the core genome of the order Streptosporangiales 
might approximate to ~1600 sequences. Another interesting observation from the data shown 
in Fig. 6.1C is the significant number of orthologues shared by Actinoallomurus with both S. 
roseum and Microbispora sp. (818) but not with A. oligospora.  
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Since only one genome sequence from representatives of the genus Actinomadura was 
used, we cannot exclude the possibility that the genome of A. oligospora is particularly 
divergent, and similar analyses with other members of this genus would show a higher 
relatedness with Actinoallomurus. Nonetheless, the results from the analyses presented here 
are also consistent with the hypothesis that Actinoallomurus might actually be similarly related 
to members of the Streptosporangiaceae family as to members of the Thermomonosporaceae 
family.  All together these data call for further phylogenetic analyses to resolve a possible 
discrepancy between 16S-based classification and whole genome comparisons. However, this 
type of analyses falls outside the scope of my PhD project and was not pursued any further. 
 
 
Figure 6.1 – Venn diagrams describing the number of shared orthologues between selected organisms. Panel A, 
comparison of the four Actinoallomurus; Panel B, comparison of the common Actinoallomurus core with other 
Thermomonosporaceae; Panel C, comparison of common Actinoallomurus core with A. oligospora and two 
members of the Streptosporongaceae family; Panel D comparison of common Actinoallomurus core with T. 
curvata and two members of the Streptosporongaceae family; 
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Finally, I concluded whole genome comparisons by analysing the extent of synteny 
existing among the Actinoallomurus genomes, including also A. oligospora, T.curvata, and 
Microbispora for comparison. A graphical representation of those results is shown Fig.  6.2.  
 
Figure 6.2 – Synteny analysis of the four Actinoallomurus genomes with those from A. oligospora, S. roseum, T. 
curvata. Each dot corresponds to homologous region. See Experimental Section for details. 
This type of analysis shows that the four Actinoallomurus strains share a high degree of 
synteny. Specifically, the genomes of ID145113 and ID145716 appear highly related, 
consistent with the high number of shared orthologues (Table 6.3 and Fig. 6.1A). In contrast, 
strain ID145698 appears to be the most divergent of the four strains in terms of shared gene 
order and content. A comparison between the genomes of ID145698 and ID145711 points to 
the existence of large inverted segments. As expected from the previous analyses, little synteny 
was observed with genomes from outside the Actinoallomurus genus. This observation 
contrasts with the synteny observed between representatives from the genera 
Streptosporangium, Planobispora and Microbispora (Tocchetti. et al., 2015), warrantying 
further analyses of one of the lesser studied genera of the Actinobacteria.  
6.3.2. Biosynthetic gene clusters 
By taking advantage of the Antismash v3.0.4 tool, it was possible to pin point a list of 
all BCGs and summarize it in Table 6.4. Overall, the number of BGCs and the fraction of the 
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genome dedicated to secondary metabolism fall within the range of filamentous actinomycetes, 
including the most prolific producers of secondary metabolites, i.e. members of the 
Streptomyces genus.(Bentley et al., 2002; Harrison and Studholme, 2014; Ikeda et al., 2003)  
 
Overall, Antismash identified 88 BGCs. Those were then regrouped in sets according 
to their biosynthetic pathway, as to facilitate a comparison between whole genome analysis 
and the results from the screening exercise (Table 6.4). At this point it was also important to 
filter the Antismash results, highlighting which Actinoallomurus BGCs presented significant 
homology to BGCs involved in the synthesis of known compounds (see Experimental Section 
Table 6.4 – List of all the gene clusters found by antiSMASH in the genomes of Actinoallomurus strains 
ID145113, ID145698, ID145711, and ID145716 
Type of Cluster Total ID145113 ID145698 ID145711 ID145716 
Terpene 16 3 4 6 3 
Lantipeptide 15 5 2 3 5 
T1PKS 9 0 4 1 4 
Other 6 1 2 1 2 
T2PKS 6 1 2 2 1 
NRPS 5 0 1 1 3 
Ectoine 4 1 1 1 1 
Siderophore 4 1 1 1 1 
Bacteriocin 3 1 0 1 1 
Lassopeptide 3 2 0 0 1 
Bacteriocin-lanthipeptide 2 0 1 1 0 
Indole 2 0 1 1 0 
Bottromycin 1 0 0 0 1 
Butyrolactone-Ladderane-OtherKS 1 0 0 0 1 
Lantipeptide-bacteriocin 1 1 0 0 0 
Lantipeptide-OtherKS 1 0 0 1 0 
NRPS-bacteriocin 1 1 0 0 0 
NRPS-terpene 1 0 0 0 1 
Otherks-lanthipeptide 1 0 1 0 0 
Otherks-t1PKS-terpene 1 1 0 0 0 
T3PKS-lassopeptide 1 0 1 0 0 
Terpene-bacteriocin 1 0 0 1 0 
Terpene-t1PKS-NRPS 1 0 0 0 0 
Terpene-t3PKS 1 0 0 0 1 
Thiopeptide-lanthipeptide-bacteriocin 1 0 1 0 0 
Total number BGCs 88 18 22 21 26 
Total size of BGCs (Mbp) 2.78 0.59 0.76 0.51 0.92 
Genome fraction 7% 6% 7% 5% 11% 
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for details). This analysis reduced the list to 55 BGCs that could be analysed in further detail 
(Table 6.5).  
Table 6.5 – Summary of the BGCs from Table 6.4 
grouped according to their biosynthetic process (second 
column). The number of BGCs with homology to known 
cluster is also indicated. 
Biosynthetic class 
BGCs BGCs with 
homology* 
Ectoine 4 3 
Indole 2 2 
Other 7 3 
polyketide 15 11 
hybrid PKS-
NRPS 
6 6 
RiPP 26 13 
non-ribosomal 
peptide 
14 11 
Siderophore 4 0 
Terpene 16 12 
Total 88 55 
* percentage of genes in the Actinoallomurus cluster with an identity ≥ 45% with the 
corresponding genes in the reference cluster. 
 
Overall, Table 6.5 shows how BGCs for RiPPs are found in relatively more abundance, 
followed by those for terpenes, polyketides and non-ribosomal peptides.  
6.3.2.1. Analysis of PKS1 Clusters 
One of the significant findings of screening Actinoallomurus was the relatively high 
frequency at which likely polyethers were detected (Chapter 2.42.). Therefore, I wondered if 
this feature was also reflected within the genomes. One strain, ID145716, presents two BGCs 
(clusters 13 and 17) with features consistent with polyether biosynthesis (data not shown): 
presence of PKS I with modules enriched with domains carrying out reductive steps; and 
presence of an epoxidase, reported as landmark enzyme for polyether biosynthesis (Jiang et al., 
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2012). The other three genomes showed no obvious BGC for the production of these 
compounds. 
6.3.2.2. Aromatic Polyketides 
As mentioned earlier the sequenced genomes originate from strains that produced or 
showed the potential to produce new compounds. Three out of four of the selected strains 
(ID145113, ID145698 and ID145711) produced an aromatic polyketide with a quinone moiety 
and hence their genomes were expected to contain a PKS II BGC. The analysis of two of such 
BGCs have been reported in Chapters 4 and 5, including how the corresponding KSβ's have 
been used to predict the polyketide length. An additional four PKS II BGCs were identified in 
the four genomes and the KSβ analysis was extended to all them to infer the likely polyketide 
scaffold. The resulting phylogenetic tree is described in Fig.  6.3. 
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Figure 6.3 –Phylogenetic tree of the KSβ from 35 different biosynthetic clusters with known product. The KSβ 
from all Actinoallomurus BGCs are represented by the ID of the strain. Supporting Table 1 provides additional 
information on the KSβ’s used for the phylogenetic analysis. 
In Fig.  6.3 it is possible to see how the already mentioned KSβ s –those believed to be 
involved in the synthesis of allocyclinone and NAI-113 – cluster within the clade for 
dodecaketide or tridecaketide carbon backbones along with an enzyme from Strain ID 145711, 
suggesting that the as yet unidentified polyketide from this strain may derive from an 
equivalent number of acetate units.  The second striking feature of Fig. 6.3 is the remaining 
three KSβs from Actinoallomurus (ID145716_Cluster18; ID145711_Cluster15; 
ID145698Cluster_2) that seem not to be correlated with any of the known KSβ clades. This 
may imply that these BGCs are involved in the synthesis of polyketides unrelated to the 
families used for phylogenetic analysis.  
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Figure 6.4 shows an alignment of the CLFs from the allocyclinone BGC and from 
Cluster 5 of strain ID145711. The two proteins share 91% identity with conservation of aa 
positions 109, 112, 116, and 133, which have been shown to play a key role in determining the 
length of the carbon backbone of aromatic polyketides (Tang et al., 2003). 
 
Figure 6.4 – Alignment of the KSβs from Allocyclinone cluster and from Cluster 5 of Strain 145711 
Due to the high similarity of the two KSβs from Fig.  6.4, and having already analysed 
the allocyclinone BGC (see Chapter 4), I decided to have a closer look at both clusters 
comparing each CDS. The results, reported in Table 6.6, show that the BGC from strain 
ID145711 is highly related to the allocyclinone cluster, showing, with one exception, the same 
composition and order of CDSs, each with a high percent identity to the cognate protein from 
the other cluster. One noteworthy feature of the allocyclinone cluster is the presence of two 
halogenases, presumably involved in different regioselective halogenations (see Chapter 4). So 
does the BGC from strain ID145711, suggesting that this cluster might also be involved in the 
synthesis of an aromatic polyketide containing two halogenated positions. The only difference 
between the two BGCs is the presence of a four-gene insertion in the ID145711 cluster, coding 
for two putative regulators, a protein of unknown function, and strikingly, an aminotransferase. 
It should be pointed out that MS analysis of an extract prepared from strain ID145711 did not 
find m/z+ values corresponding to any of the congeners in the allocyclinones complex (data not 
shown), but instead a compound with UV spectrum and MS isotopic pattern suggestive of a 
halogenated quinone (see Chapter 4). Further analyses will be necessary to characterize the 
metabolites produced by strain ID145711 and establish any association with Cluster 5. 
Table 6.6 – Comparison of CDSs from Allocyclinone biosynthetic cluster with those from 
NAI711_Cluster 5. 
Allocyclinone  NAI711_Cluster5 
CDS 
Length 
(aa) 
Putative Functiona 
Length 
(aa) 
CDS ID% 
--- --- Hydrolase 363 NAI711_2242 --- 
NAI698_9155 369 Hypothetical Protein ---  --- --- 
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NAI698_9156 961 Lux family Transcriptional Regulator 963 NAI711_2243 81 
NAI698_9157 177 Regulator Protein 175 NAI711_2244 80 
NAI698_9159 218 hypothetical protein 215 NAI711_2246 86 
NAI698_9160 301 putative DNA-binding protein 301 NAI711_2247 95 
NAI698_9161 289 putative DNA-binding protein 289 NAI711_2248 91 
NAI698_9162 172 Oxidoreductase 172 NAI711_2249 93 
NAI698_9163 262 SARP-like transcriptional regulator 262 NAI711_2250 93 
NAI698_9164 342 O-methyltransferase 342 NAI711_2251 93 
NAI698_9165 318 hypothetical protein 320 NAI711_2252 88 
NAI698_9166 308 Transcriptional regulator 303 NAI711_2253 79 
NAI698_9167 294 Putative Hydrolase 290 NAI711_2254 86 
NAI698_9168 211 Unknown Function 211 NAI711_2255 86 
NAI698_9169 108 Polyketide synthesis cyclase 108 NAI711_2256 80 
NAI698_9170 537 Decarboxylase 537 NAI711_2257 95 
NAI698_9171 138 Putative cyclase 136 NAI711_2258 89 
NAI698_9172 424 Ketoacyl synthase - alpha 425 NAI711_2259 91 
NAI698_9173 407 Ketoacyl Synthase - Beta 407 NAI711_2260 91 
NAI698_9174 243 Polyketide cyclase 246 NAI711_2261 87 
NAI698_9175 67 Hypothetical protein 68 NAI711_2262 84 
NAI698_9176 245 Acyl Carrier Protein 245 NAI711_2263 87 
NAI698_9177 112 Monooxygenase 108 NAI711_2264 88 
NAI698_9178 108 Monooxygenase 108 NAI711_2265 95 
NAI698_9179 393 Oxidoreductases 393 NAI711_2266 90 
NAI698_9180 153 Hydroxylase 155 NAI711_2267 90 
NAI698_9181 583 Acetyl-CoA carboxylase biotin carboxylase 584 NAI711_2268 84 
--- --- hypothetical protein 221 NAI711_2269 --- 
--- --- Serine/threonine kinase 644 NAI711_2270 --- 
--- --- Aspartate transaminase 386 NAI711_2271 --- 
--- --- transcriptional_regulator, _XRE_family 185 NAI711_2272 --- 
NAI698_9182 168 MarR-like transcriptional regulator 159 NAI711_2273 84 
NAI698_9183 569 Drug resistance transporter 568 NAI711_2274 89 
NAI698_9184 255 ACP-reductase 257 NAI711_2275 87 
NAI698_9185 276 O-methyltransferase 276 NAI711_2276 93 
NAI698_9186 555 Halogenase 552 NAI711_2277 94 
NAI698_9187 145 Ester Cyclase 145 NAI711_2278 94 
NAI698_9188 168 Cupin domain protein 186 NAI711_2279 85 
NAI698_9189 146 Ester Cyclase 146 NAI711_2280 88 
NAI698_9190 435 Membrane antiporter 435 NAI711_2281 83 
NAI698_9191 560 Halogenase 560 NAI711_2282 91 
NAI698_9192 147 Hypothetical protein 148 NAI711_2283 85 
NAI698_9193 530 Monoxygenase 530 NAI711_2284 88 
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NAI698_9194 590 Peptidase --- --- --- 
--- --- Transcriptional Regulator 184 NAI711_2285 --- 
a – the putative function was already assigned on chapter 5, Table 5.5.  
Dashed lines define the limits of the putative gene clusters within the Antismash output 
 
6.3.2.3.  Curious case of halogenases 
As mentioned, each of the two clusters from Table 6.6 encodes two distinct 
halogenases. Halogenated metabolites are often found encountered as products from 
Actinoallomurus (see also Chapters 3, 4 and 5) (Cruz, 2015; Cruz et al., 2015; Mazzetti et al., 
2012)  and, hence, the corresponding genomes should encode the required halogenases. This 
feature was investigated and, within three of the four genomic sequences, six genes for 
halogenases were found, with only strain ID145113 not presenting any. Strain ID145716 
presented one, strain ID145711 two, and strain ID145698 three halogenases. The protein 
sequences were then aligned and a phylogenetic tree built upon this data, as represented in Fig. 
6.5. 
 
Figure 6.5 – Phylogenetic comparison of halogenase enzymes found in all Actinoallomurus genomes (square 
boxes) with halogenases of known function. 
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As shown in Table 6.6, four of the halogenases (two from the allocyclinone cluster and 
two from the related BGC from strain ID145711) represent two highly related pairs presumably 
involved in regiospecific chlorination of two positions in related aromatic polyketides. Closely 
related to these two pairs is a third halogenase (ID145698_05879) from the allocyclinone 
producer ID145698, which is associated with a cluster identified as “Other” by Antismash. 
These five halogenases find their best match with the halogenase from the chlortetracycline 
cluster suggesting halogenation of aromatic system(s). Finally, strain ID145716 has also a 
halogenase associated to a cluster classified by AntiSMASH as “Other" but encoding some 
enzymes similar to those involved in the biosynthesis of chloropeptin, a hyper-halogenated 
heptapeptide structurally related to the glycopeptide antibiotics (Garfunkle et al., 2009) (data 
not shown). This amino acid sequence clade best with those from pyoluteorin and pyrrolonitrin 
clusters, which might indicate that this halogenase uses a pyrrole moiety as a substrate. Note 
that the previously described Actinoallomurus metabolite NAI-414 carries a halogenated 
pyrrole (Mazzetti et al., 2012). 
6.3.2.4. NRPS and PKS-NRPS hybrids 
A total of 15 clusters were identified by Antismash, and six of them are PKS-NRPS 
hybrids. Only for ten clusters antiSMASH was able to assign a similar BGC for characterized 
compounds. However, the Actinoallomurus clusters were significantly divergent from the 
identified reference clusters as to suggest unrelated secondary metabolites as the products of 
the Actinoallomurus BGCs.  
6.3.2.5. RiPPs  
AntiSMASH yielded 24 BGCs involved in RiPP formation, but only three of them show 
a significant homology with clusters directing the synthesis of known molecules. Table 6.7 
summarizes these findings. 
Table 6.7 – Identity* Of Actinoallomurus RIPP BGCs with the 
most similar gene cluster for known peptides. 
 ID145113 ID145698 ID145711 ID145716 
SSV-2083 37%    
CINNAMYCIN 33% 33% 33% 19% 
CATENULIPEPTIN    60% 
* PERCENTAGE OF GENES IN THE ACTINOALLOMURUS CLUSTER WITH AN IDENTITY ≥ 45% 
WITH THE CORRESPONDING GENES IN THE REFERENCE CLUSTER. 
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The most striking case of Table 6.6 is the discovery that a cinnamycin-like cluster was 
present in all the four strains. A detailed analysis of the CDSs present in these four clusters was 
then undertaken. As it can be seen in Fig. 6.6, three of the clusters show a conserved set of 
eight genes, while only the cluster from strain ID145716 appears to be slightly divergent. 
The CDSs from the four clusters were blasted against the MIBiG database. The 
resulting best hits are reported in Table 6.8. As it can be seen all four clusters present a high 
relatedness with the cinnamycin cluster. However, while the BGCs from strains ID145113, 
ID145698 and ID145711 encode all the proteins required for cinnamycin formation (i.e., the 
precursor peptide CinA, the bifunctional dehydratase/cyclase CinM, the Asp hydroxylase 
CinX, the transporters CinH and CinT, as well as the regulator CinR1 and a homologue of 
CinORF7), the cluster from strain ID145716 presents a lower percent of identity with the Cin 
proteins and, notably, lacks CinX and the transporters CinH and CinT, suggesting that the 
cluster in strain ID145716 might direct the synthesis of a lantibiotic more divergent from 
cinnamycin than those specified by the other three clusters. 
. 
Table 6.8 – Comparison of the CDSs from each of the Actinoallomurus Cinnamycin-like BGCs with the 
Cinnamycin CDSs 
CDS Function 
145113 145698 145711 145716 
CDS Id% CDS Id% CDS Id% CDS Id% 
CINORF7 Unknown Function 5960 66.7 3137 66.4 2356 68.1 3536 59.1 
CINA Cinnamycin prepropeptide 5961 56.4 3138 56.4 2355 56.4 3535 47.2 
CINM LanM family of proteins 5962 62.0 3139 62.2 2354 61.8 3534 57.2 
CINX hydroxylation of aspartate 5963 53.5 3140 53.3 2353 53.0   
CINT ABC transporter 5964 79.2 3141 79.0 2352 79.7 3533 65.3 
CINH ABC transporter 5965 65.3 3142 65.0 2351 66.3   
CINR1 SAR Protein 5959 55.7 3136 54.7 2357 53.2   
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Figure 6.6 – Antismash output comparing the four Actinoallomurus RiPPs gene clusters with the Cinnamycin 
Cluster. Red/Dark blue – Putative biosynthetic genes; Light Blue – Transport-related genes; Green - Regulation-
related genes; Grey – unassigned function 
 An alignment of the four precursor peptides with CinA is shown in Fig.  6.7. All four 
Actinoallomurus peptides contain the diagnostic Cys and Ser/Thr residues required for making 
the three (methyl)lanthionine bridges present in cinnamycin, as well as conserved Lys-Ser pair 
(required for the N-C bond typical of cinnamycin) and Asp residue (site of hydroxylation). 
However, the peptide from strain ID145716 is predicted to form only methyllanthionine 
bridges, in contrast to the two methyllanthionine and one lanthionine bridges present in 
cinnamycin and the other three predicted Actinoallomurus lantibiotics (Fig.  6.1, Panel B). It is 
also worth pointing out that, with respect to cinnamycin, the four Actinoallomurus peptides 
present variations at positions 2 (Gly, Gln or Ala in place of Arg), 3 (Thr in place of Gln), 7 
(Trp or Ala in place of Phe), 10 (Ile in place of Phe), 12 (Ile or Ala in place of Phe) and 18 
(Ala, Gln or Thr in place of Asn). Overall, the lanthipeptide predicted from strain ID145716 
presents itself as the most divergent one with changes (S4T, and V13I) at otherwise invariant 
positions, plus one extra amino acid (Ala) at the C-terminus. The lack of a putative Asp-
hydroxylating enzyme would also indicate that this lanthipeptide is not post-translationally 
modified at that position. 
 
Figure 6.7 – Panel A - Comparison of Cinnamycin leader peptide with correspondent sequences from gene 
clusters from the four Actinoallomurus Strains. Panel B - Comparison of Cinnamycin Propeptide with 
correspondent sequences from gene clusters from the four Actinoallomurus Strains. Prediction of Lanthionine 
bridges is also described 
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When cultivated under standard conditions (see Chapter 2.4), none of the four strains 
produce a metabolite with properties compatible with those predicted from the lanthipeptides 
of Fig. 6.7. Further preliminary investigations are reported later in this Chapter (subchapter 
6.3.3). Nonetheless, it is striking that all four sequenced strains contain a related cluster for a 
lanthipeptide with a predicted ring topology identical to that of cinnamycin, but presenting 
variations in amino acid sequences.  
6.3.2.6. Siderophores 
It was also noted that each strain possessed BGCs for a siderophore. Upon a closer look 
the BGCs from strains ID145698, ID145711 and ID145716 present a high degree of relatedness 
in gene content and order (Fig.  6.8). A similarity search of the CDS against the MIBiG database 
is reported in Table 6.8 Interestingly, all four clusters find the BGC for vibrioferrin synthesis 
as the best match and all encode the four biosynthetic enzymes required for vibrioferrin 
formation plus an ABC transporter. However, the regions flanking this core 5-gene segments 
diverge among the four genomes. The low percent identity between the Actinoallomurus 
sequences and those from the vibrioferrin BGC might suggest that the siderophore specified 
by Actinoallomurus is structurally different from vibrioferrin. Alternatively, vibrioferrin has 
been described as the product of marine Proteobacteria (Tanabe et al., 2003), so a low percent 
identity might derive from phylogenetic distance from Actinobacteria. Nonetheless, the finding 
is interesting and unveils another unexpected feature of the secondary metabolites from 
Actinoallomurus.  
 
Figure 6.8 - Comparison of the gene cluster encoding the biosynthetic machinery for the synthesis Siderophores 
from Actinoallomurus strain ID145113, ID145698, ID145711, ID145716. Red– CDS Putative biosynthetic 
genes; Light Blue – Transport-related genes; Green - Regulation-related genes; Grey – un assigned function. 
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Table 6.9 - Description of the Siderophore gene clusters from Actinoallomurus strain ID145113, ID145698, ID145711, 
ID145716. 
Most Similar Match | Accession Number 
Identity % 
ID145113 ID145698 ID145711 ID145716 
Monensin_3-O-methyl_transferase|AAO65792.1 39,3 --- --- 37,7 
NapR8|ABS50498.1 --- --- --- 36,5 
EncO|AAF81734.1 --- --- --- 43,9 
Putative_GCN5 
-related_N-acetyltransferase|ABX24478.1 51,9 --- --- --- 
DNA_helicase_IV|CBJ79907.1 --- 39,3 --- --- 
CalU19|AAM70361.1 48,9 --- --- 51,1 
CalR8|AAM70335.1 66,7 --- --- 71,2 
Vibrioferrin_biosynthesis_protein_PvsE|ABM30201.1 58,7 42,9 43,2 42,8 
Vibrioferrin_biosynthesis_protein_PvsD|BAC16547.1 32,4 31,4 31,8 31,6 
Vibrioferrin_biosynthesis_protein_PvsB|ABM30204.1 31,7 34,4 31,9 31,0 
Vibrioferrin_biosynthesis_protein_PvsA|BAC16544.1 37,0 36,7 37,6 35,8 
ATP-binding_phosphonate_ABC_transporter_PhnC|ACG70837.1 39,2 32,4 31,1 31,6 
Putative_aminoacylase|BAE95562.1 --- --- 36,3 37,2 
Peptidase_M20|AEH42498.1 --- 32,3 --- --- 
NTP_pyrophosphohydrolase|ACB47032.1 --- 40,5 --- --- 
 
6.3.3. Creation of a genomic library from 
Strain ID145113 
 Temporally, the first Actinoallomurus genome was obtained from strain ID145113 (see 
Chapter 3). I was interested in learning techniques for efficiently creating genomic libraries 
with inserts large enough to contain some clusters identified in strain ID145113, such as the 
BGCs for the aromatic polyketide NAI-113 (see Chapter 3) and the cinnamycin-like 
lanthipeptide (see above). Thus, I spent my second secondment (April 2015) at the University 
of Warwick, where the expertise and adequate conditions exist for library preparation and 
screening.  
The creation and screening of a genomic library consists of: preparation of high quality 
DNA from the chosen strain; construction of the genomic library in a vector suitable for further 
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steps; and screening the library for the desired clones. Since a well-made library can be an 
important asset to use over and over, appropriate conditions are important for storing and easily 
retrieving the individual clones. It was thus decided to adopt a technique that allows screening 
several clones at the same time and permits storing in a small amount of space. Libraries are 
usually constructed and stored in microtiter plates (96-well or more) where each clone is placed 
in a different well; screening is then performed going well by well until the desired clone is 
found. This library storage system allows a rational organization of the library but makes the 
process of library screening and storing time- and space-inefficient.  This might not be an issue 
when making a single library, but can become a limiting factors when dealing with many 
different libraries or with metagenomic libraries, which require a large number of clones. 
Gurgui and Piel have employed a strategy in which bacterial clones are stored in a semi-liquid 
medium at low CFU/mL. (Gurgui and Piel, 2010)  As shown in Fig. 6.9, this strategy can be 
easily adapted to Actinoallomurus, enabling the isolation of a single clone from a 400,000 clone 
library in significantly lower amount of time. 
 
Figure 6.9 – Workflow used for obtaining heterologous production of gene clusters from Actinoallomurus.  
Adapted from Gurgui, C. and Piel, J., 2010. (Gurgui and Piel, 2010) 
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The technique involves storing the library in separate vials of roughly 10,000 clones 
per mL each. A small sample from each vial can then be used for PCR screening. From the 
positive pools, appropriate dilutions are made into separate vials, which are then incubated for 
regrowth and subjected to a second PCR analysis, and so forth until the number of different 
clones per vial is low enough to be plated. At this point a final PCR is made to screen individual 
colonies. This way it is possible to significantly reduce the amount of storage space (one cryo 
vial with 10,000 clones instead of 100 96-well microtiter plates) and rapidly finding the desired 
clones in a process taking four to five days (Hrvatin and Piel, 2007). Although this technique 
is particularly suited for large libraries requiring millions of clones for appropriate coverage, it 
was also adapted to serve the need of my project. 
The number of clones needed for having a given probability of given DNA sequence 
from a genome can be calculated with according to  Equation (1). 
  N=ln(1-P)/ln(1-f),    N – Number of clones; P- Desired probability; f – insert size     (1) 
For this work, we used the fosmid vector pCCFOS, which combines all the stability and 
ability of harbouring larger inserts granted by the low-copy BAC vectors, but are endowed with 
a system that allows a high number of copies of the vector per host cell by induction with l-
arabinose. For this particular work we used pCC2FOS whom has also a primer sequence to 
help the end sequencing after vector screening. (Wild et al., 2002) With a genome size of 10.6 
Mbp for strain ID145113, 1400 clones would be sufficient to give a 99% probability of finding 
any gene according to formula (1). However, since we were looking for not one but two clusters 
(for NAI-113 and for the cinnamycin-like lanthipeptide) which each means that we were not 
looking just for one gene but to a set of genes, all in the same fragment. To be on the safe side, 
the library size was scaled up to 300,000 clones, which translates into a total 105Gbp of inserts, 
or roughly 10,000 genome equivalents. This was achieved as described under Experimental 
Section. 
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Figure 6.10 – Agarose gel with the PCR results from the screening of the super-pools. Top layer – Amplicons 
from Left and right flanks of the NAI-113 Cluster. Bottom layer Amplicons from Left and right flanks of the 
Cinnamycin-like Cluster. Positive Control (+) Total genomic DNA. Negative Controls (-) S.coelicolor  total 
genomic DNA and Water. 
The first round of PCR screening was made pooling 10 μL each from 10 separate vials, 
yielding about 10,000 clones. Needless to say that several positive pools were found at this 
stage (Fig.  7.10). On the basis of the observed amount of amplicon, super-pools D and H, and 
J were selected for the NAI-113 and lanthipeptide screening, respectively. 
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Figure 6.11 – Agarose gel with the PCR results from the screening of the pools. Top layer – 
Amplicons from Left and right flanks of the NAI-113 Cluster. Bottom layer Amplicons from Left and right 
flanks of the Cinnamycin-like Cluster. Positive Control (+) Total genomic DNA. Negative Control (-) S. 
coelicolor  total genomic DNA  
Upon dilution, regrowth and PCR screening (according to the scheme of Fig. 6.11), 
none of the two different super-pools yielded sub-pools containing both ends of the NAI-113 
cluster (Fig.  6.12), implicating that a larger pool size was needed to identify a complete 33-kb 
cluster. However, due to time constraint, no further work was performed. In contrast, different 
subpools were PCR-positive for both ends of the Cin-like cluster (Fig.  6.11- vial F, G, H, and 
J). After one further round, four clones containing a DNA fragment encompassing the entire 
cluster were found (Fig.  6.11). End sequencing of the resulting fosmids confirmed that the 
insert contained the entire cluster, with flanking regions of 5 and 1 kbp for a calculated insert 
size of 33.5kbp. 
Back to KtedoGen, the identified cosmid has been engineered for conjugation into 
different actinomycetes for heterologous expression, work that is currently ongoing (Dr. 
Arianna Tocchetti, personal communication). 
6.4. Discussion 
The genome characterization provided another interesting dimension to this work 
allowing to have a better picture of what Actinoallomurus can produce and where it falls within 
the grand scheme of microbial classification. This last part of the analysis was performed by 
looking at the predicted proteome and compare it to those of known organisms. As expected, 
the four Actinoallomurus strains share a large number of orthologues (Table 6.3). Strikingly, 
however, they share a similar number of orthologues with members of the 
Streptosporangiaceae (between 41 and 53%) and not with members of the 
Thermomonosporaceae (29-36%) which would be expected being all strains closely related, 
according to the phylogenetic analysis of the 16S rRNA gene. Moreover, Actinoallomurus 
strains seem to share a high homology with T. curvata (another member of the 
Thermomonosporaceae family) and with those of the Streptosporangeacea family. S. 
coelicolor, A. oligospora and A. friulensis seem to present less homologs and by consequence 
a higher percentage of singletons and paralogs. It is also noteworthy how A. oligospora – the 
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closest relative of Actinoallomurus – shows such a diminished set of homology with the 
remaining organisms.  
Taxonomy suffers always from an original sin that is being an artificial creation from 
Man to organize Nature in a systematic way, which does not seem to work in such manner. 
The orthology analysis shows again this apparent conflict between classification based on 
phylogenetic analysis of 16S rDNA gene sequences and strain relatedness based on the number 
of shared orthologues. These results suggest that the assignment of Actinoallomurus to the 
Thermomonosporaceae family and in particular its closeness to Actinomadura is worth further 
investigations. An analysis based on a single taxonomic marker might not reveal the complete 
evolutionary history of this organism and it would be interesting to perform phylogenetic 
analyses using other known markers to secure the phylogenetic position of Actinoallomurus. 
At the same time, the same orthology analysis provided other insights, for instance the high 
number of unique proteins found in each Actinoallomurus strain suggests a large pangenome 
where different BGCs are likely to be found.  
Regarding the novelty of the metabolites predicted from genome analysis, a few 
insights were obtained, for instance from the KSβs that clustered away from other known 
enzymes. Nevertheless, further investigations to actually isolate and correlate a compound with 
these BGCs are required.  
One of common characteristics of the metabolites from Actinoallomurus so far seems 
to be the presence of halogens and hence the presence of halogenases (see Chapter 6.3.2.3.). A 
phylogenetic analysis of the six halogenases identified in the four genomes allowed to separate 
the enzymes into two groups. One consists of the halogenases associated with the allocyclinone 
cluster and the related cluster from strain ID145711, together with the additional halogenase 
from strain ID145698. These five enzymes cluster together with the halogenases from 
chlorinated aromatic polyketides such as allocyclinones and chlortetracycline. The second 
group includes the halogenase identified in strain ID145716, which cluster with pyrrole-
modifying halogenases. A least an additional halogenase is predicted from strain ID145698, 
which produces a lantibiotic carrying a halogenated tryptophan (see Chapter 5) but whose 
genome sequence has not yet been determined. Thus, further analyses of Actinoallomurus 
strains may substantially expand the phylogenetic positioning of the halogenases present in this 
genus. In the end, it would be worth comparing the frequency of halogenated compounds found 
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in other actinomycete genera to evaluate the relative frequency with which they are 
encountered in different taxa.  
The genetic analysis found two BGCs (one for a cinnamycin-related lanthipeptide and 
one for a siderophore) common to the four strains. Since none of the strains was known to 
produce such molecules, these "unsuspected" compounds might play a role in the 
Actinoallomurus life cycle, thus justifying their presence across all the strains. Siderophores 
are known to play an important role in metal chelation and acquisition, so the conservation of 
one such BGC comes as no surprise. However, the presence of a cin-like BGC in all four strains 
is intriguing, especially since each of the cinA structural genes has slightly diverged among the 
different strains, accumulating mutations at amino acid positions not involved in post-
translational modifications. This finding, which contrasts with the conservation of the NAI-
107 sequence observed between Microbispora and Actinoallomurus (see chapter 5), suggests 
that these BGCs were not recent acquisitions but were rather maintained throughout this genus 
speciation. However, the role of these lanthipeptides in the Actinoallomurus life cycle remains 
to be established. It should be noted that the detection of these potentially common metabolites 
most likely would require modification in the cultivation conditions. For instance, siderophore 
production is known to require the use of media with limiting iron concentrations (Dimkpa et 
al., 2008). 
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7. GENERAL DISCUSSION 
 
7.1. Introduction 
The end of the antibiotic era is coming at a rather unexpected pace. The inefficiency of 
the most powerful antimicrobial agents is increasing and we, as a society, have not been able 
to introduce effective therapeutic alternatives. Moreover, the struggle to achieve new 
efficacious antibiotics is uncanny: between the difficulty of finding novel molecular structures 
and the requirements of the regulatory entities, antimicrobial drug discovery and development 
has become a laborious endeavour with an extremely low output and a perceived low reward. 
Therefore, new successful projects in drug discovery must replenish the pipeline of 
antibacterial drug candidates. 
Historically, natural products have represented one of the most valuable sources of 
compounds for drug discovery. However, the elevated frequency of re-discoveries of known 
antibiotics and the incrementally high difficulty to identify new structures led to the assumption 
that Nature was close to exhaustion as the most successful sources of therapeutic agents and 
alternative sources had to be sought. However, alternative sources have substantially failed to 
deliver drug candidates at a reasonable rate while we have systematically assessed the chemical 
repertoire of a small portion of living organisms, bacteria in particular, leaving a universe of 
novel sources to be analysed.  
As the pharmaceutical industry was progressively abandoning natural product 
screening, scientific and technological advantages were profoundly changing the way that 
natural products could be identified, characterized and manipulated: the accessibility of 
genomic information and the ability to handle it; major improvements in analytical techniques; 
and an understanding of biosynthetic pathways involved in secondary metabolism. The –omics 
age made available a set of tools: from the production of synthetic cell factories (e.g., 
artemisinin is a plant metabolite that can now be produced in yeast through a reconstructed 
pathway (Ro et al., 2006)) to the direct expression of environmental DNA in a surrogate host 
(e.g., production of the polyketide arixanthomycin by Strep. albus containing soil DNA)(Kang 
and Brady, 2014); from correlating metabolome profiles through MS networking (Yang et al., 
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2013) to the production of rapamycin analogues through mutasynthesis (Seto, 2012). 
Complementing these advances are improved methods in synthetic chemistry, which enable 
the creation of an improved range of semi-synthetic derivatives and de novo synthesis of natural 
products (Lam, 2007; Ling et al., 2015). 
These are all interesting approaches that are having an impact in the identification, 
production and manipulation of natural products.  However, they are bound to our knowledge 
of existing compounds, which in turn derives from exploring a limited fraction of bacterial 
diversity. Hence, the exploration of novel (i.e., previously not systematically screened) taxa is 
likely to yield new biosynthetic enzymes, new combination thereof, thus new molecular 
structures and, possibly, new interesting bioactivities. Recent examples in this direction bear 
promise (Feling et al., 2003; Piel et al., 2004). 
Among bacteria, some taxa have become versatile producers of bioactive metabolites, 
in particular many, but notably not all, taxa belonging to the Actinobacteria. Therefore, the 
main premise of this work was to use phylogeny as a predictive marker of the ability to produce 
secondary metabolites: unexplored taxa within the Actinobacteria, which are phylogenetically 
related to known producers, would have tuned and tweaked their physiology to better adapt to 
the particularities of the selective pressure to which have been subjected and, since secondary 
metabolism plays an important role in this evolutionary process, would have come up with new 
chemical space. For the reasons explained in Introduction, the focus of this project has been on 
the poorly explored genus Actinoallomurus. 
7.2. Critical overview of the results 
In this work 105 strains, out of 230 strains tested under one single condition (same 
medium and incubation parameters for all strains), produced an antibacterial activity against 
one single test strain, Staphylococcus aureus. This result indicates that Actinoallomurus, much 
as other Actinobacteria, is geared for the production of bioactive metabolites under artificial 
laboratory conditions, i.e., shake-flasks.   
When evaluating a potential new bacterial taxon for antibiotics, one can encounter two 
extreme scenarios: no positives are found against the chosen test organism, which implies that 
either the taxon does not produce antibiotics or that a different test organism must be used; or 
virtually all samples are positive, which implies that no screening has been made, since all 
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strains need still to be analysed through the next step in the process. In the latter case, the 
screening strategy needs a revision, especially if it is to be applied to a large number of samples. 
This is somehow the issue encountered in this project, in which about 50% of the strains 
possessed an antibiotic activity against S. aureus, so a large number of positives needed to be 
evaluated. However, this is a nice problem to have: now that Actinoallomurus has proven to be 
a prolific producer of antimicrobial compounds, additional tools can be implemented to allow 
prioritising the positive extracts.    
While less than half (45 out of 105) of the positive extracts were actually evaluated for 
the chemical nature of the active compound(s), a reasonable diversity was observed among the 
characterized extracts. Regarding novelty, two new antibiotics (NAI-113 and allocyclinone) 
were identified, as novel representatives of known families possessing interesting structural 
features. In addition, the rediscovery of a known lantibiotic (NAI-107) spurred the production 
of a variant (NAI-108) with enhanced antibacterial activity. Furthermore, to those compounds, 
several new polyethers were pinpointed but, for the reasons explained in Chapter 0, were not 
further pursued. 
Although the frequency of new discoveries is expected to lower as the number of 
screened strains increases, it is worth mentioning the NAICONS strain collection used in this 
work includes 1200 independently isolated Actinoallomurus strains, so the 45 strains analysed 
in this work still represent a modest fraction of that microbial diversity. 
Among the molecules produced by strain ID145698, we identified the first hyper-
halogenated aromatic polyketide. Named allocyclinone, these angucyclinones present also an 
uncommon lactone group fused to the chromophore and up to three chlorines on a single methyl 
group, with the number of chlorines being related to antibacterial potency. Allocyclinones, 
although previously unreported, might not be uncommon metabolites within the genus 
Actinoallomurus, since this family of metabolites was identified in phylogenetically distinct 
Actinoallomurus isolates. Allocyclinones represent an additional example of halogenated 
metabolites produced by Actinoallomurus. Indeed, this genus produces spirotetronates with 
multiple halogens in the pyrrole moiety (Mazzetti, C., et al, 2012) and a lantibiotic with a 
halogenated tryptophan residue (Chapter 5). 
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Sequentially next to strain ID145698 there is strain ID 145699, which was identified as 
the producer of NAI-107, a chlorinated lantibiotic effective against multi-drug resistant Gram-
positive pathogens and previously reported from the distantly related genus Microbispora.  
Inclusion of KBr in the production medium of either the Actinoallomurus or the Microbispora 
producer readily afforded brominated variants of NAI-107, which were designated as NAI-
108, while the other post-translational modifications naturally occurring in this lantibiotic 
family (i.e., hydroxylation of Pro-14 and C-terminal decarboxylation) were unaffected by the 
presence of a brominated tryptophan. In addition to being the first example of a bromine-
containing lantibiotic, NAI-108 displayed a small but consistent improvement in antibacterial 
activity against all tested strains. It should be noted that while substitution of chloride with 
bromide has been successfully achieved in two instances, NAI-414 (Mazzetti et al., 2012)and 
NAI-108 (chapter 5), this is not a general rule and it did not yield any brominated metabolites 
in the case of strain ID145698, the allocyclinone producer (data not shown). 
An additional contribution has been on the characterization of NAI-113. While the 
producer strain ID145113 had been previously marked as potentially interesting, significant 
hurdles in structural elucidation led the project to a halt. The major hindrance for structure 
elucidation was the paramagnetic nature of the molecule, which emitted no NMR signals even 
after simple derivatization. My work consisted in providing 13C-labelled NAI-113 and insights 
into NAI-113 biosynthesis through analysis of the corresponding BGC. These results, along 
with a number of chemical degradation studies, ultimately led to establishing that NAI-113 is 
a new anthracyclinone, carrying an unusual lactone moiety. For both allocyclinone and NAI-
113, bioinformatic predictions suggest that these compounds are synthesized as longer 
polyketide precursors. 
The first genomic analysis of the Actinoallomurus genus confirmed expectations for 
filamentous actinomycetes: the four sequenced strains contain large genomes (8-10 Mbp) with 
approximately 70% GC and with a significant fraction dedicated to BGCs. The four sequenced 
genomes provided a total of 3.7 Mbp dedicated to secondary metabolism subdivided into 88 
BGCs with a minimum of 19 clusters per strain.  With some exceptions, each Actinoallomurus 
strain presents a diverse set of clusters, and every strain harbours at least one BGC for each of 
the major biosynthetic classes – PKS, NRPS, RiPPs and terpenes. In terms of abundance, 
terpenes appear to be the most common, followed by RiPPs and polyketides. 
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7.3. Insights into Actinoallomurus 
As previously mentioned the Actinoallomurus strains used in this screening were 
isolated previously to beginning of this project. Actinoallomurus spp. are slightly acidophilic 
filamentous actinomycetes that can be differentiated by a different cell wall and 16S rRNA 
gene sequence. The first described species actually resulted from a reclassification of some 
strains that were previously assigned to the genus Actinomadura. (Tamura et al., 2009) 
Actinoallomurus has thus been assigned to the family Thermomonosporaceae, together with 
Actinomadura and Thermomonospora spp. This family belongs to the order 
Streptosporangiales. 
Taking advantage of the four Actinoallomurus sequenced genomes, an orthology analysis 
was performed comparing their deduced proteomes with those derived from representatives of 
other Actinobacteria. This analysis has shown that, in terms of shared homologues, 
Actinoallomurus strains are as related to members of the Streptosporangeaceae as they are to 
Thermomonospora curvata. In contrast, the number of shared homologues with Actinomadura 
oligospora is lower. While these results must await confirmation through a comparison with 
additional genome sequences from Actinomadura (only one species was used), nonetheless 
they suggest that Actinoallomurus might be as related to members of the Streptosporangiaceae 
as of the Thermomonosporaceae.   
As mentioned in the introduction a screening expedition into new taxonomical space goes 
beyond the obvious task of bringing to light new compounds. As compounds new and known 
are characterized, the work provides insights into the physiology of the new taxon. Only few 
metabolites were published from Actinoallomurus prior to the beginning of the work. (Mazzetti 
et al., 2012; Pozzi et al., 2011) The discovery of allocyclinones and NAI-113 confirms the 
existence of new chemical space within Actinoallomurus, particularly the presence of 
previously unreported features in relatively widespread classes of metabolites. These 
metabolites, in particular allocyclinones, are relatively common among Actinoallomurus. So 
are polyether-producing strains. Therefore, the work presented here provides a glimpse on 
some commonly encountered metabolites that, although not universally present, may constitute 
common encounters in this genus, as for example actinomycin and aminoglycosides are for 
Streptomyces and Micromonospora, respectively (Běhal, 2000; Mingeot-Leclercq et al., 1999). 
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Some of the possible core metabolites of Actinoallomurus have been unveiled by 
genomic analysis. Indeed, all four analysed genomes harbour a BGC for the synthesis of a 
vibrioferrin-like siderophore and one for a cinnamycin-like lanthipeptide. Siderophores play 
an important role in bacterial physiology, as they bind iron (or other heavy metals) with high 
affinity and facilitate the intracellular uptake of this essential micronutrient. While all 
actinomycete genomes harbour one or more siderophore BGC, only strains from the 
streptomycetaea family have been reported as possessing a BGC (but with no metabolite 
associated so far) for the biosynthesis of Vibrioferrin-like compounds which, in fact is a 
siderophore previously only found in some Proteobacteri. (Ichikawa et al., 2010; Nett et al., 
2009). 
Even more remarkable is the finding of the cinnamycin-like BGCs. Cinnamycin is a 
class II lanthipeptide previously described from Streptomyces spp. Lanthipeptides were long-
believed to be species-specific, but this concept has already been challenged in this work by 
the production by Actinoallomurus of a highly modified lanthipeptide previously observed only 
in Microbispora spp. The finding that all four genomes harbour BGCs for producing 
cinnamycin-like molecules, with considerable variations in their amino acid sequences, suggest 
that these lanthipeptides play an important and yet unknown role in Actinoallomurus 
physiology. Although neither the vibrioferrin-like siderophore nor the cinnamycin-like 
compounds were identified in the screened extracts, particular conditions (e.g., Fe-limited 
media for the siderophore) might be required to trigger expression of the corresponding BGCs.   
Halogenated metabolites are often encountered among the Actinoallomurus 
metabolites. Combining previous and current work, three structurally unrelated Cl-containing 
metabolites have been characterized: spirotetronates carrying halogens on a pyrrole moiety, 
(Mazzetti et al., 2012) hyper halogenated angucyclinones (Chapter 5), and NAI-107 (Chapter 
6). Furthermore, genomic analyses led to the identification of two additional BGCs encoding 
halogenases: one for an allocyclinone-related metabolite in strain ID145711, and one for a 
metabolite of unknown function in strain ID 145716. 
7.4. The concept of low-hanging fruits 
The exploration of a new region will always start by registering the main, easier to be 
acknowledge features. The same experience is to be expected from a screening program in a 
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new taxonomical region. Just like during the initial screening of Streptomyces strains, the first 
encounters are those that strike the observer the most, whether because they are produced in 
high quantities or because they have a potent activity. Furthermore, those "striking encounters" 
must occur at a relatively high frequency to catch the observer’s attention (and prevent him/her 
to switch to a different project!). Metabolites with these characteristics can be called the low 
hanging fruits in drug discovery from microbial products, in analogy to the easy-to-collect 
fruits out of a tree. As different trees bear different fruits, so one would expect different taxa to 
bear different metabolites. Since this work has been the first systematic evaluation of 
Actinoallomurus, it is not unexpected that, among the first molecules identified, are the low 
hanging fruits from this genus. The characteristics of allocyclinone fit well to those of a low 
hanging fruit: firstly, it is produced in high quantities and it has high antimicrobial activity, 
including against the E. coli mutant used in this work, a fairly rare event that made this 
compound stand out in the observer's eye with respect to the others; secondly, the high number 
of chlorines present in the active molecule was another feature that arose interest. Finally, 
several producers were found among the tested strains, hence augmenting the probability of 
allocyclinone producing strains being picked up randomly. This same reasoning could be 
applied to the putative polyethers identified but not further pursued during the screening.  
The results presented here suggest that further screening of Actinoallomurus strains will 
not yield a single class of compounds but the genus can offer a broad set of different 
compounds, although it appears to be enriched in some types of molecules. From the results 
observed so far, polyketides are probably the most common class, especially polyethers 
through the PKS I system and aromatic polyketides through PKS II. However, it is striking 
that, for both NAI-113 and allocyclinone, genomic evidence suggests that these molecules are 
produced from longer dodeca- or tridecaketide backbones, which are then somehow shortened 
into the final product. This observation, together with the relatively high frequency of 
halogenated polyketides, suggests that, even within a class of microbial products with several 
known representatives, new chemical twists are to be found. The highly divergent chain length 
factors identified through genomic sequencing may represent another potential source for novel 
chemistry, although no metabolite has been associated to the corresponding BGCs. 
Judging from the genomic sequences, additional low-hanging fruits might be 
represented by the vibrioferrin-like siderophores and the cinnamycin-like lanthipeptides. 
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However, the appropriate conditions necessary to trigger the expression of the corresponding 
BGCs currently represent terra incognita.  
7.5. The genomic potential of Actinoallomurus 
vs the screening results 
The characterization of the metabolites produced by 45 strains and the identification of 
88 BGCs from genomic analysis of four strains provide the basis for a preliminary comparison 
of the frequency of metabolites encountered with the two approaches. Interestingly, the two 
types of data only partially match. Most noticeable is the case of terpenes, one of the most 
frequent type of BGCs observed but with no terpene detected in the analysed extracts. This 
discrepancy may be due to the fact that these molecules did not show a detectable antibacterial 
activity (actually, few terpenes from actinomycetes do), that they are often volatile molecules 
that can be lost during extract preparation or that the corresponding BGCs were not expressed 
under the employed cultivation conditions.  The second most frequent class of metabolites 
predicted by Antismash is represented by RiPPs, a class from which wet-lab experiments 
yielded one compound (the lantibiotic NAI-107). The third most frequent class from genomic 
analysis is represented by the polyketides, and indeed several polyketides were actually 
identified during screening. Nevertheless, there is a discrepancy between screening data and 
genomic analysis: while the indicated high frequency of polyethers, and hence of PKS1 
clusters, only one such BGC could tentatively be assigned to polyether production.  
The above mentioned discrepancies should not come as a surprise. Screening of 
microbial fermentation extracts requires that compounds are produced under the chosen 
experimental conditions and that they are stable enough to be detected at the time extracts are 
actually prepared. If a bioassay is used to select extracts worthy of further analyses, an 
additional bias is introduced, i.e. that the metabolite is active. These limitations might help 
explain the lack of identified terpenes in the extracts and the bias for polyether and aromatic 
polyketides, which usually possess potent antibacterial activities. On the other hand, the BGCs 
identified from genomic analysis might not encode a functional biosynthetic pathway, might 
require special conditions for their expression or the cultivation medium might lack essential 
precursors or cofactors.  
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7.6. Finding new chemical classes and 
finding improved antibiotics 
The probability of bringing to light a revolutionary discovery is usually inversely 
related to the amount of knowledge available in the area of interest. For instance, discovering 
an unprecedented chemical class during screening of microbial products reflects this axiom 
quite well, since this was a common feature in the golden era of antibiotic discovery and can 
now be expected a rare event. Furthermore, the major biosynthetic pathways (i.e. those for 
polyketides, non-ribosomal peptides, RiPPs and terpenes) are common to all bacterial phyla 
that harbour the corresponding BGCs. Hence, the discovery of unprecedented biosynthetic 
classes can be expected only from the lesser abundant classes of secondary metabolites.  
As our knowledge increases, the features of a chemical class of secondary metabolites 
can be interpreted more diverse ways, whether in terms of the molecular target(s) it interacts 
with or of the potential applications. As mentioned, several compounds initially identified for 
their antibacterial or antifungal properties became successful drugs for treating cancer or as 
immunosuppressants in organ grafts. As another example, polyketide macrolactones can bind 
to the bacterial ribosome (e.g., erythromycin), to eukaryotic tubulin (e.g. epothilone) or they 
can inhibit bacterial and eukariotic tRNA synthase (e.g. borrelidin) (Goodin et al., 2004; 
Igarashi et al., 1969; Wakabayashi et al., 1997). 
Not all discoveries are expected to impact our knowledge in the same manner, as this 
depends on their ability for surprising us. At first sight, the discovery of another angucyclinone 
might attract as little interest as the discovery of a new polyether, since both events would add 
a small extent of incremental knowledge to large families of compounds with a well-established 
biosynthetic pathway. However, some unique features, such as the presence of a 
trichloromethyl group linked to an aromatic ring or the existence of two halogenases in the 
allocyclinone cluster might change this perspective.  
One of the advantages in screening microbial products is that one might encounter 
improved variants of chemical families with a limited number of representatives. Such was the 
case that led to the discovery of NAI-108, the brominated variant of the potent lantibiotic NAI-
107, which could be made by either Actinoallomurus or Microbispora in KBr-supplemented 
media. This finding indicates that the halogenases specified by the mib clusters from 
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Microbispora and by the corresponding cluster from Actinoallomurus sp. ID145699 are 
capable of efficiently incorporating Br when exposed to sufficient bromide concentrations, 
leading to the first example of a Br-containing lantibiotic. Although this substitution is 
interesting from the biochemical point of view, it also resulted in a compound slightly but 
consistently more active than the chlorinated counterpart against different bacterial pathogens. 
While this result can be explained by the importance of the hydrophobicity in the lipid II-
binding lanthionine bridges of class I lantibiotics (Maffioli et al., 2015), many brominated 
metabolites are usually less active than their chlorinated homologues (Cruz et al., 2015). 
The theoretical chemical space is estimated to be immense, and we have information 
on an infinitesimal fraction. Nevertheless, this fraction contains millions of compounds, with 
just few of them used as therapeutics. Expanding on this set to bring benefits to our society 
requires introducing new molecules that present enhanced or unexpected bioactivity properties 
within the corresponding chemical class.   
7.7. Outlook 
The results presented here present only the first insights on the screening of 230 strains 
from a library of 1200 Actinoallomurus isolates. If the activity results observed herein are to 
be extrapolated, then under the same conditions around 600 strains will produce an extract with 
activity against S. aureus. Identifying the active compound(s) within each of those theoretical 
600 active extracts requires implementing a robust screening pipeline with strict threshold 
criteria for further progress. At the same time, such a high number of positives might require 
introducing more stringent assay criteria, for examples tests able to filter out frequently 
encountered metabolites. As additional strains are evaluated, the probability of finding new 
compounds is expected to decrease, eventually reaching a point of saturation in which a large 
screening effort is required to identify new molecules. So far, out of 45 extracts analysed, 11 
different sets of active compounds were identified (9 polyethers and two aromatic polyketides), 
with each set often represented by a complex of related molecules. This high frequency of 
novelty events does encourage further investigations within this genus and suggests that the 
point of low return of Actinoallomurus screening is unlikely to be just around the corner. This 
assumption is corroborated by the genomic analysis, with several predicted classes of 
metabolites that have not been identified during the screening exercise. 
  
135 
 
To keep improving our health standards and to fight antibiotic resistance, we need to 
identify new drug candidates. Nature has provided a large number of them and all the available 
evidence indicates that it can continue to do so, provided that judicious choices are made in the 
source of chemical diversity to be explored and in the approach taken to explore it. This 
requires a continuous adjustment of conditions, especially dealing with microbial strains, since 
we have little information on the role these compounds play in the environment for the 
producing strains. In the case of Actinoallomurus, future efforts may require adjustments of the 
screening assay, to make it more selective, and exploration of different cultivation conditions, 
to identify some genome-predicted metabolites. Overall, I am confident that Actinoallomurus 
can play an important role in bringing to light and, possibly, into clinical use new antibiotics 
and other bioactive compounds. 
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APPENDIX 1 
 
Figure 1 - HPLC trace at 270 nm of the mycelium extract from a culture of Actinoallomurus sp. ID145968. The 
shaded are indicates peaks associated with antibacterial activity, where peaks corresponding to compounds 1, 2, 
3 and 4 are labelled accordingly. The dashed box highlights the hydrophilic part of the chromatogram containing 
the partially characterized compounds 5, 6 and 7, as well as other uncharacterized species related to 1–4.  
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Figure 2 - Left: Experimental HR-MS of compounds 1-4 (from left to right). Right: calculated isotopic patterns for 1-4 (top to bottom). 
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Figure 3: Comparison of the 1H-NMR spectra of Allocyclinone 1,2,3, and 4 in CDCl3 at 298K. The variation at position 3 is clearly visible: the methyl group of 
Allocyclinone 1 at 2.66 ppm becomes CH2Cl at 4.92 ppm in 2 and CHCl2 at 7.29 (near the solvent peak) in 3. In the upper expanded panel the arrows indicate the downfield 
shift for the aromatic proton in position 4 due to the increasing deshielding effect of the vicinal substituent. In the same panel the less dramatic shift of the AB system is also 
visible. 
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Figure 4. 1H-NMR of 1 in CDCl3 at 298K. 
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Figure 5. 1H-NMR of 2 in CDCl3 at 298K. 
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Figure 6. 1H-NMR of 3 in CDCl3 at 298K. 
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Figure 7: 1H-NMR of 4 in CDCl3 at 298K. 
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Figure 8. HSQC NMR of the 1–4 mixture in CDCl3 at 298K. 
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Figure 9: HMBC NMR of the 1–4 mixture in CDCl3 at 298K. 
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Figure 10: TOCSY NMR of the 1–4 mixture in CDCl3 at 298K. 
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Figure 11: 1H-MMR of 5 in CDCl3 with addition of 10μL TFA at 298K.  
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Figure 12: HSQC NMR of 5 in CDCl3 with addition of 10μL TFA at 298K 
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Figure 13: HMBC NMR of 5 in CDCl3 with addition of 10μL TFA at 298K. 
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Figure 14: 1H-NMR of 6 in CDCl3 at 298K. 
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Figure 15. HSQC NMR of 6 in CDCl3 at 298K.  
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Figure 16. Stability of Allocyclinones 2 (Panel A), 4 (Panel B) and 3 in mixture with 1 (Panel C) in DMSO 
(60°C overnight). In each panel the following traces are reported: UV at 400 nm of the starting solution (upper 
trace), UV at 400 nm (middle trace) and MS (lower trace) after 16h at 60°C in DMSO. Peaks were detected 17as 
[2M + NH4]+ ions. Allocyclinone 1 resulted stable in these conditions (see panel C)
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Figure 17: LC-MS analysis a fermentation broth showing pH 8.26 at the end of fermentation. In the left panel the UV trace at 400 nm (upper trace) and the extracted MS 
peaks for the allocyclinones 1, 2, 3 and 4 as [2M +  NH4]+; in the right panel: the same UV trace at 400 nm (up) and the extracted MS peaks of the degraded Allocyclinones 5, 
6 and 7.  
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Figure 18.  Growth kinetics of E. coli L4242 in the presence of different concentrations (µg/mL) of the 1–4 complex (same batch used for the experiments reported in Table 
5.3) 
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1.  
Figure 19: LC-MS analyses of extracts from the additional eleven allocyclinone producers listed in Table 5.4. Note the MS peaks for 1, 2, 3 and 4 as [2M +  NH4]+.
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Table 1 - Additional information on the CLFs used for the phylogenetic analysis of NAI698_9173 shown on 
Figure 4.4. 
Compound Classification 
Starter-
Extender 
Length 
(aa) 
Accession 
Number 
Aclacinomycin Anthracycline Propionyl-9 407 AAF70107.1 
Gilvocarcin Angucycline Propionyl-9 391 AAP69574.1 
Simocyclinone Angucycline Acetyil-9 404 AAB36563,1 
Oviedomycin Angucycline Acetyil-9 407 AAB36563.1 
Kinamycin Diazobenzofluorene Acetyil-9 403 AAO65347.1 
Jadomycin Angucycline Acetyil-9 404 AAB36563.1 
Urdamycin Angucycline Acetyil-9 408 CAA60570.1 
SCH-4755 Angucycline Acetyil-9 408 CAH10116.1 
Nogalamycin Anthracycline Acetyil-9 409 CAA12018.1 
Steffimycin Anthracycline Acetyil-9 410 CAJ42319.1 
Chromomycin Aureolic acid Acetyil-9 422 CAE17526.1 
Oxytetracycline Tetracycline Malonyl-8 422 AAZ78326.1 
Aranciamycin Anthracycline Acetyil-9 408 ABL09958.1 
Mithramycin Aureolic acid Acetyil-9 408 CAA61990.1 
Alnumycin Naphthoquinone Butyryl-7 428 ACI88862.1 
Frenolicin Benzoisochromanequinone Butyryl-7 426 AAC18108.1 
R1128 Anthraquinone Butyryl-7 415 AAG30188.1 
Actinorhodin Benzoisochromanequinone Acetyil-7 407 CAC44201.1. 
Medermycin Benzoisochromanequinone Acetyil-7 408 BAC79045.1 
Granatacin Benzoisochromanequinone Acetyil-7 415 CAA34370.1 
Griseorhodin Pentangular polyphenols Acetyil-12 420 AAM33654.1 
Rubromycin Pentangular polyphenols Acetyil-12 422 AAG03068.1 
Arixanthamycin Pentangular polyphenols n.d. 412 AHX24702.1 
Pradamycin Pentangular polyphenols Acetyil-11 392 ABM21748.1 
Fredericamycin Pentangular polyphenols Hexanoyl-12 403 AAQ08917.1 
Benastatin Pentangular polyphenols Hexanoyl-11 409 CAM58799.1 
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TLN-0522 Pentangular polyphenols 
Methylbutyryl-
12 423 ADB23392.1 
Griseusin Benzoisochromanequinone Acetyil-9 412 CAA54859.1 
Resistomycin - Malonyl-9 412 CAE51175.1 
Allocyclinone Angucycline Unknown 407 This work 
Inspired from the work of Ogasawara, Y., et al. 2015 3(Ogasawara et al., 2015) 
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APPENDIX 2 
Figure 1.  MS analyses of extracts from Actinoallomurus sp. ID145699 grown in medium AF-A with NaCl (trace 
1) or KBr (trace 3) and from Microbispora sp. ID107841 grown in medium AF-A with NaCl (trace 2) or KBr 
(trace 4). Note the m/z+ values corresponding to the GPA congeners ranging from 1212 to 1259. 
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Figure 2.  1H-NMR analysis of NAI-108 (black line) and NAI-107 (blue line) in CD3CN:D2O 6:4 at 
298K. The enlargement shows the aromatic portion of the spectrum, with the asterisks denoting three selected 
indolic protons. The red arrow indicates the diagnostic change in the chemical shift observed for proton 4 in NAI-
108. 
  
* * 
* * * 
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APPENDIX 3 
Table 1 - Additional information on the KSβs found in the four genomes of 
Actinoallomurus analysed 
Compound Classification 
Starter-
Extender 
Length 
(aa) 
Accession 
Number 
Aclacinomycin Anthracycline Propionyl-9 407 AAF70107.1 
Actinorhodin Benzoisochromanequinone Acetyil-7 407 CAC44201.1. 
Allocyclinone Angucycline Unknown 407 This work 
Alnumycin Naphthoquinone Butyryl-7 428 ACI88862.1 
Aranciamycin Anthracycline Acetyil-9 408 ABL09958.1 
Arixanthamycin Pentangular polyphenols n.d. 412 AHX24702.1 
Benastatin Pentangular polyphenols Hexanoyl-11 409 CAM58799.1 
Chromomycin Aureolic acid Acetyil-9 422 CAE17526.1 
Fredericamycin Pentangular polyphenols Hexanoyl-12 403 AAQ08917.1 
Frenolicin Benzoisochromanequinone Butyryl-7 426 AAC18108.1 
Gilvocarcin Angucycline Propionyl-9 391 AAP69574.1 
Granatacin Benzoisochromanequinone Acetyil-7 415 CAA34370.1 
Griseorhodin Pentangular polyphenols Acetyil-12 420 AAM33654.1 
Griseusin Benzoisochromanequinone Acetyil-9 412 CAA54859.1 
Jadomycin Angucycline Acetyil-9 404 AAB36563.1 
Kinamycin Diazobenzofluorene Acetyil-9 403 AAO65347.1 
Medermycin Benzoisochromanequinone Acetyil-7 408 BAC79045.1 
Mithramycin Aureolic acid Acetyil-9 408 CAA61990.1 
NAI-113 Tetracenomycin Unknown 432 This work 
NAI-698_Cluster15 Unknown Unknown 438 This work 
NAI-711_Cluster2 Unknown Unknown 424 This work 
NAI-711_Cluster5  Unknown Unknown 407 This work 
NAI-716_CLuster18 Unknown Unknown 418 This work 
Nogalamycin Anthracycline Acetyil-9 409 CAA12018.1 
Oviedomycin Angucycline Acetyil-9 407 AAB36563.1 
Oxytetracycline Tetracycline Malonyl-8 422 AAZ78326.1 
Pradamycin Pentangular polyphenols Acetyil-11 392 ABM21748.1 
R1128 Anthraquinone Butyryl-7 415 AAG30188.1 
Resistomycin - Malonyl-9 412 CAE51175.1 
Rubromycin Pentangular polyphenols Acetyil-12 422 AAG03068.1 
SCH-4755 Angucycline Acetyil-9 408 CAH10116.1 
Simocyclinone Angucycline Acetyil-9 404 AAB36563,1 
Steffimycin Anthracycline Acetyil-9 410 CAJ42319.1 
TLN-0522 Pentangular polyphenols 
Methylbutyryl-
12 
423 ADB23392.1 
Urdamycin Angucycline Acetyil-9 408 CAA60570.1 
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